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Colorectal cancer: treatment and prognosis
Colorectal cancer is one of  the most common diagnosed cancers worldwide, and is the second 
most important cause of  cancer mortality in Europe (1). About two thirds of  colorectal cancer 
occurs in the colon, and one third occurs in the rectosigmoid or the rectum. The current staging 
system for both colon and rectal cancer used in clinical practice is based on the tumor, nodes and 
metastasis (TNM) staging system (2,3).
For colon cancer, surgery is the primary treatment, with adjuvant chemotherapy given as the 
standard of  care in stage III and high-risk stage IIB colon cancer patients (4). Rectal cancer is 
also primarily treated by surgery, but in contrast to colon cancer, is associated with a high local 
recurrence rate. As the rectum is fixed in the smaller pelvis, this provides opportunities for 
radiation therapy. Even though treatment guidelines are updated regularly, the current staging 
system and treatment regimens are insufficient and result in both over- and undertreatment 
of  many patients. Patients with the same TNM classification present with large differences in 
patient survival and tumor recurrence, with for example varying 5-year survival rates of  60-
80% for stage II and 30-60% for stage III colon cancer (5). In addition, about 30% of  colon 
cancer patients with TNM stage I or II colon cancer, without nodal involvement at the time 
of  diagnosis, will develop distant metastases (6). The implementation of  the total mesorectal 
excision (TME) surgery technique for rectal cancer, combined with preoperative radiotherapy 
as investigated in the Dutch multicenter TME clinical trial, has resulted in a reduction in local 
recurrences of  6% (from 11% to 5%), but without an overall survival benefit (7). This also 
implicates that the majority of  rectal cancer patients (at least 94%) is unnecessarily treated with 
radiotherapy, which can be associated with comorbidities including sexual dysfunction and fecal 
and urinary incontinence (8,9). Therefore, there is a need for identification of  new biomarkers in 
colorectal cancer in order to identify high-risk patients and to guide treatment decision-making.
Biomarkers are biological markers that can be measured in for example blood or tumor tissue 
and can be used as indicators of  pathological processes and hence provide information on 
the likely clinical outcome (prognostic biomarkers) or to measure the response to therapeutic 
interventions (predictive biomarkers). Many factors have been proposed as clinically prognostic 
or predictive biomarkers in colorectal cancer. These include measurement of  carcinoembryonic 
antigen (CEA) in blood, determination of  MSS (microsatellite stability) status, KRAS mutations, 
BRAF mutations and p53 mutations, and testing for expression of  thymidylate synthase (TS) in 
colorectal cancer tissues. However, only a few of  the numerous proposed prognostic biomarkers 
have been recommended for clinical use (10). For example, CEA levels in the blood have been 
approved for postoperative surveillance (although still controversial; 11) and KRAS mutations 
in tumor cells have been validated as a predictive factor for the response to anti-EGFR therapy 
in patients with metastatic colorectal cancer (12). At present, insufficient evidence is available 
for routine implementation of  other proposed biomarkers in a clinical setting. Therefore, new 
clinically prognostic biomarkers are needed in order to better classify patients, to prevent over- 
and undertreatment, and to advance the field of  personalized medicine. Potential new biomarkers 
can be found in the many pathways involved in tumor development and progression, and can be 
at the level of  DNA (i.e. mutations, single nucleotide polymorphisms, microsatellite instability, 
copy number changes or translocations), mRNA expression or protein expression. The vast 
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majority of  research in cancer has focused on genetic changes driving tumor development, but 
in the last decade researchers have also taken an interest in the mechanisms regulating gene 
expression: epigenetics.
Genetic changes in colorectal cancer – history and current knowledge
The knowledge of  the function and changes of  the DNA in cancer has increased rapidly over 
the past century. Already since the 1920s, geneticists advocated the theory that cancer was 
most likely to originate from “ordinary” cells affected by genetic mutations. In 1953, Nordling 
proposed a theory that around seven successive mutations that promote cellular division would 
be necessary for tumor development (13). He also noted that the incidence of  cancer seemed 
to increase with age, which could be explained by the accumulation of  mutations, resulting in 
self-stimulating propagation and ultimately tumor development. In 1971 Knudson posed his 
well-known “Knudson two-hit hypothesis” based on his findings in retinoblastoma, in which he 
hypothesized that retinoblastoma is caused by two mutations in the Retinoblastoma (Rb) gene. 
He proposed that the first mutation would be inherited via germinal cells and was therefore 
present in all cells in the body. According to this hypothesis, the second mutation would occur 
in somatic cells in the retina, leaving no functional copies of  the Rb gene, which can lead to 
tumor formation (14). Then, in 1988, just before the start of  the Human Genome Project in 
1990, Vogelstein proposed a multi-step mutational sequence for colorectal cancer, the adenoma-
carcinoma sequence, in which he showed that certain mutations occur early in the carcinogenic 
process and multiple genetic aberrations accumulate with tumor progression (15). Genome 
instability– by accumulation of  mutational events – expedites the acquisition of  capabilities that 
lead to tumor development, described as the main cancer hallmarks by Hanahan and Weinberg 
in 2000 (16,17). These capabilities include, among others, evading apoptosis, limitless replicative 
potential and tissue invasion and metastasis, which allow a somatic cell to transform into a cancer 
cell. As described in the adenoma-carcinoma sequence by Vogelstein, a multi-step process of  
successive mutations in tumor suppressor genes takes place during progression from adenoma 
to carcinoma in the colon (18). New information from genomics and sequencing data has been 
added since. The most frequently detected mutations in sporadic colorectal cancers are mutations 
in the adenomatous polyposis coli (APC), KRAS, SMAD2/4 and TP53 genes (Figure 1). 
Figure 1
Shown are the various stages of  colorectal carcinoma development. Gray cells represent normal epithelial cells, black 
cells represent transformed cancer cells. Critical mutations occuring at specific stages during adenoma-to-carcinoma 
transformation are indicated with arrows.







APC KRAS TP53 
Single cell 
transformation 




Mutations in the APC gene occur early in tumor development. In patients with hereditary 
familial adenomatous polyposis (FAP), one of  the APC genes harbors a mutation, which 
predisposes these individuals to development of  numerous adenomatous polyps upon a 
second “hit” (19). Heritable mutations in one of  the mismatch repair genes (Lynch syndrome), 
including MSH2, MSH6 and MLH1 results in microsatellite instability and predisposes the 
affected individuals to develop colorectal adenocarcinomas at an early age (onset before 
age 50) (20). Despite the convincing evidence that mutations in the genes mentioned above 
contribute to tumor development, not all colorectal tumors harbor detectable gene mutations, 
indicating that other factors than genetic aberrations also play a role in carcinogenesis.
Epigenetic regulation of  gene expression
In addition to genetic aberrations, the regulation of  gene expression by epigenetic mechanisms 
has gained interest in the field of  cancer research. According to the first definition, as coined 
by Waddington in 1942, epigenetics involves “the study of  the process by which genetic 
information is translated into the substance and behavior of  an organism: specifically, the study 
of  the way in which the expression of  heritable traits is modified by environmental influences 
or other mechanisms without a change to the DNA sequence” (21). In a more contemporary 
definition, epigenetics refers to the study of  heritable changes in an organism by modification 
of  gene expression that are not caused by changes in the underlying DNA sequence. Gene 
expression is dependent on the local structure of  the chromatin, which is the complex of  DNA 
and histone proteins that ensures compaction of  the DNA in the cell nucleus. Only an open 
chromatin structure (euchromatin) allows for transcription factors to bind to gene promoters 
in order to initiate gene transcription, whereas heterochromatin regions remain densely packed 
and hence inaccessible for transcription factors (Figure 2). As epigenetic regulation is a dynamic 
process responsive to environmental stimuli and specific requirements of  the cell, these 
epigenetic mechanisms are attractive targets for anti-cancer therapy, since they are potentially 
reversible. Driver mutations in epigenetic factors involved in both DNA methylation and 
histone modifications have been described in several cancers (22,23). Reversion of  epigenetic 
changes might sensitize tumors to other therapeutic agents currently used in the clinic, including 
chemotherapy and radiotherapy. Epigenetic therapies targeting DNA methylation (24-27) or 
histone deacetylases (HDACs)(28,29) are currently tested in clinical trials.
DNA methylation
Epigenetic factors that mainly determine chromatin structure are DNA methylation and histone 
modifications. Although the existence of  5-methylcytosine was already reported in 1948 by 
Hotchkiss (30), it took several decades to establish its function(s). DNA methylation is involved 
in many cellular functions, including genomic imprinting of  gene regions, X-chromosome 
inactivation in females, silencing of  transcriptionally repressed regions including (peri-) 
centromeres and telomeres, and regulates gene expression (31). Patterns of  DNA methylation 
are cell-type specific (32,33) and play important roles during embryonic development (34,35). 
DNA methylation also protects against spontaneous mutagenesis (36). In normal tissue, DNA 
methylation on CpG dinucleotides in gene promoter regions is usually absent. 




Shown are open and closed chromatin structures. In an open chromatin structure, the distance between nucleosomes 
is about 150-170bp allowing for transcription factors to bind to the linker DNA and initiate transcription. This open 
chromatin structure is associated with unmethylated DNA and acetylated (and unmethylated) histone proteins. In a 
closed chromatin structure, nucleosomes are closer together (the distance 10-80bp) and both DNA and histone proteins 
are methylated, resulting in DNA that is inaccessible for transcription factors.
In contrast, repetitive sequences, generally found outside of  gene coding sequences, are methylated 
in normal tissue. In cancer, aberrant methylation patterns have been observed, with a general 
hypomethylation of  the genome (including repetitive sequences) and local hypermethylation of  
CpG islands in gene promoter regions (37). These changes in DNA methylation lead to aberrant 
expression of  oncogenes, including APC and MLH1 (38-40), activation of  retrotransposon 
repetitive sequences (41) and genomic instability (42), which can all contribute to the oncogenic 
transformation of  cells. DNA methylation of  many genes and non-coding sequences has been 
described to have prognostic value in cancer (43-46, among others). 
Histone modifications
Together with DNA methylation, histone modifications are major factors in determining 
chromatin structure. Eight histone proteins, in four pairs of  histones H2A, H2B, H3 and H4, 
constitute the core of  the nucleosome (Figure 3), around which around 147 basepairs of  the 
DNA are wrapped (47). Protruding histone tails can be modified by acetylation, methylation, 
phosphorylation and ubiquitination, among others (48). Each of  these histone modifications 
has a specific function (49,50). Generally, histone acetylation is associated with gene activation 
and an open chromatin structure (Figure 2). Histone methylation can have both gene activating 
and gene silencing effects, depending on the histone tail residue that is methylated. For example, 
methylation of  lysine residue 4 on histone H3 (H3K4me) is associated with gene activation 
but methylation of  H3K27 is a silencing modification. The different histone modifications 
are added to or removed from the histone tails by specific histone-modifying enzymes. For 
example, histone methylases of  the Polycomb-group (including EZH2) are responsible for 
trimethylation of  H3K27, and histone demethylase LSD1 is specific for demethylation (removal 
of  methylation) of  H3K4me1 and –me2. Histone deacetylases, including HDAC1 and 2 and 
SIRT1, are responsible for histone deacetylation (removal of  acetylation), in the case of  SIRT1 
preferentially on H3K9 and H4K16.
To add another level of  complexity, mono-, di- and trimethylation of  lysine residues also have 
different functions in the cell, on the basis of  their position on the histone tails and on different
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regions in the genome (51). For example, H3K4me1 is found within transcribed regions, whereas 
H3K4me2 and H3K4me3 are found in gene promoter regions. Histone core modifications, such 
as H3K56Ac, regulate the interactions between the histone proteins and DNA (52). Specific 
histone modifications have different interactions with proteins that specifically bind to certain 
histone modifications, including DNA binding proteins and chromatin remodelers (53). The 
complex interplay between the different histone modifications determines the chromatin 
structure and thereby gene silencing or activation of  gene transcription (54,55). In addition, 
DNA methylation and histone modifications act together during embryonic development and in 
regulating gene transcription (56,57). 
Changes in the expression of  histone modifications and histone-modifying enzymes have 
been implicated in cancer (58,59) and have been shown to have prognostic value in cancer (60-
63, among others). These changes in regulatory enzymes and modifications result in altered 
gene expression patterns, including aberrant expression of  oncogenes or silencing of  tumor 
suppressor genes, which could in turn result in enhanced mutagenesis (64). 
Figure 3
Shown are histone modifications on the different histone proteins. Histone proteins H3, H4, H2A and H2B all have 
protruding tails that can be modified by methylation, acetylation, phosphorylation or ubiquitination. Known modification 
sites with the respective modifications are shown for each of  the histone tails (lower part of  the figure). Numbers indicate 
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Thesis aim and outline
Thesis aim
The aim of  this thesis was to study epigenetic mechanisms, especially DNA methylation and 
histone modifications, as clinically prognostic biomarkers in colorectal cancer.
Thesis outline
Chapters 2 and 3 describe DNA methylation studies on repetitive sequences and on specific gene 
promoter regions, respectively. Chapter 2 describes the prognostic value of  DNA methylation 
of  a repetitive retrotransposon sequence, long interspersed element-1 (LINE-1), in rectal cancer 
tissues from patients enrolled in the Dutch multicenter total mesorectal excision (TME) clinical 
trial. In Chapter 3, DNA methylation was studied on specific apoptosis gene promoter regions 
in rectal cancer tissues from patients enrolled in the TME trial, using methylation-specific 
restriction enzymes.
Chapters 4 to 7 are focused on histone modifications in colorectal cancer, both globally and at 
gene-specific promoter regions. Chapter 4 shows the prognostic value of  nuclear expression 
of  histone deacetylases and correlated acetylated histones in colorectal cancer. In Chapter 
5, the prognostic value of  nuclear expression of  Polycomb-group proteins together with 
their accompanying histone modification H3K27me3 was studied. In Chapter 6, histone 
trimethylation at several histone tail residues was studied in early-stage colon cancer tissues in 
correlation to patient survival and tumor recurrence. Chapter 7 reports on the correlation of  
the transcriptional status of  apoptosis genes with sensitivity to treatment regimens including 
chemotherapy, immunotherapy and radiation.
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Epigenetic status of  LINE-1 
predicts clinical outcome in 
early-stage rectal cancer
Anne Benard, Cornelis J H van de Velde, 
Laurent Lessard, Hein Putter, Ling Takeshima, 
Peter J K Kuppen, Dave S B Hoon





Background: We evaluated the clinical prognostic value of  methylation of  two non-coding 
repeat sequences, long interspersed element 1 (LINE-1) and Alu, in rectal tumor tissues. In 
addition to DNA methylation, expression of  histone modifications H3K27me3 and H3K9Ac 
was studied in this patient cohort.
Methods: LINE-1 and Alu promoter methylation was assessed in DNA extracted from formalin-
fixed paraffin-embedded tissues. A pilot (30 tumor and 25 normal tissues) and validation study 
(189 tumor and 53 normal tissues) were performed. Histone modifications H3K27me3 and 
H3K9Ac were immunohistochemically stained on tissue microarrays of  the study cohort.
Results: In early-stage rectal cancer (TNM stage I-II), hypomethylation of  LINE-1 was an 
independent clinical prognostic factor, showing shorter patient survival (p=0.014; HR 4.6) and 
a higher chance of  tumor recurrence (p=0.001; HR 9.6). Alu methylation did not show any 
significant correlation with clinical parameters, suggesting an active role of  LINE-1 in tumor 
development. Expression of  H3K27me3 (silencing gene expression) and H3K9Ac (activating 
gene expression) in relation to methylation status of  LINE-1 and Alu supported this specific 
role of  LINE-1 methylation.
Conclusion: The epigenetic status of  LINE-1, but not of  Alu, is prognostic in rectal cancer, 
indicating an active role for LINE-1 in determining clinical outcome.




Under the current TNM (tumor, node, metastasis) staging system (American Joint Committee 
on Cancer, AJCC (1)) and treatment guidelines (National Cancer Institute, NCI), there is both 
over- and undertreatment of  rectal cancer patients (2). In our search for biomarkers that can 
complement the current TNM staging system as well as aid in subsequent treatment decisions 
for rectal cancer patients, we assessed genome-wide DNA methylation using repeat sequences 
LINE-1 (long interspersed element) and Alu, and global histone modifications in rectal tumor 
tissues.
Changes in epigenetic mechanisms regulating gene expression, including DNA methylation of  
CpG dinucleotides, are major factors in tumorigenesis (3). We have previously reported that 
epigenomic aberrations play a significant role in tumor progression and clinical outcome in 
rectal cancer (4-6). These studies showed that methylation of  non-coding regions can be used 
as prognostic biomarkers in colorectal cancer. Human DNA contains large numbers of  non-
coding repeat sequences, the most studied sequences being LINE and Alu repeats. LINE-1 
repeat sequences constitute about 17% of  the total human genome, are present on most of  the 
chromosomes, and comprise about 50 different subfamilies (7). Alu repeats constitute about 
11% of  the human genome (8). Because of  their abundance in the human genome, methylation 
of  LINE-1 and Alu sequences has been used as surrogate for genome-wide DNA methylation 
status (9). Hypomethylation of  both LINE-1 and Alu sequences has been associated with 
malignancies (10), including sporadic cases of  hemophilia (11) and several types of  solid tumors 
(12-18). In addition to DNA methylation, histone modifications play critical roles in regulating 
gene expression. Gene expression is dependent on the presence of  transcription factors, and 
mostly on the access of  these transcription factors to the transcription start sites. The chromatin 
structure surrounding the transcription start site, determined by the distance between individual 
nucleosomes comprised of  DNA wrapped around histone octamers, is determined by both 
DNA methylation and histone modifications and determines accessibility of  transcription 
factors to the DNA. DNA methylated at CpG sites in combination with “silencing” histone 
modifications, including trimethylation of  lysine 27 on histone H3 (H3K27me3), is associated 
with a closed chromatin structure with limited access for transcription factors to the DNA 
(illustrated in Rodenhiser et al.; 19). Unmethylated DNA in combination with “active” histone 
modifications, including acetylation of  lysine 9 on histone H3 (H3K9Ac) is associated with an 
open chromatin structure, which permits for gene transcription (19).
Given the recognized de-regulation of  these epigenetic mechanisms in cancer (3,20), we 
investigated whether both global DNA methylation and histone modification patterns can 
be used to predict clinical outcome in rectal cancer patients enrolled in a well-defined, strictly 
quality-controlled clinical trial (21).
Materials and methods
Patient selection
Formalin-fixed paraffin-embedded (FFPE) specimens were collected from patients enrolled 




no evidence of  disease after surgical resection and a median follow-up of  7 years. Patient 
characteristics are displayed in Table 1. Informed consent was obtained from all patients enrolled 
in the TME trial. The study was approved by the Medical Ethical Committee of  the Leiden 
University Medical Center. Western IRB permission was obtained for assessment of  patient 
specimens at John Wayne Cancer Institute. A pilot study was performed using 30 primary rectal 
tumor FFPE specimens, TNM tumor stages I (n=10), II (n=12) and III (n=8), and 25 normal 
rectal tissues resected at least 5 cm away from the tumor. TNM tumor stages were defined 
according to the American Joint Committee on Cancer, AJCC staging system (1).
For the validation study, a patient selection (n=189) representative for the non-irradiated arm 
of  the TME trial was made based on sex, age at randomization, and circumferential margin 
involvement, with TNM tumor stages I (n=53), II (n=43), III (n=85) and IV (n=8). 53 additional 
normal rectal tissues were collected, with 45 out of  the 53 cases having matching primary tumor 
specimens included in the study. Histone modifications were assessed on 132 tumor tissues and 
50 normal tissues included in the validation cohort of  the LINE-1 study and present on a tissue 
microarray (described below). This study was performed according to the REMARK guidelines 
(NCI-EORTC, (22)).
DNA extraction from FFPE specimens and quantification of  DNA for 
methylation assays
Tumor areas on H&E-stained sections of  FFPE tumor specimens were identified and marked by 
a pathologist. From each patient block, two 7µm FFPE sections were deparaffinized and stained 
with hematoxylin, followed by needle microdissection of  tumor areas. DNA was extracted using 
a proteinase K-based protocol as described previously (23) and quantified using a Quant-iT 
PicoGreen dsDNA kit (Molecular Probes, Eugene, OR, USA).
Bisulfite conversion and quantitative real-time PCR for methylation assays
For each sample, 200ng of  DNA was bisulfite-converted using the Epitect Bisulfite Kit (Qiagen; 
Valencia, CA); converted DNA was eluted in 50µl elution buffer. Both LINE-1 and Alu PCR-
based assays have been described previously (24,25). Quantitative real time PCR for LINE-1 
sequences (according to the MIQE guidelines; 26) was performed using universal primers and a 
locked nucleic acid (LNA) probe specific to the bisulfite-converted Methylated or Unmethylated 
LINE-1 consensus L1.2 sequence. Primer and probe sequences were as follows: LINE-1 Forward 
5’-GGGTTTATTTTATTAGGGAGTGTTAGA-3’, LINE-1 Reverse 5’-TCACCCCTTTCTT 
TAACTCAAA-3’, LINE-1 FAM-M-Probe (LNA): 5’-TG+CG+CGAGT+CGAAG-3’, 
LINE-1 FAM-U-Probe (LNA): 5’-TG+TG+TGAG+T+T+GAA+GTAG-3’. Thermal 
cycling reactions were as follows: hot start for 3 minutes at 95°C, followed by 45 cycles of  
denaturing at 95°C (15 seconds) and annealing/extension at 60°C (1 minute). For Alu repeat 
sequences, quantitative real time PCR was performed as described previously (27). Primer 
and probe sequences specific for the Alu consensus sequence were as follows: Alu Forward: 
5’-GTTTGGTTAATATGGTGAAATT-3’, Alu Reverse: 5’-ATTCTCCTACCTCAACC-3’, 
Alu FAM-M-Probe (LNA): 5’-A+AC+GCGCGCCAC-3’, Alu FAM-U-Probe (LNA): 
5’-AAC+AC+A+CACCA+CCA-3’. Thermal cycling reactions were as described for LINE-1, 
but with annealing/extension at 58°C. Quantitative PCR reactions were run on a 384 CFX
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TABLE 1.  Patient characteristics of  the pilot and validation study groups.
All patients non-
irradiated arm TME trial 
(n=769)
Pilot study Validation study
(n=30) (n=189)
n (%) n (%) n (%)
 Sex
 Male 488 63.5 16 53.3 129 68.3
 Female 281 36.5 14 46.7 60 31.7
 Age at randomization
 Mean 64.4 64.1 63.9
 Standard error 0.405 2.30 0.811
 TNM stage
 I 224 29.6 10 33.3 53 28
 II 195 25.8 12 40 43 22.8
 III 281 37.2 8 26.7 85 45
 IV 56 7.4 8 4.2
 Circumferential margin
 Negative 621 80.8 29 96.7 152 80.4
 Positive 148 19.2 1 3.3 37 19.6
 Tumor location
 Rectum 679 90.1 26 86.7 161 85.6
 Anal region 54 7.2 3 10 20 10.6
 Other 21 2.8 1 3.3 7 3.7
Patient characteristics are shown for both the pilot and validation study groups. Patient selection for the pilot study 
was based on TNM stage. Patient selection for the validation study was based on availability of  FFPE tissues and all 
listed variables, i.e. sex, age at randomization, TNM stage, circumferential margin involvement and tumor location. 
The validation study selection was representative for the entire non-irradiated patient cohort.
thermal cycler (BioRad, Benicia, CA). A serial dilution of  plasmids with either the methylated or 
the unmethylated sequence was used to generate standard curves for quantification. Triplicates 
of  each sample (20ng DNA per reaction) were run on the same plate, and mean copy numbers 
(CN) were used for statistical analyses. Measurements were repeated when triplicates varied 
>2 Cq values. Controls used in both LINE-1 and Alu methylation assays were universally 
methylated DNA (UMC; Millipore, Billerica, MA), universally unmethylated DNA obtained by 
repeated whole genome amplification of  PBL DNA (UUC; Repli-g kit Qiagen, Valencia, CA), 
and peripheral blood lymphocytes. Specific methylated cell line controls for LINE-1 methylation 
assays were melanoma cell line M12 and for Alu methylation assays breast cancer cell line 
MCF-7. Methylation percentages were calculated as follows: methylation percentage = CN 




Immunohistochemical staining and semi-automated scoring of  histone 
modifications
Tumor and normal tissue FFPE blocks with enough tissue available were selected from patients 
enrolled in the non-irradiated arm of  the Dutch TME clinical trial. Tumor cores from 496 
patients, and normal tissue cores (taken at least 5cm away from the tumor) from 334 patients 
enrolled in the Dutch TME clinical trial were included to construct a tissue microarray (TMA). 
From each donor block, three 1-mm2 tissue cores from strictly tumor areas or one tissue core 
from normal tissue areas (center) as marked by an experienced pathologist were punched and 
transferred into a recipient paraffin block using a TMA Master (3DHistech, Budapest, Hungary). 
4.5μm tissue sections of  the TMAs were cut and processed for immunohistochemical staining. 
TMA sections were stained using mouse anti-H3K27me3 (dilution 1:200; ab6002, Abcam, 
Cambridge, UK) or rabbit anti-H3K9Ac (dilution 1:600, ab8898, Abcam, Cambridge, UK), using 
a standard IHC protocol (28). Briefly, antigen retrieval was performed by heating the sections 
for 10 min at 95°C in a citrate buffer (pH 6.1; pH low Target Retrieval Solution, Dako, Heverlee, 
Belgium) after deparaffinization. Endogenous peroxidase was blocked by incubating the sections 
in a 0.3% solution of  hydrogen peroxide (in PBS) for 20 min. Sections were incubated with 
primary antibodies overnight (16 hrs). Immunohistochemical staining was visualized using 
the Dako REAL™ EnVision™ Detection System, Peroxidase/DAB+, Rabbit/Mouse (Dako, 
Heverlee, Belgium). Immunohistochemically stained tissue microarrays were scanned at 20x 
magnification on the Ariol system (Leica Microsystems, Rijswijk, The Netherlands). Expression 
of  histone modifications was scored using the semi-automated Ariol system. Tumor areas were 
marked on the computer upon visual inspection, followed by training of  the system to correctly 
identify positively stained and negative nuclei in the tissues, for each of  the markers separately. 
Intensity of  the staining was measured by the Ariol system and divided into three categories. The 
Ariol system was trained to count the number of  cells in each category and to calculate a mean 
intensity score for each tissue core. Patients were divided into high and low intensity groups for 
each histone modification based on the median intensity score.
Statistical analysis
Statistical analysis of  the data was performed in consultation with a biostatistician (H.P.) using 
statistical software SPSS version 20.0 (PASW Statistics, IBM Statistics, New York). Differences 
in mean LINE-1 methylation between the different TNM tumor stages were calculated using 
a Student’s t-test (data were normally distributed). Univariate Cox Regression analyses were 
performed to calculate differences in survival time and tumor recurrence between patients with 
a high or a low methylation index (LINE-1 and Alu) or staining intensity (histone modifications). 
Cutoff  points for the division of  patients into the different patient groups were based on median 
intensity for the histone modifications and on median methylation index for LINE-1 or Alu. 
For histone modification analyses, only patients included in the LINE-1 validation study were 
used (tumors n=132, normal tissues n=63). For each patient, three cores (either three tumor 
or three normal cores) were scored and mean intensity scores were calculated for each patient. 
Tumor cores with non-specific staining were excluded from the analyses (n=13). Kaplan-Meier 
survival curves were made to visualize survival differences between high and low methylation 
groups (LINE-1) and high and low staining intensity (histone modifications) and statistical 
significance was assessed using the log-rank test. All time-to-event variables were calculated 
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from the date of  surgery. Competing risk analyses were performed for cancer-specific survival 
and recurrence analyses in order to prevent overestimation of  the number of  events in each 
of  the categories. Multivariate analyses using LINE-1 methylation or staining intensity of  the 
histone modifications as continuous data were performed using the Cox proportional hazards 
model. Covariates entered in the multivariate model were age at time of  surgery, circumferential 
margin, TNM-stage and tumor location. For all analyses, a two-sided p-value of  0.05 or less 
was considered statistically significant. Data were censored when patients were alive or free of  
recurrence at their last follow-up date. 
Results
Methylation assay verification
To ensure a good performance and reproducibility of  the LINE-1 and Alu methylation assays, 
we performed several quality checks. To verify the reproducibility of  the assays, we ran a test set 
of  8 patient samples for both Alu and LINE-1 methylation assays, which were independently 
repeated. Variation in methylation percentages between the two experiments was 0.1-1.6% 
for LINE-1 and 0.1-1.2% for Alu. Control samples included on every plate showed minimal 
inter-plate variability (<7%). Standard deviations were 6.6% for UMC and 3.8% for PBL in the 
LINE-1 methylation assays and 4.3% for MCF-7 and 5.4% for UMC in the Alu methylation 
assays. The limit of  detection of  this assay was as low as 100 copies of  the respective plasmids 
in each reaction. Standard curves using plasmids of  either the methylated or unmethylated 
sequences were highly reproducible for all assays, with R2 values of  0.947 or higher between the 
duplicates on each of  the individual plates. Taken together, the LNA-probe-based real-time PCR 
method used in this study proved to be very robust and reproducible.
LINE-1 methylation
The pilot study for LINE-1 methylation showed decreasing levels of  methylation with increasing 
TNM tumor stage (Figure 1A). Normal tissues showed the highest LINE-1 methylation 
percentage as compared to tumor tissues, with an average difference between matching tumor 
and normal samples (n=8) of  14.2%. Levels of  LINE-1 methylation were significantly different 
across TNM tumor stages and between normal and tumor samples (normal vs T1, p=0.024; 
across TNM tumor stages, p<0.001). 
In the validation study, decreasing levels of  methylation were observed with increasing TNM 
tumor stage (p<0.001) (Figure 1B). The mean difference between the matching normal and 
tumor samples (45 out of  53) was 21.6%, with a consistently higher methylation percentage 
in the normal samples. Univariate analyses showed low levels of  LINE-1 methylation to be 
correlated with shorter survival (p=0.006; HR=5.169) and higher chance of  distant recurrence 
(p=0.003; HR=9.943) in stage I and II rectal cancer patients (Table 2). Stage III and IV patients 
did not show any significant correlation of  LINE-1 methylation with survival and recurrence. 
Subsequent analyses were done with stage I and II patients only. Multivariate analyses of  the 
validation study data showed LINE-1 methylation status to be an independent predictor of  





Mean LINE-1 methylation percentages according to TNM tumor stage in rectal cancer patients. Mean 
methylation percentages are shown for the different TNM tumor stages. Methylation percentages were calculated as 
follows: methylated copy number / (methylated copies + unmethylated copies) * 100%. A. Mean LINE-1 methylation 
percentages are shown for different TNM tumor stages of  the pilot study samples. The different TNM tumor stages 
are indicated as I, II and III, normal samples are indicated as ‘normal’. B. and C. Mean LINE-1 and Alu methylation 
percentages, respectively, are shown for different TNM tumor stages of  the validation study samples. The different TNM 
tumor stages are indicated as I, II, III and IV, normal samples are indicated as ‘Normal’. 
cancer patients (Table 2). Kaplan-Meier survival and cumulative incidence curves were generated 
(Figures 2A and 2B) to visualize differences in survival and recurrence between high and low 
LINE-1 methylation groups, based on median methylation percentage (57.4%) of  stage I and 
II patients in the validation study. The log-rank test showed that patients with low LINE-1 
methylation have shorter survival times and a higher chance of  tumor recurrence than patients 
with a higher methylation percentage. Significant differences were observed for overall survival 
(p=0.006), overall recurrence (p=0.0017) and distant recurrence-free survival (p=0.003). No 
difference was found for local recurrence (p= 0.95), which can be explained by the fact that 
survival is mainly determined by distant metastases rather than local recurrences. The multivariate 
analyses showed that patients with a low level of  LINE-1 methylation have a 9-fold higher chance 
of  distant recurrence of  the tumor and a 5-fold lower chance of  survival than patients with a 
high LINE-1 methylation level (Table 2). No correlation was found between LINE-1 methylation 
and lymphocyte infiltration (p=0.22), a factor known to impact clinical outcome in colorectal 
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TABLE 2.  Univariate and multivariate analyses for both patient survival and tumor recurrence 
in patients with stage I and II rectal tumors.






p-value(95% CI) (95% CI) (95% CI)
 LINE-1 univariate analysis
 LINE-1 methylation
5.239 0.006 0.892 0.951 9.943 0.003
(1.589-17.268) (0.0.23-34.803) (2.476-30.028)
 LINE-1 multivariate analysis
 Age
1.028 0.080 0.931 0.223 0.957 0.068
(0.997-1.061) (0.829-1.045) (0.913-1.003)
 Circumferential margin
1.352 0.642 0.513 0.962 1.778 0.609
(0.380-4.817) (0.164-2.839) (0.196-16.168)
 TNM
1.570 0.178 0.230 0.964 1.907 0.269
(0.814-3.028) (0.096-1.469) (0.607-5.995)
 Tumor location
1.336 0.437 0.346 0.974 4.606 0.001
(0.643-2.776) (0.123-1.896) (1.932-10.983)
 LINE-1 methylation
4.568 0.014 1.438 0.877 9.576 0.001
(1.359-15.351) (0.14-146.4) (4.443-47.131)
 Alu univariate analysis
 Alu methylation
1.269 0.453 1.093 0.929 1.897 0.215
(0.681-2.361) (0.154-7.763) (0.689-5.227)
 Alu multivariate analysis
 Age
1.391 0.039 0.483 0.207 0.696 0.100
(1.016-1.904) (0.156-1.494) (0.451-1.072)
 Circumferential margin
1.135 0.846 1.978 0.080 0.735 0.782
(0.316-4.077) (0.699-5.604) (0.083-6.500)
 TNM
1.209 0.500 0.245 0.165 1.462 0.427
(0.697-2.097) (0.034-1.780) (0.573-3.731)
 Tumor location
1.199 0.625 0.203 0.989 2.332 0.038
(0.579-2.484) (0.029-1.543) (1.046-5.201)
 Alu methylation
0.996 0.690 0.985 0.613 0.980 0.185
(0.979-1.014) (0.928-1.045) (0.952-1.010)
Survival analyses are shown for stage I and II patients only. The total number of  patients included in the analyses was 
n=96. Hazard ratios are displayed for both Cox proportional hazard univariate and multivariate analyses and 95% 
confidence intervals are given for LINE-1 methylation. In multivariate analyses, age was entered as a continuous variable. 
For circumferential margin the ‘negative’ group was used as reference, for TNM the stage I group was used as reference. 
Tumor location was divided into the categories rectum, anal region, or other, using rectum as the reference category. 





Survival curves of  stage I and II rectal cancer patients by LINE-1 methylation status. Kaplan-Meier curves 
were made to visualize differences in survival and recurrence between patients with high and low LINE-1 methylation 
status. Log-rank tests were performed to calculate the difference between the low and high LINE-1 methylation groups. 
Survival times were calculated as time from surgery till an event (death or recurrence, respectively). A. Kaplan-Meier 
curves showing overall survival of  the high and low methylation groups based on LINE-1 methylation status. Patients at 
risk are displayed for each of  the groups. B. Cumulative incidence curves showing distant recurrence in the high and low 
methylation groups based on LINE-1 methylation status. Patients at risk are displayed for each of  the groups.
but Alu methylation was not. Chi-square (p=0.38) and Pearson’s correlation (p= -0.306) analyses 
confirmed that Alu methylation and LINE-1 methylation indeed did not correlate. Similarly, 
in multivariate analyses, the interaction between Alu and LINE-1 methylation did not show 
significant correlation with survival (p=0.23). This confirmed that Alu and LINE-1 methylation 
did not have a similar effect on patient survival and tumor recurrence in this set of  rectal cancer 
patients, suggesting that LINE-1 may be involved in specific tumor progression events that 
affect disease outcome in rectal cancer, rather than reflecting a genome-wide methylation status.
Alu methylation
To investigate if  LINE-1 methylation did indeed represent genome-wide methylation status, 
we studied methylation of  Alu repeat sequences in the same patient cohort. The levels of  Alu 
methylation were not significantly different between normal and tumor tissues (pilot study; 
p=0.24) or between patients with or without a recurrence (pilot study; p=0.27). Alu methylation 
levels did not differ between the different TNM tumor stages in either the pilot (p=0.11) or 
the validation study (p=0.73; Figure 1C). The mean difference in Alu methylation percentage 
between normal and matching tumor tissues was 1.03% in the validation series. 
Survival analyses on the data in the validation series did not show any significant differences 
using a cutoff  based on median Alu methylation percentage (60%). Neither overall survival nor 
overall recurrence did show differences between the groups (p=0.65 and p=0.31, respectively). 
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Selection of  stage I and II patients only, as described for the LINE-1 methylation studies, did not 
change outcomes of  either univariate or multivariate survival analyses (Table 2).
Histone modifications
Histone modifications H3K27me3 and H3K9Ac were assessed by IHC on TMA sections. Only 
patients included in the LINE-1 validation study were used for histone modification analyses 
(tumors n=132, normal tissues n=63). Semi-automated analyses using the Ariol System yielded 
intensity scores for each of  the individual tumor cores. Correct identification of  positive and 
negative cells by the Ariol system is shown in Figure 3. Mean intensity scores of  three tumor 
tissue cores were calculated for each patient and used for survival analyses. Patients were divided 
into high and low intensity groups for each histone modification based on the median intensity 
score. H3K27me3 intensity scores ranged from 0 - 63.14, H3K9Ac intensity scores ranged from 
0 - 67.84. Median intensity scores were 50.59 in normal tissues and 48.20 in tumor tissues for 
H3K9Ac (p=0.053) and 49.41 in normal tissues and 51.77 in tumor tissues for H3K27me3 
(p=0.002). H3K9Ac and H3K27me3 intensities in tumor tissues showed an inverse correlation, 
with p=0.024. 
Figure 3
Identification of  positively stained and negative tumor cells by the Ariol system. The Ariol system trainer overlay 
shows correct identification of  positive (yellow dots) and negative (blue dots) cells on tumor cores. TMA slides were 
scanned using a 20x magnification. Shown for both H3K9Ac and H3K27me3 are highly positive tumor cores (A and D), 
tumor cores with both positive and negative cells (B and E) and negative tumor cores (C and F). The Ariol system was 
trained to identify positive and negative cells for each individual marker.
H3K9Ac 
A B C 
H3K27me3 
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Survival analyses are shown for H3K27me3 and H3K9Ac staining intensity. The total number of  patients included 
in the analyses was n=63 for H3K27me3 analyses and n=61 for H3K9Ac analyses, corresponding to LINE-1 low 
and high methylation categories, respectively. Hazard ratios are displayed for both Cox proportional hazard univariate 
and multivariate analyses and 95% confidence intervals are given for the histone modification intensity entered as a 
continuous variable. In multivariate analyses, age was entered as a continuous variable. For circumferential margin the 
‘negative’ group was used as reference, for TNM stage I was used as reference. Tumor location is divided into the 
categories rectum, anal region, or other, using rectum as the reference category. Statistically ignificant values are indicated 
in bold.
Both H3K27me3 (p=0.049) and H3K9Ac (p=0.14) show differences in overall survival 
between high and low intensity groups (Figures 4A and 4B, respectively). For H3K27me3, low 
intensity scores are correlated with worse overall survival, whereas for H3K9Ac, high intensity is 
correlated with worse overall survival. As for tumor recurrence, histone modification intensities 
were correlated with local recurrence with H3K27me3 (p=0.001) and H3K9Ac (p=0.084), but 
not with distant recurrence with H3K27me3 (p=0.172) and H3K9Ac (p=0.291). Multivariate 
analyses including LINE-1 methylation and histone modification intensities as continuous 
variables showed that LINE-1 methylation is a dominant factor in determining clinical outcome, 
as adding histone modification intensities did not improve the multivariate model. LINE-1 
TABLE 3.  Univariate and multivariate analyses for histone modifications in rectal cancer 
patients.
H3K27me3 H3K27me3 H3K9Ac
LINE-1 methylation low LINE-1 methylation low LINE-1 methylation high




HR p-value HR p-value HR p-value
(95% CI) (95% CI) (95% CI)
 Univariate analysis
 Intensity histone  
 modification staining




1.070 0.001 1.044 0.274 1.012 0.739
(1.030-1.113) (0.948-1.134) (0.937-1.088)
 Circumferential margin
2.003 0.198 1.187 0.852 1.150 0.309
(0.696-5.768) (0.845-6.775) (0.912-1.136)
 TNM
3.826 0.000 9.846 0.159 0.318 0.582
(1.034-5.082) (0.364-20.682) (0.116-1.863)
 Tumor location
3.329 0.115 0.249 0.968 0.415 0.979
(0.782-5.552) (0.036-0.905) (0.051-3.915)
 Intensity histone  
 modification staining
0.249 0.001 0.067 0.016 1.069 0.235
(0.107-0.582) (0.007-0.599) (0.973-1.274)
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methylation showed correlation with overall survival (with addition of  H3K27me3 p=0.062 and 
H3K9Ac p=0.15) and distant recurrence-free survival (with addition of  H3K27me3 p=0.019 
and H3K9Ac p=0.018), but not with local recurrence-free survival (with addition of  H3K27me3 
p=0.82 and H3K9Ac p=0.97). 
In order to further study the relationship between LINE-1 methylation and histone modifications, 
we stratified histone modifications according to LINE-1 methylation levels. H3K27me3 intensity 
was found to significantly correlate with overall survival (p=0.020) and local recurrence-free 
survival (p=0.017) only when LINE-1 methylation was low (Figures 5A and 5C, respectively). 
Within this patient subset with low LINE-1 methylation, patients with high H3K27me3 
intensity scores show better survival rates than patients with low presence of  H3K27me3. High 
H3K27 methylation could have a “protective” function in the cells, preventing deregulated 
gene expression when DNA methylation is absent. H3K27me3 did not show any differences 
between high and low intensity groups when LINE-1 methylation was high, with overall survival 
(p=0.37) and local recurrence-free survival (p=0.28), again indicating that LINE-1 methylation 
is a dominant factor determining clinical outcome in this patient group. Uni- and multivariate 
analyses for H3K27me3 also showed statistically significant differences between high and low 
staining intensity groups when LINE-1 methylation was low, both for overall survival (univariate 
p=0.024, multivariate p=0.001) and for local recurrence-free survival (univariate p=0.046, 
multivariate p=0.016) (Table 3). Stratifying H3K27me3 intensity scores according to Alu 
methylation status did not show any significant differences (Figures 5B and 5D). 
H3K9Ac intensity correlated with local recurrence-free survival (p=0.030) only when LINE-1 
methylation was high (Figure 5E). The presence of  H3K9 acetylation in combination with high
Figure 4
Survival curves of  histone modifications H3K27me3 and H3K9Ac by expression levels.  Survival curves were 
made to visualize differences in survival and recurrence between patients with high and low expression of  H3K27me3 
or H3K9Ac. Log-rank tests were performed to calculate the difference between the low and high H3K27me3 expression 
groups. Survival times were calculated as time from surgery till an event (death). A. Cumulative incidence curves showing 
overall survival of  the high and low methylation groups based on H3K27me3 expression. B. Cumulative incidence 
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Figure 5 (see previous page)  Survival curves of  histone modifications H3K27me3 and H3K9Ac according 
to LINE-1 or Alu methylation levels. Survival curves were made to visualize differences in survival and recurrence 
between patients with high and low expression of  H3K27me3 and H3K9Ac. Log-rank tests were performed to calculate 
the difference between the low and high H3K27me3 or H3K9Ac expression groups, respectively. Survival times were 
calculated as time from surgery till an event (death or recurrence). A. Overall survival based on H3K27me3 expression 
in the LINE-1 methylation low group. B. Overall survival based on H3K27me3 expression in the Alu methylation low 
group. C. Local recurrence-free survival based on H3K27me3 expression in the LINE-1 methylation low group. D. 
Local recurrence-free survival based on H3K27me3 expression in the Alu methylation low group. E. Local recurrence-
free survival based on H3K9Ac expression in the LINE-1 methylation high group. F. Local recurrence-free survival 
based on H3K9Ac expression in the Alu methylation high group.
levels of  DNA methylation could affect disease outcome through activation of  aberrant gene 
expression. H3K9Ac did not show any differences between high and low intensity groups when 
LINE-1 methylation was low, with overall survival (p=0.83) and local recurrence-free survival 
(p=0.68). Univariate analyses showed a trend for H3K9Ac, when LINE-1 methylation is high, 
with local recurrence-free survival (p=0.066) (Table3). Unfortunately, in multivariate analyses, 
this trend was no longer observed. H3K9Ac did not show a significant correlation with overall 
survival in either uni- or multivariate analyses. Stratifying H3K9Ac intensity according to Alu 
methylation status did not show any significant differences (Figure 5F).
Discussion
The results presented in this paper showed that LINE-1 methylation should be regarded as an 
independent prognostic biomarker in early-stage rectal cancer. LINE-1 and Alu methylation 
were assessed using quantitative PCR after needle microdissection of  tumor tissue areas, which 
were carefully marked by an experienced pathologist. Tumor tissue extracted using needle 
microdissection, in contrast to laser capture microdissection, may include more stromal tissue, 
including inflammatory cells. We therefore selected only tumor areas with >80% tumor epithelial 
cells, thereby minimizing the amount of  stroma included in these assays. Although previous 
reports showed an association of  lymphocytic infiltrates with clinical outcome (29) in colorectal 
cancer, in our rectal cancer study cohort we did not find a correlation between the amount of  
lymphocytic infiltrate and LINE-1 methylation that could influence our analyses. Therefore, it 
is not likely that our findings are influenced by stroma or infiltrating lymphocytes. In addition, 
Irahara et al. have shown, by direct comparison, that LINE-1 methylation levels are comparable 
between needle microdissected and laser capture microdissected tumor tissues, indicating that 
the effect of  contaminating cells on LINE-1 methylation is indeed minimal (30). BRAF mutation 
and MSI status were not determined in this study cohort, as the prevalence of  BRAF mutations 
(around 2%; 31,32) and MSI (around 2%; 33) is very low in rectal cancer. The impact of  these 
markers on clinical outcome in multivariate analyses would therefore be negligible.
Because we were looking for a rapid, robust, high-throughput and highly sensitive assay, we 
chose to use a quantitative real-time PCR assay instead of  pyrosequencing to measure LINE-1 
methylation. Pyrosequencing relies on PCR amplification of  the region of  interest, followed by 
sequencing of  this PCR-amplified product. According to Nelson et al. (34) and Irahara et al. (30) 
pyrosequencing of  LINE-1 sequences typically includes 3-6 CpG sites at the 5’ end of  LINE-1 
sequences, which is comparable to the quantitative real-time PCR assay conducted in this study. 
Also, as suggested in Figure 1 of  the pyrosequencing analysis by Irahara et al., the methylation 




very similar within one sample. Therefore, measuring the three CpG sites at once using the 
qPCR method, instead of  measuring individual CpG sites by pyrosequencing, is representative. 
In addition, for survival analyses conducted in this study, the median methylation percentage 
was used to divide the patients into high- and low-risk groups. As described by Irahara et al., the 
average of  the relative amounts of  methylated cytosines found using pyrosequencing was used as 
overall LINE-1 methylation level in each sample, which is a similar approach as we used with our 
qPCR data. Pyrosequencing information would probably result in a lower median methylation 
percentage, as hemimethylated CpGs can be accurately measured. However, this would yield a 
lower LINE-1 methylation percentage for every patient in our cohort and we expect this will 
not affect the distribution of  the patients into the two groups based on the median LINE-1 
methylation percentage. Therefore, we are confident the qPCR method used in this study was a 
valid method to study LINE-1 methylation.
In our study cohort, stage III and IV patients did not show a significant correlation of  LINE-1 
methylation with survival and recurrence, most likely because other clinical factors such as nodal 
status and circumferential resection margin involvement have a significant role in advanced stage 
cancers, overpowering the effect of  an earlier event in tumorigenesis. Epigenomic aberrations 
in tumors of  stage I and II patients without invasive tumor characteristics, however, may be 
associated with the development of  aggressive tumors and have clinical relevance for risk 
stratification. LINE-1 methylation has been described as an early-stage tumor marker in previous 
studies (18,35).
Methylation of  LINE-1 and Alu repeats have both been used as surrogate markers for genome-
wide methylation status (9). Based on the general hypothesis that tumorigenesis is associated 
with genome-wide DNA hypomethylation and locus-specific hypermethylation of  individual 
CpG islands (15,36), we expected to see a decrease in both Alu and LINE-1 methylation levels 
with increasing TNM tumor stage in rectal cancer tissues. However, as we showed here that 
Alu methylation, in contrast with LINE-1, did not change with tumor progression and that 
methylation levels of  LINE-1 and Alu did not correlate, our results suggest a more specific effect 
of  LINE-1 methylation in early rectal tumors instead of  reflecting a genome-wide methylation 
status. Other studies also suggest a specific role for LINE-1 methylation in tumorigenesis, while 
other repetitive sequences such as Alu repeats remain equally methylated (37). Active LINE-1 
sequences, an estimated 30-60 copies per cell, have retrotranspositional activity (38) and can 
relocate to other (non-)coding regions (7,13,39), thereby contributing to (epi)genetic variation 
(40,41). In normal cells, retrotransposition of  repeat sequence elements is repressed by methylation 
of  cytosine residues (42). Reintegration of  LINE-1 retrotransposons can disrupt genes and 
regulate their expression (43,44), as described for APC in colon cancer (16). Using the genome 
vicinity information of  the full-length active LINE-1 sequences provided in the L1base database 
(Max-Planck Institute Berlin and University of  Würzburg; 45), we found that several LINE-1 
sequences are located near or in (intronic) gene regions. As neighbouring DNA methylation 
patterns can influence nearby promoter regions (46,47) or longer stretches of  DNA, up to 
2kb distant (48), demethylation of  LINE-1 sequences might therefore represent demethylation 
events of  the coding gene promoters in their vicinity and hence influence expression of  genes 
in these regions, translating into worse clinical outcome for the patient. This hypothesis was 
further supported by Hur et al., who show that specific LINE-1 sequences residing in intronic 
regions of  several proto-oncogenes were hypomethylated in metastatic tissues compared to the 
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corresponding primary tumors (49), indicating that differentially methylated LINE-1 sequences 
can indeed influence progression of  colorectal tumors. 
Recent articles by Goel et al. and Ogino et al. describe that LINE-1 hypomethylation is correlated 
with shorter survival, independent of  clinical or molecular features, in non-MSI (microsatellite 
instability) familial tumors (50,51). Mechanisms predisposing patients with a family history 
of  (and thus early-onset) colorectal cancer, but with no evidence of  MSI or other molecular 
features, for the development of  a tumor are still unknown. The authors of  both articles 
conclude that LINE-1 might be an important factor promoting tumor growth in familial 
cases of  (MSS) colorectal cancers. In our study, consisting of  MSS rectal cancer patients, we 
also show a significant prognostic role for LINE-1 hypomethylation in determining clinical 
outcome. Together, these studies suggest that LINE-1 methylation might represent a frequently 
deregulated regulatory epigenetic mechanism that might promote primary tumor progression 
and metastasis of  rectal tumors. Hence, LINE-1 methylation may potentially serve as a new 
biomarker to identify high-risk patients. Future studies will have to be performed to validate the 
clinical utility of  LINE-1 in rectal cancer. 
The histone modifications reported in this study support the clinical impact of  genome-
wide changes in epigenetic modifications in rectal cancer patients. On the basis of  our 
current knowledge about the interplay between histone modifications and DNA methylation, 
we hypothesized that silencing modification H3K27me3 should follow the same pattern as 
LINE-1 methylation, as both epigenetic mechanisms are involved in silencing of  gene expression. 
Indeed, low expression of  H3K27me3 was associated with worse survival. The finding that 
H3K27me3 was associated with clinical outcome only when LINE-1 methylation is low, 
supports the generally accepted hypothesis that DNA methylation and histone modifications 
together control gene expression and thereby define the cellular phenotype. Activating histone 
modification H3K9Ac was expected to show opposite results, as the presence of  this histone 
modification will lead to (aberrant) activation of  gene expression. Indeed, high expression of  
H3K9Ac was associated with a shorter survival and higher chance of  recurrence compared 
to patients with low H3K9Ac expression. As both H3K27me3 and H3K9Ac expression only 
correlate with LINE-1 methylation and not with Alu methylation, we again conclude that 
LINE-1 methylation may be involved in specific tumor progression events in rectal cancer, 
rather than reflecting genome-wide methylation status in these tumors. Histone modifications 
H3K27me3 and H3K9Ac intensity scores can further subdivide rectal cancer patients into 
high- or low risk groups when stratified according to LINE-1 methylation status. This indicates 
that LINE-1 methylation and histone modifications work closely together in determining gene 
expression and hence tumor progression and ultimately clinical outcome.
In conclusion, we have shown in this study that LINE-1 methylation is an independent predictor 
of  survival and recurrence in early-stage rectal cancer. Expression of  histone modifications 
H3K9Ac and H3K27me3 further supports an active role in rectal cancer progression of  
LINE-1. Further research should be conducted to investigate the exact function of  LINE-1 
elements, and their influence on neighbouring genes, in order to better understand the complex 
nature of  the rectal tumorigenic process. We show here that methylation of  LINE-1 repeat 
sequences can be used as a biomarker to distinguish rectal cancer patients with a high risk of  
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Deregulation of  the apoptotic pathway, one of  the hallmarks of  tumor growth and -progression, 
has been shown to have prognostic value for tumor recurrence in rectal cancer. In order to 
develop clinically relevant biomarkers, we studied the methylation status of  promoter regions 
of  key apoptosis genes in rectal cancer patients, using methylation-sensitive restriction enzymes. 
DNA was extracted from fresh-frozen tumor tissues of  49 stage I-III rectal cancer patients 
and 10 normal rectal tissues. The results of  this pilot study were validated in 88 stage III tumor 
tissues and 18 normal rectal tissues. We found that methylation of  the intrinsic apoptotic pathway 
genes Apaf1, Bcl2 and p53 correlated with the apoptotic status (M30) of  the tumor. Combined 
survival analyses of  these three genes, on the basis of  the number of  genes showing high 
methylation (all low, 1 high, 2 high or all high), showed shorter patient survival and recurrence-
free periods with an increasing number of  methylated markers. Multivariate analyses showed 
significant differences for overall survival (p=0.01; HR=0.28 (0.09-0.83)), cancer-specific survival 
(p=0.004; HR=0.13 (0.03-0.67)) and distant recurrence-free survival (p=0.001; HR=0.22 (0.05-
0.94)). The shortest survival was observed for patients showing low methylation of  all markers, 
which – as was expected - correlated with high apoptosis (M30), but also with high proliferation 
(Ki-67). The study of  epigenetic regulation of  apoptosis genes provides more insight in the 
tumorigenic process in rectal cancer and might be helpful in further refining treatment regimens 
for individual patients.




Apoptosis is one of  the major pathways frequently deregulated in cancer (1-3). Deregulation 
of  this pathway provides the tumor cell with a survival advantage and thereby promotes tumor 
growth and -progression. The apoptotic process is complicated and can be activated by stress or 
damage to the cell (intrinsic pathway), or by external factors (initiation by the immune system; 
extrinsic pathway), with both pathways converging at the level of  the caspase cascade. This 
cascade eventually leads to cleavage of  key proteins for cell structure and -function, causing 
fragmentation of  the DNA, membrane blebbing and ultimately removal of  the destructed cell 
by macrophages (4). Previous studies have demonstrated that high levels of  apoptosis in rectal 
cancer specimens correlated with low levels of  local tumor recurrence (5-7). A malfunctioning 
apoptotic pathway could also explain a poor response to anti-cancer treatment strategies such as 
pre-operative radiotherapy (RT).
Current treatment regimens of  rectal cancer patients include radical removal of  the primary 
tumor including all regional tumor cell deposits according to the Total Mesorectal Excision 
(TME) technique. In addition to TME surgery, the majority of  stage I and II patients and all 
stage III patients receive pre-operative RT in order to reduce the local recurrence rate (8), on the 
basis of  data provided by several large randomized clinical trials (9-11). Unfortunately, treating 
all rectal cancer patients with pre-operative RT results in overtreatment of  many individuals, 
as only a small number of  patients - those who would develop a local recurrence - potentially 
benefit from this treatment and not all of  these patients will respond to the therapy. Most of  the 
patients treated with pre-operative RT will suffer from the side-effects such as increased risks of  
poor anal and sexual function, small bowel toxicity with obstruction and secondary malignancies 
(12-14).
The goal of  this study was to investigate the regulation of  the apoptotic pathway through DNA 
methylation, in order to better understand the biological processes underlying tumor growth 
and -progression in rectal cancer. Epigenetic mechanisms, responsible for regulation of  gene 
transcription, have been shown to be deregulated in many cancers (15-18), thereby altering 
the expression levels of  many genes in tumor cells. We aim to develop biomarkers that will 
assist in treatment decisions in rectal cancer patients. For this study we chose to focus on the 
apoptosis genes Apaf1, Bcl2, p53, Fas (CD95), and TrailR2, as a review of  the current literature 
indicated these apoptotic proteins to have prognostic value in cancer (19-27). We hypothesized 
that methylation of  the promoter region of  these genes would represent deregulation of  the 
apoptotic pathway and, therefore, would correlate with patient survival and tumor recurrence 
in rectal cancer. Methylation assays were performed on DNA extracted from frozen tumor 
tissues of  patients enrolled in the Dutch Total Mesorectal Excision (TME) trial (28,29) using 
a methylation-sensitive restriction enzyme-based approach (30). We also assessed tumor 
cell proliferation status in this study, as a delicate balance may exist between apoptosis and 
proliferation in determining clinical outcome.
Materials and methods
Patient selection




of  the Dutch TME trial (28,29). We selected patients with no evidence of  disease after surgical 
resection of  the tumor and of  whom frozen tissue blocks were available (n=137) (28,29,31). 
Samples were collected between 1996 and 1999 and stored at -80ºC. The median follow-up 
time in this study cohort was 6 years. Trial eligibility criteria and follow-up protocols have been 
described previously (31-33). Informed consent for the use of  tumor specimens was obtained 
from all patients enrolled in the TME trial and the study has been approved by the Medical 
Ethical Committee of  the Leiden University Medical Center. For the pilot study, frozen tumor 
tissues of  49 patients with stage I, II, or III rectal cancer were collected. In addition, normal 
colorectal tissues, taken at least 5 cm away from the tumor, were collected from 10 patients 
included in this study. The validation study consisted of  a set of  88 frozen tumor tissues of  
patients with stage III rectal cancer of  whom sufficient frozen tissue was available, and 18 normal 
rectal tissue samples. Clinicopathological parameters of  all patients included in this study have 
been summarized in Table 1. This study was performed according to the REMARK criteria (34).
DNA extraction and enzyme digestion
DNA was extracted from frozen tissues using a Trizol-based protocol according to 
manufacturer’s recommendations (Life Technologies Corp, Bleiswijk, the Netherlands). DNA 
was dissolved in Tris-EDTA buffer pH 8.0 and quantity was measured using a Nanodrop 
spectrophotometer (Thermo Scientific, Wilmington, DE). To analyze the methylation status 
of  specific promoter regions, we used methylation-sensitive restriction isoschizomers MspI 
(New England Biolabs, Ipswich, MA; R0106L) and HpaII (New England Biolabs, Ipswich, MA; 
R0171L). The isoschizomeric restriction enzymes share restriction site C^CGG but whereas 
MspI cuts the DNA irrespective of  DNA methylation, HpaII is blocked by methyl groups at 
CpG dinucleotides. Reactions were optimized according to the manufacturer’s procotol (New 
England Biolabs, protocol “Optimizing restriction endonuclease reactions”). 250 ng of  DNA 
was used for each digestion reaction. Per reaction, 25 units of  HpaII and 100 units of  MspI were 
used in combination with their respective buffers (5μl) in a total reaction volume of  50 µl. Mock 
digestions were included for every sample, substituting the restriction enzymes with 5 µl 50% 
glycerol. Overnight incubation for 16 hours at 37°C of  all reaction mixtures was followed by heat 
inactivation for 20 min at 65°C, and subsequent cooling down of  the samples to 4°C. Incubation 
times and conditions were optimized using the active (non-methylated) housekeeping gene β2-
microglobulin (B2m) and the silenced (methylated) gene Myogenic differentiation 1 (MYOD1) 
that is only activated in muscle tissue. Methylated (universally methylated DNA, UMC; Millipore, 
Billerica, MA) and unmethylated (DNA from peripheral blood leukocytes, PBL, 5 different 
patients) controls were included in every digestion assay and on every PCR plate. We verified 
for every digestion procedure that >75% of  the DNA participated in the digestion reactions, 
measured as Ct>2 between the MspI- and mock-treated samples, and that the PCR product after 
digestion with HpaII was less than the product in the mock-treated samples. 
Real-time PCR
PCR was performed in duplicate for apoptosis markers Apaf1, Bcl2, TrailR2, p53 and Fas 
(CD95) using genomic DNA primers surrounding (but not including) at least two enzyme 
restriction sites per amplicon. PCR was performed using 20 ng DNA, 2 pmol/µl primers 
DNA methylation of  apoptosis genes in rectal cancer
41
3
and PerfeCTa® SYBR® Green SuperMix for iQ™ (Quanta Biosciences, Gaithersburg, MD, 
USA) in a final volume of  10 µl. Melting curves were used to ensure a single PCR product 
for each of  the markers, and PCR products were run on a 1% agarose gel to ensure for 
correct size of  the products. Quantitative PCR reactions were run on a 96 well CFX thermal 
cycler (BioRad, Benicia, CA). Methylated (UMC) and unmethylated controls (DNA from 
PBL) were included on every PCR plate. Thermal cycling reactions were as follows: hotstart 
for 3 min at 95°C, followed by 40 cycles of  denaturing for 10 sec at 95°C and annealing/
extension for 30 sec at the optimal melting temperatures for each primer set, as indicated 
below. Primer sequences and melting temperatures per primer set were as follows: Apaf1 
Forward 5’- TTGACTGCTCCGCTGTC -3’; Apaf1 Reverse 5’- TCCCCACCTCTGGTTCT 
-3’ (Tm 63°C); Fas Forward 5’- CCAACTTCCCAGGTTGAA -3’; Fas Reverse 
5’- GCACAAATGGGCATTCC -3’ (Tm 63°C); p53 Forward 5’- GTATCTACGGCACCAGGTC 
-3’; p53 Reverse 5’- CATGACAAGTAAGGGCAACT -3’ (Tm 62°C); Bcl2 Forward 
5’- GGTCCCGTGGATAGAGAT -3’; Bcl2 Reverse 5’- GCAGATGAATTACAATTTTCAG 
-3’ (Tm 56°C); TrailR2 Forward 5’- CCTGGGAAGGGGAGAAGAT -3’; TrailR2 Reverse 
5’- AGTTGAGGGAGGCACTTGG -3’ (Tm 60°C). Primer sequences for methylation controls 
B2m and MYOD1 were as follows: B2m Forward 5’- GCCTTCTTAAACATCACGAG 
-3’; B2m Reverse 5’- CCAGCCAATCAGGACAA -3’ (Tm 58°C); MYOD1 Forward 
5’- TACAGCCGCTCTACCCAT -3’; MYOD1 Reverse 5’- CTCCAACACCCGACTGC -3’ (Tm 
60°C). Methylation percentages were calculated as follows: methylation percentage = 2^- (Ct 
HpaII-treated samples – Ct mock-treated samples) x 100%. The amount of  product detected 
after digestion with MspI was used to calculate the percentage of  the DNA that was digested by 
the restriction enzymes, using the following formula: 2^-(Ct MspI-treated samples – Ct mock-
treated samples) x 100%. 
Immunohistochemical staining and scoring
Whole tumor tissue sections (4μm) of  117 patients of  whom enough paraffin-embedded 
tumor tissue was available were IHC stained using a primary M30 antibody (Roche Diagnostics, 
Germany), staining for caspase-cleaved cytokeratin 18 (7). Whole tissue sections (4μm) of  40 
patients in the validation study, representative of  the complete series of  stage III patients, were 
IHC stained at predetermined optimal concentrations using anti-Apaf1 (ab53152; Abcam, 
Cambridge, UK), anti-Bcl2 (ab7973; Abcam, Cambridge, UK), or anti-p53 (M7001; Dako, 
Glostrup, Denmark). A tissue microarray (TMA) was constructed including 495 patients 
from the non-irradiated arm of  the Dutch TME trial. Three 1mm2 tumor tissue cores were 
punched from each tumor block and transfered to a recipient block using a TMA Master (3D 
Histech, Budapest, Hungary). TMA sections, including 119 patients of  our study cohort, were 
IHC stained at a predetermined optimal concentration with primary Ki-67 antibodies (Dako, 
Glostrup, Denmark; clone MIB-1). For all IHC stainings, tissue sections were incubated with 
the respective primary antibodies overnight (16 hrs). IHC staining was visualized using the Dako 
REAL™ EnVision™ Detection System, Peroxidase/DAB+, Rabbit/Mouse (Dako, Glostrup, 
Denmark). The level of  apoptosis was scored as the number of  M30-positive cells per mm2, as 
described previously (5). Patients were classified into high or low apoptosis groups, on the basis 
of  the median number of  M30-positive cells. The level of  proliferation (Ki-67) was scored as the 




(3 tumor cores) was used to classify patients into either high or low proliferation groups, on 
the basis of  the median percentage of  Ki-67-positive tumor cells. For Apaf1, Bcl2 and p53, the 
percentage of  positive tumor cells was scored in three different randomly chosen fields within 
the tumor tissue (similar to three tissues cores on a tissue microarray). For each tumor field, the 
percentages of  negative, weak, moderate and strong staining in tumor cells was scored. For each 
of  these categories, an average percentage was calculated over the three tumor fields. For each 
marker and for each patient separately, a histoscore – as a measure of  marker expression - was 
calculated as follows: histoscore = (0 x mean percentage negative tumor cells) + (1 x mean 
percentage weak positive tumor cells) + (2 x mean percentage moderate positive tumor cells) + 
(3 x mean percentage strong positive tumor cells). 
Statistical analysis
Only samples with a difference of  ≥2 Ct between MspI- and mock-treated samples and < 1 Ct 
difference between the supplicate PCR reactions were considered for statistical analyses. The 
distribution of  data of  each individual methylation marker was tested for normality using the 
Shapiro-Wilk test (35). Methylation levels of  each marker were defined as high or low methylation 
based on the median methylation percentage. Univariate and multivariate Cox proportional 
hazard models were used to statistically test the differences between the groups. Chi-square 
tests were performed to compare the level of  apoptosis (M30 staining) and the methylation 
percentage of  individual markers. Interpolation plots were made to visualize the correlation 
between methylation and protein expression (IHC staining) data for Apaf1, Bcl2 and p53. We 
then studied combinations of  two markers, both of  the intrinsic and the extrinsic apoptosis 
pathways (Apaf1 and Bcl2, Apaf1 and p53, Bcl2 and p53, Fas and TrailR2). The patient groups 
were divided into three groups: 2 high (both markers showing high methylation), 1 high and 
0 high (both markers showing low methylation). To obtain more power for statistical analyses, 
markers Apaf1, Bcl-2 and p53 were combined into a new variable. Data of  all three markers 
were available for 78 patients in the validation cohort. The combined-marker set was divided 
into four groups: all low (low methylation in all 3 markers), 1 high (1 out of  3 markers high 
methylation), 2 high (2 out of  3 markers high methylation) and all high (high methylation in 
all 3 markers). Univariate and multivariate Cox proportional hazard analyses were performed 
to assess the correlation of  the combined marker patient groups with overall survival (OS), 
cancer-specific survival (CSS), local recurrence-free survival (LRFS) and distant recurrence-
free survival (DRFS). Multivariate analyses included covariates age, gender, circumferential 
margin and tumor location. Kaplan-Meier curves were used to visualize differences between the 
combined marker patient groups. Cumulative incidence curves were calculated for CSS, LRFS 
and DRFS, accounting for death due to other causes (36). For all survival analyses we used a pre-
established patient group, the patient group with the expected shortest survival and recurrence-
free periods (the “all high” patient group), as the reference group. We assessed both apoptosis 
(M30) and proliferation (Ki-67) in the tumor specimens of  the validation cohort. Only patients 
with both M30 and Ki-67 data available (n=76) were included in these analyses. Combining 
both apoptosis and proliferation based on high versus low level of  IHC staining resulted in four 
patient groups: low apoptosis and low proliferation (n=16), low apoptosis and high proliferation 
(n=13), high apoptosis and low proliferation (n=16) and high apoptosis and high proliferation 
(n=31). Kaplan-Meier curves were used to visualize differences between the patients groups. 





Using methylation-sensitive restriction enzymes, we investigated the methylation status of  key 
apoptosis genes Apaf1, Bcl2, p53, Fas and TRAILR2 in DNA extracted from frozen rectal cancer 
tissues. For quality control purposes, we verified performance of  the enzyme assays using control 
genes B2m and MYOD1. Based on optimization of  the assays using active housekeeping gene 
B2m and silenced gene MYOD1, incubation of  enzyme reactions was set to 16 hrs (overnight) 
at 37°C, followed by 20 min heat inactivation at 65°C and subsequently cooling the samples at 
4°C for one hour. The mean methylation percentages were 86% (78-100%) for MYOD1 and 
38% (18-68%) for B2m. Standard deviations for the controls included in every digestion and on 
every PCR plate ranged from 7.5-8.2% for UMC DNA, and from 0.14-1.71% for PBL DNA. 
The methylation percentages of  these controls ranged from 65-100% for UMC DNA, and from 
1-6.5% for PBL DNA. For every digestion procedure, we verified that >75% of  the DNA was 
actually digested in the digestion reactions, measured as Ct ≥2 between the MspI- and mock-
treated samples, and a lower Ct value after digestion with HpaI as compared to the product in the 
mock-treated samples. Correct PCR product sizes were confirmed by running the products on a 
1% agarose gel. Based on these results, we continued with statistical analyses of  the patient data. 
Pilot study results for individual markers
The patient cohort of  the pilot study was representative of  the complete non-irradiated patient 
cohort of  the Dutch TME trial with respect to the main clinicopathological parameters (Table 
1). Methylation percentages in the tumor samples were significantly different from the normal 
samples analyzed for Apaf1, Bcl2, TrailR2 and p53 (Figure 1). No significant differences were 
observed for Fas. Chi-square tests showed significant correlation of  a high methylation of  two 
of  the markers with a low level of  apoptosis based on M30 staining, with Apaf1 (p=0.03) and 
p53 (p=0.04). No significant correlation with apoptosis status was found for the markers Fas, 
Bcl2 or TrailR2 using Chi-square analyses. However, correlation analyses did show a negative 
correlation for these markers between protein expression and methylation index, indicating a 
decreasing amount of  methylation with a higher number of  apoptotic cells, with values between 
-0.2 and -0.3. No significant difference in methylation of  the individual markers, apoptosis (M30) 
or proliferation (Ki-67) was observed between the tumor stages (data not shown). Therefore, we 
continued with stage III patients for the validation study.
Validation study results for individual markers
In the validation study, we included only stage III rectal cancer patients, as large differences 
in patient survival and tumor recurrence are observed within this specific patient group 
(37,38), and these patients will likely benefit the most from finding new biomarkers that could 
complement the current TNM staging system. Patients included in the validation study were 
representative of  the non-irradiated patient cohort of  the Dutch TME trial with respect to 
the main clinicopathological parameters (Table 1). Mean methylation percentages in the tumor 
tissues in the validation study were similar to those found in the pilot study for all markers. 




Patient characteristics are shown for both the pilot and validation study groups. The pilot study included stage I-III rectal 
cancer patients (n=49), the validation study stage III patients only (n=88). Variables listed are standard clinicopathological 
factors used in multivariate analyses, i.e. gender, age at randomization, TNM stage, tumor location, and circumferential 
margin involvement. P-values representing the difference between the TME trial patients and the pilot or validation 
study cohort, respectively, were calculated using a Student’s t-test.
methylation percentages in the normal samples included in the validation study (Figure 1). DNA 
methylation percentages of  the individual markers were not normally distributed. Therefore, the 
median methylation percentage for each individual marker was used as a cut-off  value to divide 
patients into low and high methylation groups. To verify that a lower methylation status indeed 
corresponded with higher apoptosis levels in the tumor, we compared the methylation percentage 
of  each of  the different markers to the known apoptotic status (based on M30 IHC data) in each 
of  the tumors. A representative example of  IHC staining results of  M30 staining is shown in 
Supplementary Figure 1. Chi-square tests showed significant correlation of  a high methylation 
of  Apaf1 (p=0.05) and Fas (p=0.01) with a low level of  apoptosis (Supplementary Figure 2A). 
Methylation of  the other markers (Bcl2, p53 and TrailR2) did show a similar correlation with 
M30 apoptosis levels, although not statistically significant. Linear regression using the number of










n (%) n (%) p-value n (%) n (%) p-value
Gender
 Male 432 63.1 35 71.4
0.24
181 64.4 62 70.5
0.3
 Female 253 36.9 14 28.6 100 35.6 26 29.5
Age at randomization
 Mean 64.3 66
0.31
63.37 62.59
0.58 Standard  
 error 0.43 1.58 0.67 1.3
TNM stage
 I 209 30.5 14 28.6
0.13 n.a. II 195 28.5 25 51
 III 281 41 10 20.4 281 100 88 100
Tumor location
 Rectum 607 88.6 41 83.3
0.45
246 89.5 84 95.4
0.06
 Anal region 48 12.4 8 16.7 21 10.5 4 4.5
Circumferential margin
 Negative 555 81 36 73.5
0.34
187 66.5 67 76.1
0.1
 Positive 129 19 13 26.5 93 33.5 21 23.9




Methylation values and means of  individual markers in normal, pilot and validation study tissues. Shown are 
methylation percentages for normal and tumor tissues (in both pilot and validation studies) for each of  the apoptosis 
markers separately. Mean methylation percentages are indicated with horizontal bars. Methylation percentages were 
calculated as follows: methylation percentage = 2^- (Ct HpaII treated samples – Ct mock treated samples) * 100%. 
P-values comparing the pilot and validation tumor samples with their normal counterparts were calculated using paired 
samples t-tests. N= normal, P=pilot series, V=validation series.
M30-positive (apoptotic) cells per mm2 in each of  the tumors and the methylation percentages of  
each of  the individual markers as continuous variables showed a significant correlation between 
the methylation status and apoptosis status for Apaf1 (p=0.03), Bcl2 (p=0.01) and p53 (p=0.04) 
(Supplementary Figure 2B). No significant correlation was found for markers Fas and TrailR2. 
Subsequently, we analyzed if  methylation of  the three markers Apaf1, Bcl2 and p53, correlated 
to protein expression (representative IHC staining results are shown in Supplementary Figure 1). 
As can be observed in the interpolation plots in Figure 2, Bcl2 and Apaf1 methylation correlated 
well with protein expression, with R2 values of  0.610 (Bcl2, Figure 2A) and 0.320 (Apaf1, Figure 
2B). For p53, methylation did not directly correlate with protein expression (Figure 2C), which 
might be explained by differences in p53 mutation status. Unfortunately, p53 mutation status was 
not known for these patients. Survival analyses did not yield any significant difference between 
samples with high or low methylation for any of  the individual markers, based on the median 
methylation percentage. Using Kaplan-Meier curves, we did observe that for Apaf1, Bcl2 and 
p53, high methylation in the tumor tissues was associated with shorter patient survival and 
higher probability of  tumor recurrence, although not statistically significant. We hypothesized 
that combining the intrinsic apoptotic pathway markers might result in better classification of  
rectal cancer patients in our study cohort.
Combined marker analyses
First, we studied combinations of  two markers within the intrinsic or the extrinsic apoptosis 


































Methylation compared to protein expression for Apaf1, Bcl2 and p53. Interpolation plots show methylation 
versus protein expression for Apaf1, Bcl2 and p53. Protein expression was scored as percentage of  tumor cells showing 
negative, weak, moderate or strong IHC staining. The histoscore was calculated as follows: histoscore = (0 * percentage 
negative) + (1 * percentage weak) + (2 * percentage moderate) + (3 * percentage strong). R-squared values indicate the 
degree of  correlation between methylation and protein expression for each of  the markers.
TABLE 2.  Univariate and multivariate analyses of  combined markers Apaf1, Bcl2 and 
p53 in the validation series.















(95% CI) (95% CI) (95% CI) (95% CI)
 Univariate analyses
 Combined marker 
 group  
0.44 0.05 0.19 0.01 0.28 0.006 0.14 0.21
(0.24-0.89) (0.04-0.68) (0.16-0.87) (0.04-1.04)
 Multivariate analysis
 Age 1.94 0.5 1.46 0.85 1.89 0.43 1.69 0.68
 Gender 0.68 0.32 0.72 0.47 0.84 0.69 1.29 0.75
 Circumferential 
 margin 2.1 0.1 3.04 0.03 4.62 0.005 6.29 0.03
 Tumor location 2.1 0.11 2.93 0.07 2.78 0.12 5.37 0.12
 Combined marker 
 group  
0.28 0.01 0.13 0.004 0.22 0.001 0.07 0.17
(0.09-0.83) (0.03-0.67) (0.05-0.84) (0.01-1.06)
Univariate and multivariate analyses are shown for combined markers Apaf1, Bcl2 and p53. The “all high” group (with 
high methylation of  all three markers) was used as the reference group. Combined marker groups were defined as 
follows: all high (high methylation in all 3 markers), 2 high (2 out of  3 markers high methylation), 1 high (1 out of  3 
markers high methylation) and all low (low methylation in all 3 markers). Hazard ratios are shown for both the univarite 
and the multivariate analyses, with a 95% confidence interval for the combined marker group. Statistically significant 
values (p<0.05) are indicated in bold.
A C B 
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observed for the combination of  Apaf1 and Bcl2 for LRFS, with p = 0.09 (HR 0.59, 95% 
CI 0.33-1.09) in univariate and p = 0.1 (HR 0.58; 95% CI 0.28-1.17) in multivariate analyses. 
Also for the combination of  Bcl2 and p53 a trend was observed in multivariate analyses for 
DRFS, with p = 0.07 (HR 1.51; 95% CI 0.96-2.38). For the other combinations, no significant 
differences were observed. To obtain more power for statistical analyses, all three intrinsic 
pathway markers (Apaf1, Bcl-2 and p53) were combined into a new variable. Methylation of  
markers Apaf1, Bcl2 and p53 was combined into one variable, on the basis of  the number 
of  markers showing high methylation (all low, 1 high, 2 high, or all high). Methylation of  the 
three combined markers showed a correlation to apoptosis status as measured by M30 (p=0.07). 
Cox proportional hazard models were used to assess the differences in patient survival and 
tumor recurrence between the groups in both univariate and multivariate analyses (Table 2). In 
univariate analyses, significant differences were observed for overall survival (p=0.05), cancer-
specific survival (p=0.01) and distant recurrence-free survival (p=0.006). Multivariate analyses 
included covariates gender, age at the time of  surgery, circumferential margin and distance to 
the anal verge. Significant differences were observed for OS (p=0.01), CSS (p=0.004), and 
DRFS (p=0.001). No significant differences were observed for LRFS, in neither univariate 
nor multivariate analyses. The differences in patient survival and tumor recurrence between 
the combined marker groups were visualized using Kaplan-Meier survival curves (for OS) and 
cumulative incidence curves (for CSS and DRFS) (Figure 3). The curves indicated that the more 
markers show high methylation, the shorter the survival and recurrence-free periods. The patient 
group with high methylation for only one out of  the three markers (“1 high” group) showed the 
best survival, directly followed by the patient group with two out of  three markers showing high 
methylation (“2 high” group). The patient group with high methylation of  all three markers (“all 
high” group) showed even shorter survival and recurrence-free periods, but the shortest survival 
Figure 3
Survival curves of  combined markers Apaf1, Bcl2 and p53. Intrinsic apoptotic pathway markers Apaf1, Bcl2 and 
p53 were combined based on the number of  markers showing high methylation. Only patient with data for all three 
markers available were included in the survival analyses (n=78). The resulting combined marker groups were: all low (low 
methylation in all 3 markers), 1 high (1 out of  3 markers high methylation), 2 high (2 out of  3 markers high methylation) 
and all high (high methylation in all 3 markers). A. Kaplan-Meier curves were made to visualize differences in patient 
survival and tumor recurrence between the different methylation groups for OS. Survival times were calculated as the 
time from surgery till an event (death or recurrence, resp.). Cumulative incidence curves were calculated for CSS (B) 
and DRFS (C).
igure 3  































































p=0.054 p=0.014 p=0.006 
Survival since surgery (yrs) 
0         2.5         5.0       7.5       10.0       12.5     
Cancer-specific survival (yrs) 
0         2.5         5.0       7.5       10.0      12.5     
Distant recurrence-free survival (yrs) 
0         2.5         5.0       7.5       10.0      12.5     
2  high (n=16) 
All low (n=22) 
1 high (n=19) 
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2 high (n=16) 
All low (n=22) 
1 high (n=19) 
All high (n=21) 
2 high (n=16) 
All low (n=22) 
1 high (n=19) 




and disease-free periods were observed for the patient group with low methylation on all three 
markers (“all low” group). In addition to low methylation of  Apaf1, Bcl2 and p53 in the “all 
low” combined marker patient group, low methylation of  Fas and TRAILR2 was observed for 
96% and 81% of  the patients in this group, respectively. No difference in patient characteristics 
was observed between the combined marker groups that could explain these results, suggesting 
that other tumor-intrinsic factors might be responsible for the shorter patient survival and 
recurrence-free periods.
Proliferation and apoptosis analyses
In order to explain the survival and recurrence data observed for the “all low” combined marker 
patient group, we also assessed tumor proliferation (as measured by Ki-67 IHC staining, see 
Supplementary Figure 1) for patients in the validation study. Only patients with both M30 and
Figure 4
Apoptosis and proliferation for combined markers Apaf1, Bcl2 and p53. Apoptosis (M30, IHC) and proliferation 
(Ki-67, IHC) were combined and compared to the methylation percentages of  the markers Apaf1, Bcl2 and p53. Patients 
with data for all markers available (n=78) were classified into high or low apoptosis or proliferation groups based on the 
median number or percentage of  positive tumor cells, respectively. A. For all combined marker groups, the number of  
patients in each of  the combined apoptosis-proliferation categories was determined. B. Kaplan-Meier curves were made 
to visualize survival differences for the combined apoptosis-proliferation categories. 
Figure 4 
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Ki-67 data available (n=76) were included in the analyses. Missing data were due to unavailability 
of  tumor specimens or missing punches on the TMA sections. In the “all low” group showing 
low methylation of  Apaf1, Bcl2 and p53, 15 out of  22 patients (68%) showed both high apoptosis 
and high proliferation (Figure 4A). For the other combined marker groups (1 high, 2 high and 
all high), the same numbers of  patients were observed in each of  the combined apoptosis-
proliferation groups. As shown in Figure 4B, this also translated into differences in survival 
for each of  the combined apoptosis-proliferation patient groups, although not statistically 
significant (p=0.19). The patient group with both high proliferation and high apoptosis indeed 
showed the shortest survival, which corresponds to the poor survival observed for patients with 
low methylation of  all three apoptosis markers. 
Discussion
Changes in the regulation of  the apoptotic process, one of  the hallmarks of  cancer (1,2), 
provides tumor cells with a survival advantage and could hence promote tumorigenesis. 
Epigenetic aberrations have been shown to contribute to the process of  tumorigenesis in many 
ways (16). As the outcome of  the apoptotic pathway has been proven to correlate with patient 
outcome parameters in rectal cancer (6), we hypothesized that studying the epigenetic regulation 
of  the apoptotic process might provide more insight in this crucial but complicated cellular 
process. Furthermore, it may bring us one step closer to the discovery of  new clinically relevant 
prognostic biomarkers in rectal cancer.
In this study, methylation of  key apoptosis genes using a restriction enzyme-based protocol 
was correlated to patient survival and tumor recurrence. We showed that combining multiple 
markers (intrinsic pathway markers Apaf1, Bcl2 and p53) resulted in better patient stratification 
and therefore better prognostication as compared to the individual markers or combinations of  
only two markers. With little modifications, including varying amounts of  enzyme and DNA 
added to the digestion reactions, the enzyme-based protocol presented in this paper can be used 
to analyze small amounts of  DNA without any loss of  DNA due to prior processing steps, 
which is a major advantage compared to the current bisulfite modification-based methods used 
to detect DNA methylation. In a clinical setting this approach will be useful, as the amount of  
DNA available for analyses, usually derived from tumor biopsies, is limited and should be used 
with great care. 
Current literature indicates that methylation of  apoptosis proteins Apaf1, Bcl2 and p53 have 
prognostic value in various cancers (26,39-42). In colorectal cancer, reduced Apaf1 expression 
was found to be associated with tumor progression and adverse prognosis (25,43). High co-
expression of  Bcl2 and p53 proteins was found to be associated with poor prognosis in colorectal 
cancer (44), gastric MALT lymphoma (45) and B-cell lymphoma (45,46). Piris et al. suggested 
aberrant expression of  both p53 and Bcl2 to be part of  a multistep process of  dysregulation 
of  the apoptotic machinery critical for progression of  tumors (46). Abnormal expression of  
p53 itself  has been related to a poor patient prognosis in colorectal cancer (47). Methylation of  
the investigated apoptosis markers Apaf1, Bcl2 and p53 has been reported in various cancers, 
including lung cancer (Bcl2; 39), renal cell carcinoma (Apaf1; 40), melanoma (Apaf1; 41) and 




To our best knowledge, the study presented here is the first study combining methylation data 
of  several apoptosis genes at the same time, on the basis of  their functions in the intrinsic 
apoptotic process (48). The methylation percentages of  the combined markers Apaf1, Bcl2 
and p53 correlated significantly with the apoptotic status of  the tumors (M30 IHC staining) 
and disease outcome (patient survival and disease recurrence). We therefore conclude that 
gene promoter methylation status can be a useful surrogate marker for the apoptotic status 
of  individual tumors, but also provides additional information about specific apoptosis-related 
genes as compared to a ‘general’ apoptotic status as determined by M30 staining. 
Previous research of  our group has shown that the risk of  a local recurrence is lower when 
tumor intrinsic levels of  apoptosis are high (6). In this study we showed that low methylation 
is correlated with higher levels of  apoptosis, indeed correlating with better survival and longer 
recurrence-free periods. This finding is supported in literature, where high expression of  Apaf1 
and Bcl2 was reported to be significantly correlated with better overall survival (49). Although 
mean methylation levels were significantly lower in tumor tissues as compared to normal tissues 
for all of  the markers suggesting higher apoptotic activity, in individual tumors we found that 
higher levels of  methylation of  the combined markers Apaf1, Bcl2 and p53 correlated to 
shorter patient survival and recurrence-free periods as compared to the patients showing low 
expression of  one or two of  the markers. The patient group showing low methylation of  all 
three markers, however, did not comply with our expectations, as this patient group showed 
the shortest survival and recurrence-free periods. To explain this phenomenon, we studied cell 
proliferation in addition to apoptosis. We observed that patients showing both high apoptosis 
and high proliferation, of  which 68% of  the patients corresponded to the “all low” combined 
marker group, showed the shortest survival. This finding is supported by literature, in which 
both increased apoptosis and increased proliferation were reported in rectal tumors with lymph 
node metastases as compared to non-metastatic tumors (50). The distorted balance between the 
apoptosis pathways and cellular proliferation in the “all low” combined marker group hence 
might explain the observed survival data. Dysfunctioning of  the apoptotic pathway could not 
be demonstrated in this patient group based on the results presented for the studied apoptosis 
genes, as methylation was reported to be low for all five markers. Of  course, there might be 
other apoptotic factors involved that could compromise proper functioning of  the apoptotic 
pathway in this patient group, which have not been investigated in this study. Epigenetic 
mechanisms other than DNA methylation at gene promoters could also be involved in the 
regulation of  apoptosis gene expression in these tumors, as was suggested by the work of  
Hinoue et al. (51). Using a genome-wide approach, cancer-specific methylation of  multiple gene 
regions has been described in CpG island methylator phenotype (CIMP)-high colorectal cancers, 
with characteristic genetic and clinical features. In addition, 48 of  112 genes were also found 
to be transcriptionally downregulated in non-CIMP tumors, but this could not be correlated to 
higher DNA methylation at these specific regions, suggesting involvement of  other (epigenetic) 
mechanisms. In contrast to these genome-wide studies, a more pathway-focused approach was 
used in our study that facilitated the identification of  new biomarkers in rectal cancer prognosis.
In conclusion, in this study we found that methylation of  apoptotic genes is correlated with the 
overall apoptotic status of  a tumor, and that this status can be used to assess clinical outcome 
in terms of  patient survival and tumor recurrence. The methylation analysis presented using 
methylation-sensitive restriction enzyme digestion provides a biological explanation for the 
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differences in apoptotic status in individual tumors. High methylation of  combined intrinsic 
apoptosis pathway markers Apaf1, Bcl2 and p53, suggesting deregulation of  the apoptotic 
pathway, was associated with poor prognosis in our study cohort of  colorectal cancer patients. 
High proliferation and high apoptosis were observed when methylation of  the intrinsic apoptosis 
pathway markers was low. The study of  epigenetic regulation of  apoptosis genes will provide 
more insight in the tumorigenic process in rectal cancer and might be helpful in further refining 
treatment regimens for individual patients.
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Representative IHC staining results of  individual markers. Shown are representative IHC staining results of  the 
individual markers M30, Ki-67, Apaf1, Bcl2 and p53 on the tumor of  one patient included in our study. Images were 
taken at a 20x magnification and scales are indicated in the figures. Apoptosis using M30 was scored as the number of  
positive cells (indicated with arrows), proliferation using Ki-67 was scored as the percentage of  positively stained tumor 
cells. For Apaf1, Bcl2 and p53 a histoscore was calculated on the basis of  staining intensity and the percentages of  
positive cells (as discussed in Materials and Methods). 
Supplementary Figure 1 
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Chi-squared and linear regression analyses validation study.  A. Chi-squared analyses comparing M30 staining with 
the methylation status of  all individual markers in the validation study (high or low based on median expression) are 
shown, including the χ2 p-values. B. Scatter plots of  the linear regression models are shown for each of  the individual 
markers in the validation study are shown in panel, including the linear regression p-values.
Supplementary TABLE 1 (next page)
Univariate and multivariate analyses are shown for the combinations of  two markers. Hazard ratios and 95% confidence 
intervals (95% CI) are shown for both the univariate and multivariate analyses, as well as the p-values. Patient groups for 
the combined marker analyses were defined as follows: 2 high (both markers showing high methylation, 1 high and 0 high 
(both markers showing low methylation). OS= overall survival; CSS= cancer-specific survival; LRFS= local recurrence-
free survival; DRFS= distant recurrence-free survival. Trends (p ≤ 0.1) are indicated in Italic.  
Low High Total 
Low 9 21 30 
High 19 15 34 
Total 28 36 64 
Low High Total 
Low 9 25 34 
High 18 13 31 
Total 27 28 65 
Low High Total 
Low 10 18 28 
High 14 19 33 
Total 24 37 61 
Low High Total 
Low 11 17 28 
High 14 17 31 
Total 25 34 59 
Low High Total 
Low 9 17 26 
High 13 19 32 
















Apaf1 Fas Bcl2 
TrailR2 p53 
Supplementary Figure 2 
χ2: p=0.05 χ2: p=0.01 χ2: p=0.6 
χ2: p=0.7 χ2: p=0.8 
A   Chi-squared analyses validation study 
B   Linear regression analyses validation study 
p=0.03 p=0.07 p=0.01 
p=0.1 p=0.04 
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Supplementary TABLE 1.  Univariate and multivariate analyses of  combinations of  2 markers
 Apaf1 and Bcl2









(95% CI) (95% CI) (95% CI) (95% CI)
 Univariate analyses
 Combined markers
0.89 0.4 0.83 0.3 0.59 0.09 1.01 0.9
(0.66-1.19) (0.58-1.18) (0.33-1.09) (0.70-1.44)
 Multivariate analysis
 Combined markers
0.92 0.6 0.95 0.8 0.58 0.1 1.12 0.6
(0.66-1.27) (0.64-1.39) (0.28-1.17) (0.76-1.66)
 Apaf1 and p53









(95% CI) (95% CI) (95% CI) (95% CI)
 Univariate analyses
 Combined markers
1.13 0.4 1.09 0.6 0.89 0.7 1.17 0.4
(0.84-1.53) (0.76-1.57) (0.50-1.61) (0.81-1.69)
 Multivariate analysis
 Combined markers
1.14 0.5 1.16 0.5 0.83 0.6 1.26 0.2
(0.81-1.59) (0.78-1.70) (0.43-1.61) (0.85-1.88)
 Bcl2 and p53









(95% CI) (95% CI) (95% CI) (95% CI)
 Univariate analyses
 Combined markers
1.13 0.4 1.11 0.6 0.82 0.5 1.3 0.2
(0.82-1.55) (0.76-1.64) (0.46-1.46) (0.89-1.96)
 Multivariate analysis
 Combined markers
1.15 0.4 1.17 0.5 0.75 0.4 1.51 0.07
(0.79-1.67) (0.76-1.79) (0.38-1.49) (0.96-2.38)
 Fas and TRAILR2









(95% CI) (95% CI) (95% CI) (95% CI)
 Univariate analyses
 Combined markers
0.97 0.8 0.79 0.2 0.92 0.8 0.85 0.3
(0.74-1.28) (0.58-1.09) (0.56-1.53) (0.62-1.16)
 Multivariate analysis
 Combined markers
0.92 0.5 0.79 0.2 0.87 0.6 0.85 0.3
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Aims: Epigenetic changes are of  crucial importance in cancer development and are potentially 
reversible, thus presenting as interesting targets for anti-cancer therapy. We investigated the 
clinical prognostic value of  histone deacetylases SIRT1, HDAC1 and HDAC2 and histone 
modifications H4K16Ac and H3K56Ac in colorectal cancer.
Methods and results: The epigenetic markers were immunohistochemically stained on tissue 
microarrays containing colorectal tumor (n=254) and normal colorectal tissues (n=50). Nuclear 
expression was assessed on the semi-automated Ariol system. Multivariate trend survival analyses 
of  the combined markers showed better patient survival and less tumor recurrence when more 
markers showed high nuclear expression. For the combination of  the histone deacetylases and 
H3K56Ac, the hazard ratio (HR) for overall survival (OS) was 0.82 (0.72-0.94; p=0.005) and 
for distant recurrence-free survival (DRFS) was 0.77 (0.64-0.92; p=0.003) per additional marker 
showing high expression. Similarly, for the combination of  histone deactylases and H4K16Ac, a 
HR of  0.86 (0.76-0.97; p=0.01) for OS and 0.79 (0.68-0.93; p=0.006) for DRFS were observed 
per additional marker showing high expression.
Conclusions: The studied epigenetic markers showed clinical prognostic value in colorectal 
cancer, both as individual markers and when combined into multi-marker analyses. These results 
indicate that epigenetic mechanisms play an important role in colorectal carcinogenesis.




There is a need to identify new biomarkers in colorectal cancer in order to better stratify patients 
for treatment based on their individual tumor characteristics. For TNM stage I-III colorectal 
tumors, patient survival and tumor recurrence vary widely among patients, indicating that the 
current TNM staging system needs further refinement. New biomarkers may be found by 
unraveling the underlying biology of  individual tumors. Epigenetics is a promising field for 
biomarker research, since changes in epigenetic status have been frequently reported in tumor 
tissues compared to their normal counterparts (1). In addition, epigenetic mechanisms are 
potentially reversible, which makes them suitable targets for the development of  new therapies 
(1).
Epigenetic mechanisms include DNA methylation and histone modifications, which directly 
influence chromatin structure and thereby accessibility of  the DNA for transcription factors 
(2). Several research groups have found global expression of  histone modifications to have 
prognostic value in different cancers, including prostate (3), lung and kidney (4), breast cancer 
(5), and colorectal cancer (6). In addition to histone modifications, expression of  histone-
modifying enzymes, including histone deacetylases (7), have also been shown to have prognostic 
value in colorectal cancer.
Specific histone modification patterns are associated with regions of  the genome that are either 
actively transcribed or repressed (8). One of  the histone modifications that is strongly linked 
to gene activation and can by itself  prevent chromatin compaction is H4K16Ac (9). The major 
H4K16 deacetylase in mammalian cells is SIRT1 (Sirtuin 1), a class III histone deacetylase (10). 
Human SIRT1 has been shown to be involved in many (disease) processes (11) and altered 
expression of  SIRT1 has been described in several cancers, including colorectal cancer (12). 
Global levels of  H4K16Ac are dependent on the balance between SIRT1 and class I histone 
deacetylases HDAC1 and HDAC2. Both HDACs have been shown to contribute to the process 
of  non-homologous end-joining (13), which is important for error-free repair of  DNA double 
strand breaks, through deacetylation of  histone modification H3K56Ac. Dysregulation in these 
cellular processes could facilitate carcinogenesis.
Using immunohistochemistry (IHC), we analyzed nuclear expression of  histone deacetylases 
SIRT1, HDAC1 and HDAC2 and histone modifications H3K56Ac and H4K16Ac in tumor 
specimens of  254 TNM stage I-III colorectal cancer patients from a consecutive patient 
cohort with extensive clinical follow-up data. We analysed the correlations of  expression of  the 
individual markers and combinations of  the histone deacetylases with each of  the respective 
histone modifications with clinical outcome. 
Materials and methods
Patient selection
Tumor tissues were collected from a consecutive series of  409 (TNM-stage I-IV) patients who 




between 1991 and 2001 and of  whom tumor tissue was available. All specimens were handled 
with a standard protocol for fixation, dissection and histopathological reporting. Patients with 
pre-operative treatment, multifocal tumors, or a history of  cancer (other than basal cell carcinoma 
or in situ tumors) were excluded from analyses. We included only patients with a histologically 
proven colorectal adenocarcinoma and TNM tumor stage I-III cancer, as determined by an 
experienced pathologist. Complete clinicopathological data were available for 259 TNM stage 
I-III patients, and complete covariate and study marker data were available for 254 patients 
(Table 1), with a mean follow-up of  8.6 years. Clinicopathological parameters of  patients in the 
study cohort were representative for the complete patient cohort. Data were censored when 
patients were alive or free of  recurrence at their last follow-up date. Patient records information 
was anonymized and de-identified prior to analysis according to national ethical guidelines 
(“Code for Proper Secondary Use of  Human Tissue”, Dutch Federation of  Medical Scientific 
Societies), and approved by the Medical Ethical Committee of  the Leiden University Medical 
Center (LUMC). MSI status was tested using the PCR-based MSI Analysis System, Version 
1.2 (Promega, Mannheim, Germany), as described previously (14). This study was performed 
according to the REMARK guidelines (NCI-EORTC) (15).
Immunohistochemistry and scoring
Formalin-fixed paraffin-embedded (FFPE) tissues from each of  the patients in this retrospective 
study were used to construct a tissue microarray (TMA) with 0.6 mm tissue cores, as described 
previously (16). Sections of  4μm were cut from each of  the TMA blocks including 254 colorectal 
tumor tissues and 50 histopathologically normal colorectal tissues and used for IHC (manual 
protocol). TMA sections were incubated overnight (16 hours) using primary antibodies at 
predetermined optimal dilutions. Antibodies used in this study were: anti-H3K56Ac (ab76307, 
Abcam, Cambridge, UK), anti-H4K16Ac (ab61240, Abcam, Cambridge, UK), anti-SIRT1 
(ab32441, Abcam, Cambridge, UK), anti-HDAC1 (ab19845, Abcam, Cambridge, UK) and anti-
HDAC2 (ab39669, Abcam, Cambridge, UK), using a standard IHC protocol (17). Briefly, antigen 
retrieval was performed by heating the sections for 10 min at 95°C in a citrate buffer (pH 6.1; pH 
Low Target Retrieval Solution, Dako, Glostrup, Denmark) after deparaffinization. Endogenous 
peroxidase was blocked by incubating the sections in a 0.3% solution of  hydrogen peroxide 
(in PBS) for 20 min. Staining was visualized using the Dako REAL™ EnVision™ Detection 
System, Peroxidase/DAB+, Rabbit/Mouse (Dako, Glostrup, Denmark). In each TMA block, 
control tissues (colon, spleen and liver) were included serving as positive controls across TMA 
sections for nuclear staining. A no-antibody control section was used as negative control. 
Stained tissue microarrays were scanned using a 20x magnification and nuclear expression of  
all markers was assessed using the semi-automated Ariol system (Leica Microsystems, Wetzlar, 
Germany). Tumor areas (tumor tissues) and colon epithelium (normal tissues) were marked on 
the computer screen upon visual inspection. The semi-automated Ariol system is specifically 
designed to recognize cells, nuclei, cell membranes and pixel intensity and was trained carefully 
for each individual staining. For each TMA section, several random cores were evaluated by 
visual inspection after automatic analysis in order to verify correct identification of  positively 
stained nuclei.
Histone deacetylases, H3K56Ac and H4K16Ac
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TABLE 1.  Patient characteristics of  the study cohort (n=254)
n (%) n (%)
 Age at operation  MSS status
 <50 32 12.6  MSI 34 13.4
 50-75 161 63.4  MSS 175 68.9
 >75 61 24  Unknown 45 17.7
 Gender  Tumor location
 Male 128 50.4  Colon 187 73.6
 Female 126 49.6  Rectum 67 26.4
 TNM stage  Tumor size
 I 53 20.9  Mean 4.69
 II 113 44.5  Standard 
 error 2.32 III 88 34.6
 pT stage  Number of  lymph nodes retrieved
 T1 19 7.5  Mean 8.09
 T2 38 15.0  Median 8
 T3 166 65.4  <12 250 98.4
 T4 31 12.2  ≥12 4 1.6
 pN stage  Location in the colon
 N0 168 66.1  Proximal 94 37.0
 N1 54 21.3  Distal 160 63.0
 N2 32 12.6  Tumor in follow-up *
 Histological Subtype  No 215 84.6
 Adenocarcinoma 190 74.9  Yes 39 15.4
 Mucinous 34 13.6  Adjuvant therapy
 Cribriform 14 5.5  No 206 81.1
 Tubulovillous 5 2.0  Yes 48 18.9
 Undifferentiated 10 3.9
 Signet ring cell 1 0.1
Patient characteristics are shown for the study cohort (n=254). Patients with unknown status for any of  the covariates 
are not reported in this table, except for MSS status.   * = second primary tumor during follow-up period. 
Statistical analysis
Data were analyzed in consultation with a statistician (H.P.) using SPSS 20.0 for Windows (SPSS 
Inc, Chicago, USA). The Cox proportional hazard model was used for univariate and multivariate 





Identification of  positively stained and negative nuclei by the Ariol system. The Ariol system trainer overlay 
shows correct identification of  positive (indicated by yellow dots) and negative (blue dots) nuclei in tumor tissues using 
immunohistochemistry. TMA slides were scanned using a 20x magnification. Shown for all markers are negative tumor 
cores (top row), tumor cores with both positive and negative cells (middle row) and highly positive tumor cores (bottom 
row). The Ariol system was trained to identify positive and negative cells for each marker individually.
TNM tumor stage (tumor stages I-III), tumor location, tumor size and microsatellite stability 
(MSS) status. Covariates “tumor in the follow-up” (second primary tumor) and “adjuvant 
therapy” were entered as time-dependent covariates. Normality of  the data was tested using 
the Shapiro-Wilk test, and non-parametric Wilcoxon signed rank tests were performed to 
test for statistical differences in expression between normal and tumor samples and between 
the expression levels of  histone modifications and histone deacetylases in individual tumors. 
Spearman’s rank correlation coefficient was used to test the correlation between the expression 
of  histone deacetylases and the respective histone modifications. Median expression was used 
as a cut-off  value to divide patients into high or low expression groups. Kaplan-Meier curves 
or cumulative incidence plots were generated to visualize the differences in patient survival 
or tumor recurrence. We performed trend analyses using combined markers with the group 
numbers as continuous variables. Cox regression analyses were performed using the combined 
markers as categorical variables to assess the hazard ratios for each of  the individual patient 
Figure 2 (see next page) Paired analyses of  normal versus tumor and histone deacetylases versus histone 
modifications. A. Boxplots showing mean expression (indicated as the percentage of  immunohistochemically stained 
positive nuclei). Normal samples (n=50) are shown on the left of  each figure (labeled “N”) and mean expression of  the 
tumor samples (n=254) is shown on the right (labeled “T”). P-values indicate the results of  the non-parametric Wilcoxon 
signed rank test. B. Histograms showing the difference in expression (percentage of  positive nuclei as determined 
after immunohistochemistry) between the histone modifications and histone deacetylases are displayed for H3K56Ac 
and H4K16Ac against each of  the individual histone deacetylases. The difference in expression (y-axis) was calculated 
for each individual patient (x-axis), according to the following formula: expression difference = expression histone 
modification – expression histone deacetylase. Negative values indicate higher expression of  the histone deacetylase, 
positive values indicate higher expression of  the histone modification. P-values represent the results of  the Spearman’s 
correlation analysis.
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groups. Competing risk analyses were performed to assess disease-specific survival. Kaplan-
Meier curves or cumulative incidence plots were generated to visualize the differences in patient 
survival and tumor recurrence between the five groups. For individual marker analyses, the low 
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was used as reference group. Overall survival (OS) was defined as the time from surgery until 
death (by any cause). Disease-specific survival (DSS) was defined as the time from surgery until 
death by colorectal cancer, and was based on autopsy reports, where available, and otherwise 
on death certification. Loco-regional recurrence-free survival (LRRFS) was defined as the time 
from surgery until the occurrence of  a (loco)regional recurrence or death by cancer. Distant 
recurrence-free survival (DRFS) was defined as the time from surgery until the occurrence of  a 
distant recurrence or death by cancer. For all statistical analyses, a two-sided p-value of  0.05 or 
less was considered statistically significant. 
Results
Expression in normal versus tumor tissues
To minimize observer bias, nuclear expression of  all markers in both tumor cells (tumor tissues) 
and colon epithelium (normal tissues) was scored using the semi-automated Ariol system 
(Figure 1). We analyzed expression of  SIRT1, HDAC1, HDAC2, H3K56Ac and H4K16Ac in 
normal and tumor tissues. The expression data were not normally distributed for any of  the 
markers (data not shown). SIRT1 and H4K16Ac showed lower nuclear expression in tumor 
samples compared to normal tissue samples (both p<0.001), whereas HDAC2 showed higher 
nuclear expression in tumor samples compared to normal tissue samples (p<0.001) (Figure 2A). 
The expression of  HDAC1 (p=0.80) and H3K56Ac (p=0.89) did not differ between normal and 
tumor samples when analyzing the whole patient cohort (Figure 2A). However, within individual 
tumors, differences between normal and tumor samples were observed for both HDAC1 and 
H3K56Ac (Figure 3A). For both markers, approximately 50% of  the tumor tissues showed higher 
expression compared to paired normal tissues, and the other 50% showed lower expression in 
tumor tissues compared to normal tissues. This also translated into survival differences between 
patients with higher expression and patients with lower expression in the tumor as compared to 
the normal tissues (Figure 3B).
Paired analyses of  expression of  histone deacetylases and histone modifications
The differences in expression levels between each of  the histone deacetylases and either of  the 
histone modifications were plotted for the whole study cohort (Supplementary Figure 1) and 
for each individual tumor (Figure 2B). In individual tumors, high expression of  the histone 
modifications correlated to low expression of  the histone deacetylases (positive values), and 
vice versa (negative values). Spearman’s correlation analyses showed that for all three histone 
deacetylases, there was a significant inverse correlation with the respective histone modifications 
(p≤0.001). 
Survival analyses of  individual markers
The median expression for each of  the markers, used to divide patients into high and low 
expression groups, was as follows: SIRT1 (30%), HDAC1 (68%), HDAC2 (95%), H3K56Ac 
(93%) and H4K16Ac (63%). Median survival was 9.3 years (for both OS and DSS), median 
recurrence-free survival was 8.8 years for LRRFS and 9.2 years for DRFS. All markers showed 




Expression of  HDAC1 and H3K56Ac in tumor and normal tissues of  individual patients. A. Histograms showing 
the difference in expression (indicated as the percentage of  immunohistochemically stained positive nuclei) between 
paired normal and tumor tissues are displayed for HDAC1 and H3K56Ac. The difference in expression (y-axis) was 
calculated for each individual patient (x-axis), according to the following formula: expression difference = expression in 
tumor tissue – expression in normal tissue. Negative values indicate higher expression in normal tissues, positive values 
indicate higher expression in tumor tissues. B. Kaplan-Meier curves were made to visualize differences in overall survival 
between patients with higher expression and patients with lower expression in tumor tissues as compared to normal 
tissues. P-values represent the results of  multivariate Cox proportional hazards survival analyses. 
highly significant correlations with patient survival and tumor recurrence, in both univariate and 
multivariate analyses (Table 2). Patients with high nuclear expression of  either of  the markers 
showed better survival and a lower chance of  tumor recurrence, which was confirmed by plotting 
Kaplan-Meier curves or cumulative incidence plots for both patient survival (OS and DSS) and 
tumor recurrence-free survival (LRRFS and DRFS) (data not shown).
Survival analyses of  combined markers
As we know that most of  these markers work together in multi-protein complexes in order 
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deacetylases SIRT1, HDAC1 and HDAC2 together with either H3K56Ac or H4K16Ac. We 
divided the patients into five groups, based on the number of  markers with “high expression” 
for this specific group of  patients, i.e. all low (group 1), one high (group 2), two high (group 3), 
three high (group 4) and all high (group 5). All multivariate trend analyses showed significant 
TABLE 2.  Univariate and multivariate survival analyses individual markers
SIRT1 HDAC1 HDAC2 H3K56Ac H4K16Ac
 OS
 Univariate
 p-value 0.8 0.07 0.3 0.004 0.03
 HR 1.0 0.7 0.8 0.6 0.7
 (95% CI) (0.69-1.33) (0.53-1.02) (0.60-1.16) (0.45-0.86) (0.50-0.97)
 Multivariate
 p-value 0.2 0.03 0.1 0.02 0.02
 HR 0.8 0.7 0.7 0.7 0.7
 (95% CI) (0.58-1.15) (0.49-0.97) (0.54-1.07) (0.47-0.94) (0.47-0.94)
 DSS
 Univariate
 p-value 0.05 0.02 0.05 0.1 0.009
 HR 0.6 0.6 0.6 0.7 0.5
 (95% CI) (0.36-0.99) (0.34-0.92) (0.36-1.003) (0.42-1.11) (0.31-0.84)
 Multivariate
 p-value 0.01 0.009 0.03 0.2 0.02
 HR 0.5 0.5 0.6 0.7 0.5
 (95% CI) (0.29-0.87) (0.29-0.84) (0.33-0.95) (0.44-1.21) (0.31-0.89)
 LRRFS
 Univariate
p-value 0.2 0.01 0.03 0.2 0.03
 HR 0.7 0.6 0.6 0.7 0.6
 (95% CI) (0.48-1.15) (0.37-0.88) (0.39-0.95) (0.49-1.16) (0.40-0.95)
 Multivariate
 p-value 0.05 0.008 0.009 0.07 0.03
 HR 0.6 0.5 0.5 0.6 0.6
 (95% CI) (0.41-1.01) (0.34-0.85) (0.34-0.86) (0.41-1.03) (0.38-0.95)
 DRFS
 Univariate
 p-value 0.1 0.03 0.09 0.2 0.06
 HR 0.7 0.6 0.7 0.8 0.7
 (95% CI) (0.45-1.10) (0.39-0.94) (0.43-1.06) (0.50-1.19) (0.42-1.01)
 Multivariate
 p-value 0.04 0.02 0.04 0.1 0.07
 HR 0.6 0.6 0.6 0.7 0.7
 (95% CI) (0.38-0.98) (0.35-0.89) (0.38-0.98) (0.44-1.11) (0.41-1.04)
Shown are the results of  the univariate and multivariate analyses of  all individual markers, with all p-values and hazard 
ratios (HR) with their 95% confidence intervals (95% CI). OS = overall survival, DSS = disease-specific survival, LRRFS 
= locoregional recurrence-free survival, DRFS = distant recurrence-free survival. For each marker, the low expression 
group (below median expression) was used as reference group. Differences in clinical outcome between patient groups 
are presented as hazard ratios compared to the reference group. Significant p-values are indicated in bold, p-values show-
ing a trend (between 0.05 and 0.1) in Italic.
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differences in patient survival and tumor recurrence (Table 3). For the combined analyses of  the 
histone deacetylases and H3K56Ac, each increase of  one unit (one additional marker showing 
high expression) compared to the “all low” patient group resulted in a hazard ratio (HR) of  0.82 
(0.72-0.94; p=0.005) for OS, 0.72 (0.59-0.88; p=0.001) for DSS, 0.74 (0.62-0.88; p=0.001) for 
LRRFS and 0.77 (0.64-0.92; p=0.003) for DRFS. Similarly, for the combination of  the histone 
deactylases and H4K16Ac, a HR of  0.86 (0.76-0.97; p=0.01) for OS, 0.73 (0.60-0.88; p=0.001) 
for DSS, 0.77 (0.66-0.90; p=0.001) for LRRFS and 0.79 (0.68-0.93; p=0.006) for DRFS were 
observed per unit of  increase. Competing risk analyses showed that the more markers showed 
high expression, the lower the cumulative incidence (Figures 4A and 4B). For each of  the 
individual patient groups, a decrease in hazard ratio was observed when more markers showed 
high expression (Figure 4C and Supplementary Table 1). The lowest hazard ratio was observed 
for patients with high expression of  all markers (group 5) as compared to the reference group 
with low expression of  all markers (group 1). A similar stratification of  patient groups was 
observed for overall survival.
Discussion
It is becoming increasingly clear that epigenetics plays an important role in tumor development. 
Increasing knowledge about the role of  epigenetic mechanisms in cancer has guided the 
development of  new epigenetic anti-cancer therapies, often combined with existing therapies 
(1). To date, however, such epigenetic therapies have only been proven effective in hematological 
diseases and treatment of  solid cancers has proven challenging. For solid tumors, epigenetic 
therapies may require the development of  therapies that for example target multi-protein 
complexes. In ongoing research an increasing number of  such multi-protein complexes are 
being identified (18). In this study, we investigated three histone deacetylases that act together 
to remodel the chromatin in response to DNA damage and are important regulators of  
gene expression during embryonic development (19) and play a role in tumor initiation and 
progression (20). Deregulation of  these histone deacetylases could result in tumor development 
and progression (12,21). In this study, we demonstrated an increased nuclear expression of  
HDAC2, and decreased nuclear expression of  SIRT1 and H4K16Ac in tumor cells as compared 
to normal cells. Other groups also reported similar changes in expression between normal 
and tumor tissues in literature.(7,12) Loss of  H4K16Ac has been described to be a common 
hallmark of  human cancers (22), which was mostly linked to hypomethylation of  DNA repetitive 
sequences during tumor progression. This might be correlated to LINE-1 hypomethylation, 
which we previously showed to correlate with shorter patient survival and higher chances of  
tumor recurrence in early-stage rectal cancer (23). 
Table 3 (see next  two pages). Shown are the results of  the univariate and multivariate trend analyses of  the combined 
markers using the group numbers as continuous variables, with all p-values and hazard ratios (HR) with their 95% 
confidence intervals (95% CI). Displayed hazard ratios reflect the hazard ratio with an increase of  1 unit, meaning 
an increase in the number of  markers showing high expression (reflected in a higher group number). OS = overall 
survival, DSS = disease-specific survival, LRRFS = locoregional recurrence-free survival, DRFS = distant recurrence- 








p-value HR (95% CI) p-value HR (95% CI)
 Combined markers 0.02 0.86 (0.75-0.98) 0.003 0.75 (0.62-0.91)
 Multivariate
 Combined markers 0.005 0.82 (0.72-0.94) 0.001 0.72 (0.59-0.88)
 Age at operation <0.001 1.86 (1.55-2.23) 0.009 1.37 (1.08-1.73)
 Gender 0.86 1.03 (0.73-1.46) 0.9 1 (0.59-1.68)
 TNM stage 1 0.005 <0.001
2 0.13 1.5 (0.89-2.55) 0.07 2.47 (0.91-6.68)
3 0.002 2.43 (1.38-4.29) <0.001 8.02 (2.93-21.98)
 Tumor location 0.24 1.26 (0.85-1.87) 0.08 1.67 (0.94-2.94)
 Tumor size 0.01 1.09 (1.02-1.18) 0.05 1.11 (1.00-1.24)
 MSS status MSS 0.79 0.3
MSI 0.5 0.84 (0.49-1.41) 0.2 0.55 (0.23-1.32)
Unknown 0.89 0.97 (0.59-1.58) 0.6 1.2 (0.59-2.41)
 Tumor in follow-up * 0.002 2.18 (1.32-3.59) 0.2 1.71 (0.69-4.20)
 Adjuvant therapy 0.69 1.1 (0.67-1.81) 0.1 0.57 (0.29-1.13)
 Univariate 
LRRFS DRFS
p-value HR (95% CI) p-value HR (95% CI)
 Combined markers 0.004 0.78 (0.66-0.93) 0.01 0.81 (0.68-0.95)
 Multivariate
 Combined markers 0.001 0.74 (0.62-0.88) 0.003 0.77 (0.64-0.92)
 Age at operation 0.05 1.23 (1.00-1.50) 0.02 1.29 (1.04-1.59)
 Gender 0.67 0.91 (0.58-1.42) 0.7 0.93 (0.58-1.48)
 TNM stage 1 <0.001 <0.001
2 0.3 1.51 (0.72-3.18) 0.2 1.62 (0.72-3.67)
3 0.001 3.63 (1.69-7.80) 0.001 3.99 (1.73-9.21)
 Tumor location 0.03 1.71 (1.05-2.78) 0.2 1.4 (0.84-2.35)
 Tumor size 0.004 1.14 (1.04-1.25) 0.004 1.15 (1.04-1.26)
 MSS status MSS 0.36 0.6
MSI 0.33 0.69 (0.34-1.44) 0.4 0.71 (0.34-1.48)
Unknown 0.37 1.32 (0.72-2.39) 0.8 1.07 (0.56-2.02)
 Tumor in follow-up * <0.001 3.39 (1.84-6.27) <0.001 3.89 (2.07-7.30)
 Adjuvant therapy 0.13 0.62 (0.33-1.16) 0.3 0.69 (0.36-1.32)
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SIRT1, HDAC1, HDAC2 and H4K16Ac
 Univariate 
OS DSS
p-value HR (95% CI) p-value HR (95% CI)
 Combined markers 0.06 0.89 (0.79-1.003) 0.002 0.75 (0.63-0.90)
 Multivariate
 Combined markers 0.01 0.86 (0.76-0.97) 0.001 0.73 (0.60-0.88)
 Age at operation <0.001 1.91 (1.59-2.29) 0.006 1.39 (1.01-1.77)
 Gender 0.8 1.05 (0.74-1.47) 0.8 0.93 (0.56-1.55)
 TNM stage 1 0.005 <0.001
2 0.07 1.61 (0.95-2.73) 0.07 2.54 (0.94-6.86)
3 0.002 2.6 (1.42-4.14) <0.001 7.72 (2.82-21.13)
 Tumor location 0.3 1.26 (0.85-1.86) 0.09 1.62 (0.92-2.88)
 Tumor size 0.01 1.1 (1.02-1.18) 0.02 1.14 (1.03-1.27)
 MSS status MSS 0.9 0.4
MSI 0.6 0.88 (0.53-1.47) 0.2 0.59 (0.24-1.42)
Unknown 0.9 0.96 (0.59-1.56) 0.6 1.23 (0.61-2.48)
 Tumor in follow-up * 0.005 2.02 (1.24-3.29) 0.2 1.72 (0.80-4.24)
 Adjuvant therapy 0.8 1.06 (0.65-1.73) 0.1 0.57 (0.29-1.13)
 Univariate 
LRRFS DRFS
p-value HR (95% CI) p-value HR (95% CI)
 Combined markers 0.003 0.79 (0.68-0.93) 0.01 0.81 (0.69-0.95)
 Multivariate
 Combined markers 0.001 0.77 (0.66-0.90) 0.006 0.79 (0.68-0.93)
 Age at operation 0.03 1.25 (1.02-1.54) 0.01 1.32 (1.06-1.63)
 Gender 0.5 0.85 (0.54-1.33) 0.6 0.87 (0.54-1.39)
 TNM stage 1 0.001 0.001
2 0.2 1.57 (0.75-3.29) 0.2 1.66 (0.73-3.76)
3 0.001 3.49 (1.62-7.53) 0.001 3.94 (1.70-9.12)
 Tumor location 0.04 1.67 (1.02-2.72) 0.2 1.37 (0.81-2.31)
 Tumor size 0.001 1.16 (1.06-1.27) 0.002 1.17 (1.06-1.28)
 MSS status MSS 0.4 0.7
MSI 0.4 0.76 (0.36-1.57) 0.5 0.76 (0.36-1.58)
Unknown 0.3 1.34 (0.74-2.45) 0.8 1.08 (0.57-2.06)
 Tumor in follow-up * <0.001 3.22 (1.76-5.90) <0.001 3.75 (2.01-6.99)





Survival analyses of  the combined marker groups. Shown are cumulative incidence curves after competing risk 
analyses for multi-marker analyses using histone deacetylases SIRT1, HDAC1 and HDAC2 combined with either 
H3K56Ac (A) or H4K16Ac (B). Group numbers 1-5 indicate the patient groups based on the number of  markers 
showing high expression, with group 1 (all low), group 2 (one high), group 3 (two high), group 4 (three high), and 
group 5 (all high). In panel C, the hazard ratios (HR; y-axis) related to disease-specific survival (DSS) are shown for the 
combined HDACs (SIRT1, HDAC1 and HDAC2) with each of  the histone modifications (H3K56Ac or H4K16Ac) 
compared to the reference group (group 1) for both univariate and multivariate analyses. HRs are indicated with ■, the 
corresponding 95% confidence intervals are indicated with protruding black lines.
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It seems paradoxical that although both HDAC1 and H3K56Ac showed no significantly different 
overall nuclear expression levels in normal versus tumor tissues in the whole study cohort, within 
individual tumors an inverse correlation was observed. Several studies have suggested different 
roles for HDAC1 in early stage versus advanced tumors (21,24), which suggests a qualitative 
difference rather than a quantitative difference between normal and tumor tissues. For both 
markers, survival differences were observed between patients with high and low nuclear 
expression in tumor cells of  the respective markers, indicating that in individual tumors, aberrant 
expression of  these markers could contribute to the tumorigenic process.
We have shown in this study that by combining multiple histone-modifying enzymes and histone 
modifications, distinct patient groups can be identified, stressing the importance of  analyzing 
multi-protein complexes together. A higher number of  markers showing high nuclear expression 
correlated with better patient survival and a lower chance of  tumor recurrence. This finding 
can be explained by regarding the cellular functions of  the histone deacetylases and the histone 
modifications. Higher expression of  the histone deacetylases might prevent aberrant activation of  
oncogenes and DNA repetitive sequences. Higher levels of  H4K16Ac, as discussed above, could 
be associated with silenced (methylated) repetitive sequences, which may result in less genomic 
events such as retrotransposition (LINE-1), translocations, or DNA double strand breaks. High 
levels of  H3K56Ac are necessary for proper non-homologous end-joining, resulting in less 
error-prone repairs of  double strand breaks and hence lower chances of  developing rapidly 
mutating and aggressive tumors.
The immunohistochemical stainings presented in this study can be easily implemented in a 
clinical setting, as all stainings are performed on paraffin-embedded tissues. With the present-
day technological advances using computer-based recognition software, the semi-automated 
scoring we used might be a first step towards automated scoring of  nuclear staining in a clinical 
setting, thereby reducing the influence of  subjectivity of  human interpretation of  color and 
color-intensity. Future studies could address the differences in epigenetic regulation between 
the tumor center and the tumor invasive front on whole tumor sections, as many studies have 
already reported differential expression of  various proteins at different sites within the tumor 
(25). In addition, comparing tumor cells and the tumor microenvironment might provide useful 
information in understanding the role of  epigenetic changes in colorectal cancer development 
and/or progression.
In conclusion, we have shown in this study that global nuclear expression of  histone modifications 
and histone deacetylases were correlated to clinical outcome in colorectal cancers. Combining 
multiple markers gives us more insight into the complex interplay between histone modifiers 
and histone modifications. These results are a first indication that combining multiple epigenetic 
markers results in identification of  distinct patient groups, and provide insight in the involvement 
of  epigenetic mechanisms in colorectal cancer growth. More research is needed to study the 
exact functions of  the studied histone deacetylases and their associated histone modifications, 
and to identify other combinations of  epigenetic markers that play a role in colorectal cancer. 
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Expression of  histone modifications versus histone deacetylases. Shown are boxplots indicating mean nuclear 
expression levels (as determined using immunohistochemistry) in tumor cells of  the histone modifications versus each 
of  the individual enzymes. P-values represent paired students t-test results.
Supplementary TABLE 1 (see next two pages)
Shown are the results of  the univariate and multivariate analyses of  the combined markers using the patient groups as 
categorical variables, with all p-values and hazard ratios (HR) with their 95% confidence intervals (95% CI). OS = overall 
survival, DSS = disease-specific survival, LRRFS = locoregional recurrence-free survival, DRFS = distant recurrence- 
free survival. Patients groups were made based on the number of  markers showing high (above-median) expression: all 
low (group 1), 1 high (group 2), 2 high (group 3), 3 high (group 4) and all high (group 5). Significant values are shown in 
bold, p-values showing a trend (between p=0.05 and p=0.1) in Italic. * =second primary tumor during follow-up period.
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Numerous changes in epigenetic mechanisms have been described in various types of  tumors. In 
search for new biomarkers, we investigated the expression of  Polycomb-group (PcG) proteins 
EZH2, BMI1 and SUZ12 and associated histone modification H3K27me3 in colorectal cancer. 
PcG proteins and histone modification H3K27me3 were immunohistochemically (IHC) 
stained on a tissue microarray (TMA), including 247 tumor tissues and 47 normal tissues, and 
nuclear expression was scored using the semi-automated Ariol system. Tumor tissues showed 
higher expression of  EZH2 (p=0.05) and H3K27me3 (p<0.001) as compared to their normal 
counterparts. Combined marker trend analyses indicated that an increase in the number of  
markers showing high expression was associated with better prognosis. High expression of  all 
four markers in the combined marker analyses was correlated with the best patient survival 
and the longest recurrence-free survival, with overall survival (p=0.01, HR 0.42 (0.21-0.84)), 
disease-free survival (p=0.007, HR 0.23 (0.08-0.67)) and local recurrence-free survival (p=0.02, 
HR 0.30 (0.11-0.84)). In conclusion, we found that expression of  PcG proteins and H3K27me3 
showed prognostic value in our study cohort. Better stratification of  patients was obtained by 
combining the expression data of  the investigated biomarkers as compared to the individual 
markers, underlining the importance of  investigating multiple markers simultaneously.




New prognostic biomarkers are warranted in colorectal cancer that could improve decisions for 
treatment of  individual patients in addition to the current TNM (American Joint Committee on 
Cancer, AJCC (1)) staging system, as even patients with the same TNM classification present 
with large differences in patient survival and tumor recurrence (2,3). Epigenetic mechanisms 
have been identified as factors frequently deregulated in tumors and are attractive targets for 
biomarker research, because of  their roles in regulating gene expression and their potentially 
reversible nature. Numerous changes in DNA methylation, histone modifications and their 
modifying enzymes have been described in various tumor types, including colorectal cancer 
(4-6). In this study, we focused on expression of  histone-modifying enzymes of  the Polycomb-
group (PcG) and their associated histone modification, trimethylation of  lysine 27 on histone 
H3 (H3K27me3), in colorectal cancer tissues.
The PcG proteins act in large multi-protein complexes, the so-called Polycomb repressive 
complexes (PRC) 1 and 2 (7). PcG proteins play an important role in embryonic development 
and cell proliferation (8,9), and are also involved in inducing epithelial-mesenchymal transition 
(EMT) (10). Aberrant expression of  several PcG proteins and correlations with patient outcome 
have been reported in various cancers. For example, expression of  BMI1 polycomb ring finger 
oncogene (BMI1), a component of  PRC1 and an important factor in stem cells (11,12), was 
found to be correlated to patient outcome in several types of  cancer (13-16). Enhancer of  zeste 
homolog 2 (EZH2), a key protein in the PRC2 complex, was also found to have prognostic value 
in several types of  cancer (17-20). SUZ12 polycomb repressive complex 2 subunit (SUZ12), 
another key component of  the PRC2 complex, was found to have tumor-promoting functions in 
several cancers, including colon cancer (21-23). The associated histone modification H3K27me3 
was found to be higher expressed in tumor tissues, and to be associated with better prognosis in 
non-small cell lung cancer (24) and breast cancer (19). 
Using immunohistochemical staining (IHC) and semi-automated scoring, we studied the 
expression of  PcG proteins EZH2, BMI1 and SUZ12 and their associated histone modification 
H3K27me3 in a cohort of  247 TNM stage I-III colorectal cancer patients, in correlation with 
clinical outcome. As the PcG proteins act together on the same histone modification, we 
hypothesized the combination of  all four markers would be more informative with respect to 
clinical outcome as compared to each of  the individual markers. 
Materials and methods
Patient selection
Tumor tissues were collected from a consecutive series of  408 colorectal cancer patients 
who underwent surgical resection of  their primary tumor at the Leiden University Medical 
Center (LUMC) between 1991 and 2001. Patients who underwent pre-operative treatment, 
who had bilateral tumors, or a history of  cancer other than basal cell carcinoma or in situ 
tumors, were excluded from the study analyses. In addition, we included only patients with a 




pathologist. This resulted in a study cohort of  259 patients, with a mean follow-up of  8.6 years. 
Clinicopathological data were available for all patients in the study cohort. Data were right-
censored when patients were alive or free of  recurrence at their last follow-up date. Patient 
characteristics are displayed in Table 1. Patient records information was anonymized and 
de-identified prior to analysis according to national ethical guidelines (“Code for Proper 
Secondary Use of  Human Tissue”, Dutch Federation of  Medical Scientific Societies), and 
approved by the Medical Ethical Committee of  the Leiden University Medical Center (LUMC). 
This study was performed according to the REMARK guidelines (NCI-EORTC) (25).
Tissue microarray construction and immunohistochemistry
Formalin-fixed paraffin-embedded (FFPE) tumor tissues from each of  the patients in the 
consecutive series of  colorectal cancer patients (n=408) were collected from the LUMC pathology 
archives and used to construct a tissue microarray (TMA), as described previously (26). Sections of  
4µm were cut from each TMA block and used for IHC staining. Histologically normal colorectal 
tissues, as determined by an experienced pathologist, from 47 patients with corresponding 
tumor tissues included in this study were also collected and prepared for IHC. The following 
antibodies were used for IHC: anti-EZH2 (612667, BD Biosciences, San Jose, CA, USA), anti-
BMI1 (ab14389, Abcam, Cambridge, UK), anti-SUZ12 (ab12073, Abcam) and anti-H3K27me3 
(ab6002, Abcam). All antibodies have been validated for use in immunohistochemistry by Western 
blot (27-30). All primary antibodies were used at predetermined optimal dilutions and IHC was 
performed using a standard IHC protocol (31). Briefly, endogenous peroxidase was blocked by 
incubating the sections in a 0.3% solution of  hydrogen peroxide (in PBS) for 20 min. Antigen 
retrieval was performed by heating the sections for 10 min at 95ºC in a citrate buffer (pH 6; pH 
Low Target Retrieval Solution, Dako, Glostrup, Denmark) for EZH2, BMI-1 and H3K27me3 
and by heating the sections for 10 min at 95ºC in a Tris-EDTA buffer (pH 9; pH High Target 
Retrieval Solution, Dako) for SUZ12. TMA sections were incubated with the respective primary 
antibodies overnight (16 hrs). Staining was visualized using the Dako REAL™ EnVision™ 
Detection System, Peroxidase/DAB+, Rabbit/Mouse (Dako). The stained TMA sections were 
scanned using a 20x magnification on the semi-automated Ariol system (Leica Microsystems, 
Wetzlar, Germany). Tumor cell areas (tumor tissues) and colon epithelium (in normal tissues) 
were marked on the computer screen upon visual inspection, followed by careful training of  
the Ariol system to correctly identify positively stained and negative nuclei within the marked 
tissue areas, for each of  the markers separately. Nuclear expression, defined as the percentage of  
positively stained nuclei in the marked area of  each tissue core, was then assessed by the Ariol 
software. Several random cores were evaluated for each TMA section by visual inspection after 
automated analysis in order to verify correct identification of  positively stained nuclei.
Statistical analyses
Data were analyzed in consultation with a statistician (H.P.) using SPSS 20.0 for Windows (SPSS 
Inc, Chicago, USA). 12 patients were excluded from the statistical analyses, as not all data of  
all four markers was available for these patients, resulting in a final patient cohort consisted of  
247 patients. As the individual marker data were not normally distributed (Shapiro-Wilk test),
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TABLE 1.  Patient characteristics of  the study cohort
All patients Study cohort
(n=408) (n=247)
n (%) n (%) p-values
 Age at randomization
 <50 45 11 32 13
 50-75 267 65.4 155 62.8
 >=75 96 23.6 60 24.3 0.69
 Gender
 Male 202 49.5 127 51.4
 Female 206 50.5 120 48.6 0.66
 TNM stage
 I 78 19 52 21.1
 II 149 36.7 110 44.5
 III 114 27.9 85 34.4 0.21
 IV 67 16.4
 Tumor location
 Colon 289 71 181 73.3
 Rectum 119 29 66 26.7 0.6
 Tumor size
 Mean (cm) 4.68 4.71
 Standard error 2.22 1.53 0.95
 MSS status
 MSS 275 67.2 169 68.4
 MSI 46 11.2 34 13.8
 Unknown 87 21.6 44 17.8 0.76
 Tumor in follow up
 No 347 85 209 84.6
 Yes 61 15 38 15.4 0.91
 Adjuvant therapy
 No 323 79.2 199 80.6
 Yes 85 20.8 48 19.4 0.97
Patient characteristics are shown for both the omplete colorectal cancer series (n=408) and the study cohort (n=247). 
Patient selection was based on availability of  FFPE tissues and available data for all four studied markers. The study 
cohort selection was representative for the entire colorectal cancer series. P-values represent the results of  Student’s 





non-parametric Wilcoxon signed-rank tests were performed to assess the differences in nuclear 
expression between tumor and paired normal tissues (n=47) for each of  the markers. Spearman’s 
signed rank correlation analyses were performed to investigate the correlation between 
nuclear expression of  the individual PcG proteins and histone modification H3K27me3. 
Cox proportional hazard trend analyses were performed for univariate and multivariate 
survival analyses of  individual markers. Covariates included in all multivariate analyses were 
age at operation, gender, TNM tumor stage (tumor stages I-III), tumor location, tumor size, 
microsatellite stability (MSS) status. Covariates “tumor in the follow up” and “adjuvant therapy” 
were entered as time-dependent covariates. Overall survival (OS) was defined as the time from 
surgery until death (by any cause). Disease-free survival (DFS) was defined as the time from 
surgery until the occurrence of  a second primary colorectal tumor, locoregional recurrence or 
distant recurrence, or death by colorectal cancer. Locoregional recurrence-free survival (LRRFS) 
was defined as the time from surgery until the occurrence of  a locoregional recurrence or death 
by cancer. Distant recurrence-free survival (DRFS) was defined as the time from surgery until 
the occurrence of  a distant recurrence or death by cancer.
On the basis of  the skewed distribution of  expression data of  each of  the individual markers, 
the median expression was used to divide the patients into high expression (above-median) 
and low expression (below-median) groups. The four markers were then combined into a new 
variable, based on the number of  markers showing high nuclear expression, resulting in the 
following grouping: all low (group 1), 1 high (group 2), 2 high (group 3), 3 high (group 4) and 
all high (group 5). Univariate and multivariate Cox proportional hazard analyses were performed 
using the group numbers as a categorical variable, using group 1 (all low) as the reference group. 
On the basis of  these results we decided to combine patient groups 2, 3, and 4 into one patient 
group; all further statistical analyses were performed using three patient groups. In addition to 
the Cox proportional hazard analyses, trend analyses were performed using the group numbers 
as continuous variables to assess the influence of  the combined markers on patient survival 
and tumor recurrence. Resulting hazard ratios (HR) represent the HR for each unit of  increase 
(increase in group number). Cumulative incidence curves were made for DFS, LRRFS and DRFS, 
accounting for competing risks (32). Kaplan-Meier curves were used to visualize differences 
between the three patient groups for OS. For all statistical analyses, two-sided p-values ≤ 0.05 
were considered statistically significant, and p-values 0.05 < p ≤ 0.1 were considered a trend.
Results
Expression in tumor versus paired normal colorectal tissues
Nuclear expression of  all individual markers (EZH2, BMI1, SUZ12 and H3K27me3) in tumor 
tissues was compared to nuclear expression in paired normal colorectal tissues. When analyzing 
expression differences in the study cohort as a whole, only median H3K27me3 and EZH2 
expression were significantly different between tumor and normal tissues (p<0.001 and p=0.05, 
respectively; Figure 1A). In individual tumors, however, all markers showed marked differences 
in expression compared to their normal counterparts (Figure 1B). Survival analyses based on 
below- or above-median expression in the normal tissues did not show differences in patient 
survival or tumor recurrence (data not shown).




Figure legends: see next page




























































































Normal (median)  10.1 
Tumor (median)    17.7 
Normal (median)  12.6 
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Figure 1 (see previous page)  A. Differences in nuclear expression between normal and tumor tissues of  individual 
markers.. Displayed are differences in nuclear expression, measured as the percentage of  positively stained nuclei, 
between normal and tumor tissues (n=47). Boxplots show the median and range of  expression of  each of  the individual 
markers in normal (N) and tumor (T) samples. The median percentages of  positive nuclei are given for each of  the 
markers. P-values represent statistical differences between normal and tumor samples, calculated using the Wilcoxon 
signed rank test.. B. Histograms show the difference in expression between tumor and paired normal tissues (y-axis) for 
each of  the individual patients (x-axis). Differences in expression were calculated as follows: expression difference = 
expression in tumor tissue – expression in normal tissue. Negative values indicate higher expression in normal tissues, 
positive values indicate higher expression in tumor tissues.
Individual marker analyses in tumor tissues
Examples of  identification of  positive and negative tumor cell nuclei for each of  the individual 
markers by the Ariol system are shown in Figure 2. We first analyzed if  the expression of  histone 
modification H3K27me3 was correlated to the expression of  the individual PcG proteins. 
The nuclear expression (percentage of  positive nuclei) of  H3K27me3 was indeed positively 
correlated with expression of  EZH2 (p<0.001), BMI1 (p<0.001) and SUZ12 (p=0.05). No 
correlation was observed between the expression of  the individual markers and TNM tumor 
stage. For survival analyses, patients were divided into low and high expression groups on the 
basis of  the median expression of  each of  the individual markers, as given in Figure 1A. In 
survival analyses of  individual markers, BMI1 showed strong correlations to patient survival (OS 
and DFS) and tumor recurrence (LRRFS and DRFS) in both univariate and multivariate analyses 
(Table 2). EZH2 and H3K27me3 showed significant correlations for DFS only.
Figure 2
Identification of  positive and negative tumor cell nuclei by the Ariol system. The Ariol system trainer overlay 
shows correct identification of  positive (indicated by yellow dots) and negative (blue dots) nuclei in tumor cores. TMA 
slides were scanned using a 20x magnification. Shown for all markers are positively stained tumor cores (top row) and 







Polycomb proteins and H3K27me3
85
5
TABLE 2.  Univariate and multivariate survival analyses individual markers
EZH2 BMI1 SUZ12 H3K27me3
 OS
 Univariate
 p-value 0.07 0.05 0.9 0.5
 HR 0.74 0.73 1.03 0.89
 (95% CI) (0.54-1.03) (0.53-1.00) (0.73-1.47) (0.64-1.24)
 Multivariate
 p-value 0.3 0.009 0.3 0.5
 HR 0.84 0.62 0.83 0.88
 (95% CI) (0.60-1.18) (0.44-0.89) (0.57-1.20) (0.62-1.24)
 DFS
 Univariate
 p-value 0.04 0.08 0.8 0.07
 HR 0.64 0.68 0.95 0.66
 (95% CI) (0.42-0.99) (0.44-1.04) (0.60-1.49) (0.42-1.03)
 Multivariate
 p-value 0.08 0.03 0.2 0.05
 HR 0.67 0.61 0.71 0.64
 (95% CI) (0.43-1.05) (0.39-0.96) (0.44-1.17) (0.41-0.99)
 LRRFS
 Univariate
 p-value 0.06 0.03 0.8 0.2
 HR 0.67 0.63 1.06 0.76
 (95% CI) (0.44-1.03) (0.41-0.96) (0.67-1.68) (0.49-1.18)
 Multivariate
 p-value 0.1 0.005 0.6 0.2
 HR 0.71 0.52 0.88 0.76
 (95% CI) (0.46-1.11) (0.33-0.82) (0.55-1.42) (0.49-1.19)
 DRFS
 Univariate
 p-value 0.04 0.06 0.6 0.4
 HR 0.64 0.66 1.11 0.83
 (95% CI) (0.42-0.99) (0.48-1.02) (0.69-1.77) (0.53-1.29)
 Multivariate
 p-value 0.1 0.02 0.7 0.6
 HR 0.73 0.58 0.91 0.89
 (95% CI) (0.46-1.15) (0.36-0.92) (0.56-1.48) (0.57-1.42)
Shown are the results of  the univariate and multivariate analyses of  all individual markers, with all p-values and hazard 
ratios (HR) and their 95% confidence intervals (95% CI). The “low expression” group was used as the reference group. 
OS = overall survival, DSS = disease-specific survival, LRRFS = locoregional recurrence-free survival, DRFS = distant 
recurrence-free survival. Significant p-values are indicated in bold, p-values showing a trend (between 0.5 and 1.0) in 
Italic.
For all three markers (BMI1, EZH2 and H3K27me3), high expression was associated with better 
patient survival as compared to the patients showing low expression, with p-values for DFS of  
p=0.07 (BMI1), p=0.04 (EZH2) and p=0.06 (H3K27me3). SUZ12 did not show any differences 






We hypothesized that combining multiple markers would result in better stratification of  
patients. Therefore, we performed statistical analyses on combinations of  the histone-modifying 
enzymes. These analyses showed that combining multiple markers indeed resulted in statistically 
significant differences between the patient groups and more pronounced hazard ratios, indicating 
a more pronounced effect on patient survival. The combination of  histone-modifying enzymes 
EZH2 and BMI1 showed significant differences for both patient survival and recurrence-free 
survival, with p=0.02 (HR=0.72; 95% CI 0.54-0.94) for DFS and p=0.012 (HR=0.71; 95% CI 
0.54-0.92) for LRRFS in multivariate analyses. Combining EZH2 and SUZ12 showed a trend 
for DFS in multivariate analyses, with p=0.08 (HR=0.77; 95% CI 0.57-1.04). The combination 
of  BMI1 and SUZ12 showed significant differences for patient survival, with p=0.02 (HR=0.76; 
95% CI 0.61-0.96) for overall survival and p=0.05 (HR=0.73; 95% CI 0.54-1.00) for DFS.
Figure 3
Trend analyses and hazard ratios of  combined marker groups. Patient groups were made on the basis of  the 
number of  markers showing high expression: all low (group 1), one high (group 2), two high (group 3), three high 
(group 4) and all high (group 5). A. Univariate and multivariate Cox regression trend analyses were performed using the 
combined marker groups as continuous variables. Hazard ratios per unit increase of  each of  the patient groups were 
plotted (B) and listed (C) for both the univariate and multivariate  Cox regression trend analyses using the combined 
marker groups as categorical variables. The numbers of  patients in the individual patient groups were: group 1 (n=28), 
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p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) 
Univariate 0.09 0.88 (0.77-1.02) 0.04 0.83 (0.69-0.99) 0.08 0.85 (0.71-1.02) 0.12 0.86 (0.72-1.04) 
Multivariate 0.05 0.87 (0.76-1.00) 0.01 0.79 (0.65-0.95) 0.04 0.83 (0.69-0.99) 0.12 0.86 (0.71-1.04) 
Overall survival combined markers 
   
Univariate p-value HR (95% CI) 
Group 1 0.07     
Group 2 0.02 0.53 (0.31-0.92) 
Group 3 0.02 0.52 (0.29-0.90) 
Group 4 0.07 0.62 (0.36-1.04) 
Group 5 0.01 0.41 (0.21-0.80) 
        
Multivariate p-value HR (95% CI) 
Group 1 0.2     
Group 2 0.3 0.73 (0.41-1.29) 
Group 3 0.2 0.67 (0.37-1.20) 
Group 4 0.3 0.77 (0.44-1.34) 
Group 5 0.02 0.42 (0.21-0.84) 
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Because the three PcG proteins act together in multi-protein complexes to regulate H3K27me3 
expression, we hypothesized that combining all markers (BMI1, EZH2, SUZ12 and H3K27me3) 
into one variable would result in even better stratification of  patients. Patients were divided 
into five groups on the basis of  the number of  markers showing high nuclear expression. This 
resulted in the following patient groups: all low (group 1), one high (group 2), two high (group 
3), three high (group 4) and all high (group 5). Patient characteristics of  the 5 patient groups 
were comparable to the study cohort (Table S1). Multivariate trend analyses of  the combined 
markers, using the patient group numbers as continuous variables, showed overall hazard ratios 
of  0.79-0.88 for each additional marker showing high nuclear expression in both univariate and 
multivariate analyses, indicating better patient survival and lower chances of  tumor recurrence 
for each additional marker showing high expression (Figure 3A). When the patient group 
numbers were entered as categorical variables, a similar trend was observed (Figures 3B and 
3C). Generally, hazard ratios for OS decreased with increasing group number, indicating a better 
patient survival when more markers were highly expressed compared to the “all low” expression 
group (group 1). Patients showing high expression of  all markers, the “all high” group (group 5), 
showed the best overall survival (p=0.01, HR=0.42, 95% CI 0.21-0.84) as compared to reference 
group 1, which showed the shortest survival. Groups 2, 3 and 4 showed similar hazard ratios 
(Figures 3B and 3C), which was also reflected in the Kaplan-Meier survival curves that run 
close together as compared to the survival curves of  groups 1 and 5. Therefore, we decided 
to combine the three patient groups 2,3 and 4 into one group, resulting in three patient groups 
(group 1, groups 2-4 and group 5). Kaplan-Meier curves and cumulative incidence plots showed 
significant differences between the three resulting patient groups for OS, DFS, LRRFS and a 
trend for DRFS, which were also reflected in the 5-year survival rates (Figure 4). The best patient 
survival and longest recurrence-free periods were observed for patients showing high expression 
of  all four markers (“all high”, group 5) in the tumor samples, with 5-year survival rates of  77% 
for OS, 83% for DFS and DRFS, and 86% for LRFS. Patients in combined groups 2-4 showed 
shorter OS, DFS and LRFS, with 5-year survival rates of  67% for OS and DFS, 69% for LRFS 
and 72% for DRFS. Patients in the “all low” group (group 1) showed significantly shorter OS, 
DFS and LRFS compared to either of  the other patient groups, with 5-year survival rates of  
43% for OS and LRFS, 49% for DFS and 55% for DRFS. Taken together, 5-year survival rates 
were lower when more markers showed low expression. The hazard ratios in both univariate 
and multivariate also reflected these findings (Table 3): group 5 shows the lowest hazard ratio as 
compared to reference group 1 (for example, multivariate HR=0.23 (0.08-0.67) for DFS). This 
indicates a lower risk of  an event (patient death or locoregional tumor recurrence) for patients in 
the “all high” group for OS, DFS and LRFS. For DRFS, statistically significant results were only 
observed in univariate analyses. 
Discussion
In addition to gene mutations, aberrant expression patterns of  epigenetic regulators have 
been recognized as crucial events in the tumorigenic process, resulting in marked changes 
in gene expression. Changes in the expression of  these epigenetic regulators include DNA 
methyltransferases and consequent changes in DNA methylation profiles, and histone-modifying 





Survival curves for the combined marker groups. Combined marker (EZH2, BMI1, SUZ12 and H3K27me3) 
expression groups were divided into three patient groups: group 1, groups 2-4 and group 5. The numbers of  patients 
in the individual patient groups were: group 1 (n=28), group 2 (n=59), group 3 (n=55), group 4 (n=74) and group 5 
(n=31). Kaplan-Meier curves were made for overall survival (A) and cumulative incidence curves are shown for disease-
free survival (B), locoregional recurrence-free survival (C) and distant recurrence-free survival (D). 5-year survival rates 
are given for each patient group. Tables below the curves indicate the numbers at risk (#) per group for the different 
time points.
Figure  
# at risk  5  10  15 20 
Group 1 12 9 3  1  
Group 2-4 126 87 28 1 
Group 5 24 13 7 0 
# at risk         5  10  15 20 
Group 1 10 9 3  1  
Group 2-4 104 77 25 1 
Group 5 22 13 7 0 
# at risk  5  10  15 20 
Group 1 11 9 3  1  
Group 2-4 110 81 26 1 
Group 5 23 13 7 0  
# at risk  5  10  15 20 
Group 1 11 9 3  1  
Group 2-4 112 82 26 1 
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TABLE 3.  Univariate and multivariate analyses combined markers
Univariate Multivariate
p-value HR (95% CI) p-value HR (95% CI)
 OS  Group 1 0.018 0.05
 Groups 2-4 0.014 0.56 (0.35-0.89) 0.21 0.72 (0.44-1.19)
 Group 5 0.009 0.41 (0.21-0.80) 0.01 0.42 (0.21-0.84)
 DFS  Group 1 0.07 0.03
 Groups 2-4 0.1 0.64 (0.33-1.21) 0.2 0.61 (0.31-1.22)
 Group 5 0.02 0.32 (0.12-0.86) 0.007 0.23 (0.08-0.67)
 LRRFS  Group 1 0.06 0.03
 Groups 2-4 0.2 0.64 (0.34-1.22) 0.96 1.02 (0.49-2.09)
 Group 5 0.02 0.31 (0.11-0.83) 0.02 0.30 (0.11-0.84)
 DRFS  Group 1 0.12 0.24
 Groups 2-4 0.11 0.59 (0.31-1.13) 0.66 0.85 (0.41-1.75)
 Group 5 0.05 0.38 (0.15-0.98) 0.11 0.44 (0.16-1.20)
Results of  Cox proportional hazard univariate and multivariate analyses are shown for combined markers EZH2, BMI1, 
SUZ12 and H3K27me3, with p-values and hazard ratios with their 95% confidence intervals. Patient groups were made 
based on the number of  markers showing high expression: all low (group 1), one, two or three high (groups 2-4) and 
all high (group 5). Group 1 was used as the reference group. Covariates included in all multivariate analyses were age 
at operation, gender, TNM tumor stage, tumor location, tumor size, microsatellite stability (MSS) status, tumor in the 
follow up and adjuvant therapy. Significant values are shown in bold, p-values showing a trend (between 0.5 and 1.0) 
in Italic.
investigated the expression of  three PcG proteins (EZH2, BMI1 and SUZ12) and associated 
histone modification H3K27me3 in colorectal cancer tissues. Aberrant expression of  each of  
these histone-modifying enzymes, and of  histone modification H3K27me3, has been indicated 
to contribute to tumorigenesis in several types of  cancer and has been correlated to patient 
outcome (11-24). Studies in literature show conflicting results regarding the prognostic value 
of  the Polycomb-group proteins in colorectal cancer. For example, high EZH2 expression has 
been associated with poor prognosis in a series of  colorectal cancer patients by Wang et al. (33), 
whereas high EZH2 expression was found to be associated with better relapse-free survival in 
colon cancer patients (but not in rectal cancer patients) by Fluge et al. (34). In addition, high 
expression of  BMI1 was found to correlate with good prognosis in breast cancer in a study by 
Pietersen et al. (35), whereas high BMI1 was associated with poor prognosis in colon cancer in a 
study by Du et al. (36). In our study cohort, survival data for the individual markers showed that 
high expression of  all markers was correlated with better patient survival and longer recurrence-
free periods as compared to patients showing low expression. The results found in this study 
correspond to our previous findings that high expression of  H3K27me3 was associated with 
better patient survival in rectal tumors (4). In this study, we showed that high expression of  




periods. As we showed that the expression of  the PcG proteins was directly related to the 
expression of  H3K27me3, we expected a similar correlation of  expression of  the PcG proteins 
with clinical outcome, which was indeed confirmed by the results presented in this manuscript. 
High levels of  H3K27me3, because of  aberrant expression of  PcG proteins, might prevent 
aberrant expression of  oncogenes, activation of  retrotransposon sequences (such as LINE-1; 
4), and result in other (epi)genomic events that promote tumor aggressiveness.
In addition to the individual markers, combinations of  PcG proteins in correlation with patient 
outcome have been studied by several research groups. For example, co-expression of  EZH2 
and BMI1 was reported to be associated with poor prognosis in various cancers (37-39). In 
contrast, overexpression of  EZH2 and BMI1 were reported to have different influences on 
patient prognosis in breast cancer (35), and was found to have no prognostic value in urothelial 
carcinoma of  the bladder (40). In our colorectal cancer study cohort, all combinations of  
histone-modifying enzymes showed prognostic value. In order to obtain more information 
about epigenetic pathways with potential prognostic value in colorectal cancer, we performed 
multivariate survival analyses using combined expression data of  multiple PcG proteins (EZH2, 
BMI1 and SUZ12) and their associated histone modification H3K27me3. Combining the 
three PcG proteins and their associated histone modification resulted in significantly better 
stratification of  patient groups as compared to the individual markers. In combined marker 
analyses, the best patient survival and longest recurrence-free periods were observed for patients 
showing high expression of  all four markers (“all high”) in the tumor samples. Patients in the 
“all low” group showed significantly shorter OS, DFS and LRFS compared to either of  the other 
patient groups. The results of  the combined marker analyses underline the co-operation of  these 
three enzymes in PcG complexes, and thus provide a better risk stratification of  patients.
In addition to the roles of  EZH2, BMI1 and SUZ12 in epigenetic regulation of  chromatin 
structure and gene expression, direct regulation of  protein function has been described for EZH2 
and BMI1, including protein phosphorylation and ubiquitination. A cytosolic EZH2 and SUZ12-
containing methyltransferase complex has been linked to actin polymerization, an important 
process in cell proliferation (41). Shuttling of  the EZH2 and SUZ12 containing complex between 
different cellular compartments may explain the weak cytosolic staining observed for EZH2 
and SUZ12 in addition to the strong nuclear staining for these markers, as compared to the 
strict nuclear staining observed for BMI1. Another non-histone protein methylated by EZH2 is 
cardiac transcription factor GATA4. Methylation reduces its transcriptional activity, resulting in 
inhibition of  proper cardiac development (42). These examples indicate that aberrant expression 
of  these PcG proteins influences key processes such as gene transcription and cell proliferation, 
promoting the transformation of  normal cells into tumor cells.
In conclusion, we showed that combined expression of  PcG proteins EZH2, BMI1 and SUZ12 
and their associated histone modification H3K27me3 has prognostic value in our colorectal 
cancer study cohort. Combined marker expression resulted in better stratification of  patients 
as compared to the individual markers and hence provides more insight into the roles of  these 
epigenetic proteins and –modifications in colorectal cancer. Other combinations of  epigenetic 
mechanisms should be investigated in colorectal cancer to further unravel the underlying biology 
in individual tumors. This will advance the search for new biomarkers to be used in a clinical 
setting in order to better classify patients for treatment.
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for immunohistochemistry.
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Patient characteristics are shown for all patient groups as used in the combined-marker analyses. The patient groups 
show comparable patient characteristics to the complete study cohort of  247 patients (Table 1). P-values represent the 
Jonckheere-Terpstra test used to test if  samples came from the same distribution. For the variable “tumor size”, a one-
way ANOVA test was performed to test for statistical differences between the patient groups. * = second primary tumor 
during follow-up period. MSS = microsatellite stable, MSI = microsatellite instable.
 











p-valuesn (%) n (%) n (%) n (%) n (%)
Age at randomization
<50 1 3.6 9 15.3 9 16.4 10 13.5 3 9.7
0.81
50-75 15 53.6 41 69.5 36 65.5 47 63.5 16 51.6
>=75 12 42.9 9 15.3 10 18.2 17 23 12 38.7
Gender
Male 14 50 28 47.5 27 49.1 36 48.6 15 48.4
0.99Female 14 50 31 52.5 28 50.9 38 51.4 16 51.6
TNM stage
I 7 25 12 20.3 12 21.8 14 18.9 7 22.6
0.56
II 9 32.1 27 45.8 25 45.5 31 41.9 18 58.1
III 12 42.9 20 33.9 18 32.7 29 39.2 6 19.4
Tumor location
Colon 18 64.3 44 74.6 40 72.7 61 82.4 18 58.1
0.85Rectum 10 35.7 15 25.4 15 27.3 13 17.6 13 41.9
Tumor size
Mean (cm) 4.55 4.5 4.72 4.89 4.77
0.91
Standard 
error 0.55 0.31 0.32 0.37 0.41
MSS status
MSS 18 64.2 44 74.6 35 63.6 51 68.9 21 67.7
0.73
MSI 5 17.9 7 11.9 10 18.2 8 10.8 4 12.9
Unknown 5 17.9 8 13.6 10 18.2 15 20.3 6 19.4
Tumor in follow up*
No 25 89.3 52 88.1 45 81.8 65 87.8 22 71
0.52Yes 3 10.7 7 11.9 10 18.2 9 12.2 9 29
Adjuvant therapy
No 25 89.3 45 76.3 48 87.3 55 74.3 26 83.9
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Background: Post-translational modification of  histone tails by methylation plays an important 
role in tumorigenesis. In this study, we investigated the nuclear expression of  H3K4me3, 
H3K9me3 and H4K20me3 in early-stage colon cancer in relation to clinical outcome.
Methods: Tumor tissue cores of  254 TNM stage I-III colorectal cancer patients were 
immunohistochemically stained for H3K4me3, H3K9me3 and H4K20me3 and scored using 
the semi-automated Ariol system. Cox proportional hazard trend analyses were performed to 
assess the prognostic value of  the combined markers with respect to patient survival and tumor 
recurrence.
Results: The histone methylation markers only showed prognostic value in early-stage (TNM 
stage I and II) colon cancer. Therefore, only this patient set (n=121) was used for further 
statistical analyses. Low nuclear expression of  H3K4me3, and high expression of  H3K9me3 
and H4K20me3 were associated with good prognosis. In combined marker analyses, the patient 
group showing most favorable expression (low H3K4me3, high H3K9me3 and high H4K20me3) 
was associated with the best prognosis. Multivariate trend analyses showed significantly increased 
hazard ratios (HR) for each additional marker showing unfavorable expression, as compared 
to the “all favorable” reference group. The HR for disease-free survival was 3.81 (1.72-8.45; 
p=0.001), for locoregional recurrence-free survival 2.86 (1.59-5.13; p<0.001) and for distant 
recurrence-free survival 2.94 (1.66-5.22; p<0.001).
Conclusions: Combined nuclear expression of  histone modifications H3K4me3, H3K9me3 
and H4K20me3 is prognostic in early-stage colon cancer. The combination of  expression of  the 
three histone modifications provides better stratification of  patient groups as compared to the 
individual markers and provides a good risk assessment for each patient group.




In tumor cells, numerous changes in epigenetic regulation of  gene expression have been reported 
(1). As epigenetic mechanisms are potentially reversible, they represent suitable targets for the 
development of  new anti-cancer therapies. Both DNA methylation and histone modifications 
might therefore present as possible new biomarkers in cancer. In this study, we investigated the 
clinical prognostic value of  several histone modifications in early-stage (TNM stage I and II) 
colon cancer.
Epigenetic regulation of  gene expression through post-translational modification of  histone 
proteins by methylation plays an important role in many biological processes, including cell-
cycle regulation, DNA damage- and stress response, embryonic development and cellular 
differentiation (2). The most extensively studied histone methylation sites include histone 
H3 lysine 4 (H3K4), H3K9 and H4K20. Altered expression of  these - and other - histone 
modifications has been reported in cancer (3). For example, expression of  H3K4me3 was shown 
to have prognostic value in hepatocellular carcinoma (4) and renal cell carcinoma (5). Cancer-
associated upregulation of  H3K9me3 was prognostic in acute myeloid leukemia (6), salivary 
carcinoma (7) and bladder cancer(8). Expression of  H4K20me3 was shown to be correlated 
to tumor progression and prognosis in non-small cell lung cancer (9). Marión et al. showed that 
loss of  H4K20me3 contributed to telomere reprogramming and hence a higher tumorigenic 
potential (10). As these three histone methylation markers have been found to contribute to the 
tumorigenic process in various cancers, we hypothesized that these histone modifications would 
correlate to clinical outcome in colon cancer. 
In addition to the individual functions of  the histone modifications, they work together regulating 
gene expression and chromatin structure in different regions of  the genome. H3K4me3 and 
H3K9me3 both regulate gene promoter activity and are mutually exclusive at promoter regions 
(11). H4K20me3 and H3K9me3 are both present on pericentric regions (12,13) and are critical 
for condensation of  chromatin at these regions. Both H3K9me3 and H4K20me3 have also been 
found to be enriched on imprinted genes (14). The study by McEwen et al. also showed that all 
three histone methylation marks H3K4me3, H3K9me3 and H4K20me3 form a tri-mark signature 
on imprinting control regions (14). On the basis of  the overlapping functions of  the three 
histone methylation marks, we hypothesized that combining these three modifications in survival 
analyses would be more informative than the individual markers with respect to patient survival 
and tumor recurrence. A combination of  high expression of  activating histone modification 
H3K4me3 and low expression of  silencing modifications H3K9me3 and H4K20me3 was 
expected to correlate with poor clinical outcome in colon cancer. Using immunohistochemistry 
and semi-automated scoring, nuclear expression of  H3K4me3, H3K9me3 and H4K20me3 was 




Tumor tissues were collected from a consecutive series of  409 colorectal cancer patients who 




Center (LUMC) between 1991 and 2001. Patients were excluded from the study analyses 
when patients had a history of  cancer other than basal cell carcinoma or in situ tumors, had 
multifocal tumors or received preoperative treatment. Data were right-censored when patients 
were alive or free of  recurrence at their last follow-up date. Patient records information was 
anonymized and de-identified prior to analysis according to national ethical guidelines (“Code 
for Proper Secondary Use of  Human Tissue”, Dutch Federation of  Medical Scientific Societies), 
and approved by the Medical Ethical Committee of  the LUMC. In the study cohort, we only 
included patients with TNM stage I-III tumors (n=259). Of  254 patients, complete data on 
all the studied markers were available. This study was performed according to the REMARK 
guidelines (NCI-EORTC) (15). 
Tissue microarray construction and immunohistochemistry
Formalin-fixed paraffin-embedded (FFPE) tumor tissues from 409 colorectal cancer patients 
were collected from the LUMC pathology archives and used to construct a tissue microarray 
(TMA), as described previously (16). Three tumor tissue cores, and if  available one normal tissue 
core, were included in the TMA for each patient. Sections of  4µm were cut from each TMA 
block and used for immunohistochemical (IHC) staining. Histologically normal colon tissues, as 
determined by an experienced pathologist, from 29 patients were also included and IHC stained. 
The following antibodies were used for IHC: anti-H3K4me3 (ab8580, ABcam, Cambridge, UK), 
anti-H3K9me3 (07-442, Millipore, Billerica, MA, USA) and anti-H4K20me3 (ab9053, Abcam). 
All primary antibodies were used at predetermined optimal dilutions and IHC was performed 
using a standard IHC protocol (17). Briefly, endogenous peroxidase was blocked by incubating 
the sections in a 0.3% solution of  hydrogen peroxide (in PBS) for 20 min. Antigen retrieval was 
performed by heating the sections for 10 min at 95ºC in a citrate buffer (pH 6; pH Low Target 
Retrieval Solution, Dako, Glostrup, Denmark), followed by overnight (16 hrs) incubation of  
the respective primary antibodies. Staining was visualized using the Dako REAL™ EnVision™ 
Detection System, Peroxidase/DAB+, Rabbit (Dako). The stained TMA slides were scanned 
using a 20x magnification on the Ariol system (Leica Microsystems, Wetzlar, Germany), followed 
by marking the tumor cell areas or normal colon epithelium for each tissue punch upon visual 
inspection on the computer screen. The Ariol system is specifically designed to recognize cells, 
nuclei, cell membranes and pixel intensity. For each type of  staining (membranous, cytoplasmatic 
or nuclear), different software packages are available. In the nuclear staining package, the 
system can be trained to recognize nuclei with a minimum pixel intensity that corresponds to 
positive staining. By carefully fine-tuning of  the shape and intensity settings for each individual 
immunohistochemical staining, we verified that the system only counted positively stained nuclei. 
For each TMA section, several random cores were evaluated by visual inspection after automatic 
analysis in order to verify that the system correctly identified positively stained nuclei. Automatic 
analysis of  the percentage of  positively stained nuclei (nuclear expression) was performed by the 
Ariol system for each individual tissue core.
Statistical analyses
Data were analyzed in consultation with a statistician (H.P.) using SPSS 20.0 for Windows (SPSS 
Inc, Chicago, USA). The mean percentage of  positive nuclei of  the three tumor cores was 
calculated for each individual patient and this percentage was used for all statistical analyses. 
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TABLE 1.  Patient characteristics of  the study cohort
Study cohort Colon stage I+II
(n=254) (n=121)
n (%) n (%)
 Age at randomization
 <50 32 12.6 11 9.1
 50-75 161 63.4 80 66.1
 >75 61 24 30 24.8
 Gender
 Male 128 50.4 61 50.4
 Female 126 49.6 60 49.6
 TNM stage
 I 53 20.9 30 24.8
 II 113 44.5 91 75.2
 III 88 34.6
 Tumor location
 Colon 187 73.6 121 100
 Rectum 67 26.4
 Tumor size
 Mean 4.69 4.57
 Standard error 2.32 0.21
 MSS status
 MSS 175 68.9 20 16.5
 MSI 34 13.4 75 62
 Unknown 45 17.7 26 21.5
 Tumor in follow up*
 No 215 84.6 105 86.8
 Yes 39 15.4 16 13.2
 Adjuvant therapy
 No 206 81.1 117 96.7
 Yes 48 18.9 4 3.3
Patient characteristics are shown for both the study cohort (n=254) and the patients with TNM stage I and II colon 
cancer as used for the statistical analyses (n=121).  Patient selection was based on availability of  FFPE tissues. available 
data for all three markers. and information about the listed covariables. The study cohort selection was representative 
for the entire colorectal cancer series. * = second primary tumor during follow-up period. MSS = microsatellite stable, 




Normality of  the data was tested using the Shapiro-Wilk test. Non-parametric Wilcoxon signed-
rank tests were performed to assess the differences in mean nuclear expression between the 
paired tumor and normal tissues (n=29) for each of  the individual markers. The Cox proportional 
hazard model was used for univariate and multivariate survival analyses of  individual and 
combined markers. Covariates included in all multivariate analyses were age at operation, gender, 
TNM tumor stage (tumor stages I-III), tumor location, tumor size, microsatellite stability (MSS) 
status. Additionally, covariates tumor in the follow up and adjuvant therapy were entered as time-
dependent covariates. Patients in the study cohort (TNM stage I and II colon patients only) were 
divided into high and low expression groups based on the median expression of  each of  the 
markers separately. On the basis of  the cellular function of  each of  the histone modifications, 
we expected low H3K4me3, high H3K9me3 and high H4K20me3 to be associated with a 
better prognosis (“all favorable”). For combinatorial analyses, patients were divided into groups 
on the basis of  the number of  favorable markers (all favorable, 1 favorable, 2 favorable and 
all unfavorable). Univariate and multivariate trend analyses were performed using the group 
numbers as continuous variables to assess the influence of  the combined markers on patient 
survival and tumor recurrence. Resulting hazard ratios (HR) represent the HR for each unit of  
increase (increase in group number, and hence an increase in the number of  markers showing 
unfavorable expression). Overall survival (OS) was defined as the time from surgery until death 
(by any cause). Disease-specific survival (DSS) was defined as the time from surgery until death 
by colorectal cancer. Loco-regional recurrence-free survival (LRRFS) was defined as the time 
from surgery until the occurrence of  a (loco)regional recurrence or death by cancer. Distant 
recurrence-free survival (DRFS) was defined as the time from surgery until the occurrence of  a 
distant recurrence or death by cancer. Cumulative incidence curves were made for DSS, LRRFS 
and DRFS, accounting for competing risks (18). Kaplan-Meier curves (for OS) or cumulative 
incidence curves (for DSS, LRRFS and DRFS) were used to visualize differences between the 
three patient groups for OS. For all statistical analyses, two-sided p-values ≤ 0.05 were considered 
as statistically significant, and p-values 0.05 < p ≤ 0.1 were considered a trend.
Results
Patient selection for statistical analyses
In this study, we analyzed 254 patients with TNM stage I-III colorectal cancer, with no prior 
history of  cancer or preoperative treatment and of  whom complete clinicopathological data 
were available (Table 1). Combined marker analyses, on the basis of  the number of  favorable 
markers (as will be discussed below), showed statistically significant discrimination between 
patient groups in early-stage (TNM stage I and II) colon cancer (n=121). Multivariate trend 
analyses showed significant differences between the patient groups for patients with TNM 
stage I or II colon cancer (p=0.005), but no significant differences for patients with TNM stage 
I or II rectal cancer (p=0.256). For patients with TNM stage III, no significant differences were 
observed for patients with either colon (p=0.7) or rectal cancer (p=0.6). Together, these results 
indicate prognostic value of  H3K4me3, H3K9me3 or H4K20me3 expression in early-stage 
colon cancer patients. Therefore, patients with TNM stage III colorectal cancer or TNM stage I 
and II rectum cancer were excluded from further analyses. The resulting patient cohort consisted 
of  121 patients with TNM stage I or II colon cancer, with a mean follow-up of  9.4 years.
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Nuclear expression in tumor versus normal tissues
Comparison of  expression between paired tumor and normal tissues was preceded by testing 
normality of  expression distribution data in the stage I and II colon cancer tissues per histone 
modification using the Shapiro-Wilk test. As the data of  the individual markers were not 
normally distributed, we used the Wilcoxon signed-rank test to compare the expression in the 
paired tumor and normal tissues (n=29). Marker expression was defined as the percentage of  
positively stained nuclei per tissue core. Representative staining of  tumor tissue cores is shown in 
Figure 1. Statistically significant differences between tumor and normal samples were observed 
for H3K9me3 (p=0.001) and H4K20me3 (p=0.01), but not for H3K4me3 (p=0.9) (Figure 2A).
Figure 1
Correct identification of  positively stained and negative nuclei for each individual marker. The Ariol system 
trainer overlay shows correct identification of  positive (indicated by yellow dots) and negative (blue dots) nuclei in tumor 
tissues. TMA slides were scanned using a 20x magnification. Shown for all individual markers are positively stained nuclei 
(top row) and negative tumor cores (bottom row). 
Survival analyses of  individual markers
Median expression of  each individual marker was used to divide the patients into high and low 
expression groups. The median expression for each of  the individual markers in tumor tissues 
was 12.1% for H3K4me3, 65.5% for H3K9me3 and 65.4% for H4K20me3. Low expression of  
H3K4me3 was associated with better patient survival and lower chances of  tumor recurrence 
(Figure 2B). In contrast, high expression of  both H3K9me3 and H4K20me3 was associated 
with better patient survival and lower chances of  tumor recurrence in our study cohort (Figure 
2B). These findings are also reflected in the 5-year survival rates (Table 2). Both univariate and 
multivariate Cox regression analyses show significant differences between the low and high 










Nuclear expression and survival analyses of  individual markers.  A. Displayed are differences in nuclear 
expression, measured as the percentage of  positively stained nuclei (y-axis), between normal and tumor tissues (n=29). 
Boxplots show the median and range of  expression of  each of  the individual markers in normal (N) and tumor (T) 
samples (x-axis). P-values represent statistical differences between normal and tumor samples, calculated using the 
Wilcoxon signed rank test.  B. Cumulative incidence curves, accounting for competing risks, showing the difference in 
survival between high and low expression groups of  each of  the individual markers. 5-year survival rates are included 
as percentages (in gray); p-values represent the statistical differences between the two patient groups in multivariate 
analyses. Numbers of  patients in each group are indicated in each figure (n).
Survival analyses of  combinations of  two markers
We analyzed the prognostic value of  combinations of  two of  the histone methylation markers. 
As both H3K4me3 and H3K9me3 are mostly found on gene promoter regions, and H4K20me3 
and H3K9me3 in constitutive chromatin at pericentric regions, we hypothesized that these 
combinations of  two histone modifications would result in better stratification of  patients as 
compared to the individual markers. Multivariate analyses showed that combining the histone 
modifications indeed resulted in better separation of  the patient groups with respect to patient 
survival and tumor recurrence. For the combination of  gene promoter-associated modifications 
H3K4me3 and H3K9me3, we observed that the patient group with the most unfavorable 
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TABLE 2.  Survival analyses single markers in TNM stage I and II colon cancer patients
OS DSS LRRFS DRFS
 H3K4me3
 Univariate  p-value 0.4 0.02 0.01 0.01
 HR 1.26 4.45 3.54 3.63
 (95% CI) (0.75-2.11) (1.29-15.38) (1.32-9.49) (1.36-9.73)
 Multivariate  p-value 0.3 0.04 0.01 0.01
 HR 1.36 3.79 3.86 3.57
 (95% CI) (0.79-2.33) (1.06-13.56) (1.38-10.77) (1.29-9.81)
 5-year survival rates  Low expression 73% 95% 93% 94%
 High expression 76% 82% 74% 77%
 H3K9me3
 Univariate  p-value 0.07 0.02 0.07 0.02
 HR 0.61 0.30 0.47 0.36
 (95% CI) (0.36-1.04) (0.12-0.86) (0.21-1.08) (0.16-0.85)
 Multivariate  p-value 0.2 0.01 0.05 0.01
 HR 0.69 0.26 0.42 0.29
 (95% CI) (0.39-1.24) (0.09-0.77) (0.17-1.01) (0.12-0.75)
 5-year survival rates  Low expression 64% 78% 71% 74%
 High expression 86% 96% 92% 92%
 H4K20me3
 Univariate  p-value 0.1 0.01 0.02 0.04
 HR 0.67 0.24 0.34 0.41
 (95% CI) (0.40-1.12) (0.08-0.72) (0.14-0.81) (0.18-0.95)
 Multivariate  p-value 0.02 0.02 0.008 0.01
 HR 0.51 0.21 0.29 0.31
 (95% CI) (0.29-0.89) (0.06-0.67) (0.12-0.72) (0.13-0.77)
 5-year survival rates  Low expression 67% 80% 74% 77%
 High expression 80% 94% 90% 91%
Shown are the results of  the univariate and multivariate analyses of  all individual markers in TNM stage I and II colon 
cancer patients, with all p-values and hazard ratios (HR) with their 95% confidence intervals (95% CI). OS = overall 
survival, DSS = disease-specific survival, LRRFS = locoregional recurrence-free survival, DRFS = distant recurrence- 
free survival. The low expression group (below-median expression) was used as reference group. 5-year survival rates 
are given for both low and high expression groups. Statistically significant differences (defined as p<0.05) are shown in 
bold, trends (p<0.1) in Italic.
survival (trend analysis HR 2.05; p=0.004) and distant recurrence-free survival (trend analysis 
HR 1.96; p=0.001) as compared to the other patient groups. For the combination of  pericentric 
region-associated modifications H4K20me3 and H3K9me3, the group with the most favorable 
expression (high expression of  both markers) showed significantly better disease-free survival 






Trend and survival analyses of  all markers combined.  A. Results of  the univariate and multivariate trend analyses 
of  combined markers H3K4me3, H3K9me3, and H4K20me3. HR represents the hazard ratio for each unit of  increase, 
thus each additional marker showing unfavorable expression. 95% CI: 95% confidence interval for each HR. OS: overall 
survival; DSS: disease-specific survival; LRRFS: locoregional recurrence-free survival; DRFS: distant recurrence-free 
survival.  B. Kaplan-Meier curves are shown for OS, including the number of  patients in each patient group (n), based 
on the number of  markers showing unfavorable expression. Patients were divided into the following groups: all favorable 
(group 1; H3K4me3 low and both H3K9me3 and H4K20me3 high), one out of  three unfavorable (group 2), two out 
of  three unfavorable (group 3), and all unfavorable (group 4; H3K4me3 high and both H3K9me3 and H4K20me3 
low). Cumulative incidence curves, accounting for competing risks, are shown for DSS, LRRFS and DRFS. Multivariate 
p-values have been included in each of  the combined marker graphs.
Trend analyses H3K4me3, H3K9me3 and H4K20me3
Univariate Multivariate
p-value HR (95% CI) p-value HR (95% CI)
OS 0.06 1.25 (0.99-1.58) 0.1 1.22 (0.93-1.59)
DSS 0.003 2.1 (1.29-3.42) 0.004 2.05 (1.25-3.36)
LRRFS 0.008 1.68 (1.15-2.46) 0.005 1.75 (1.18-2.59)
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Survival analyses of  H3K4me3, H3K9me3 and H4K20me3 combined
To further improve the stratification of  patients, we performed Cox regression survival 
analyses using the combined expression patterns of  all three markers H3K4me3, H3K9me3 
and H4K20me3. Low expression of  activating modification H3K4me3 and high expression of  
silencing modifications H3K9me3 and H4K20me3 was expected to be associated with good 
prognosis, and was therefore used as the “all favorable” reference group. Patients were divided 
into 4 groups, on the basis of  the number of  markers showing clinically favorable or unfavorable 
expression. This resulted in the following grouping: all favorable (group 1; H3K4me3 low and 
both H3K9me3 and H4K20me3 high), one out of  three unfavorable (group 2), two out of  
three unfavorable (group 3), and all unfavorable (group 4; H3K4me3 high and both H3K9me3 
and H4K20me3 low). Both univariate and multivariate trend analyses showed that the more 
markers showed unfavorable expression, the shorter the patient survival (DSS) and recurrence-
free survival times (both LRRFS and DRFS) (Figure 3A). The survival plots of  OS, DSS, LRRFS 
and DRFS are shown in Figure 3B. Hazard ratios for the individual patient groups could not be 
calculated accurately, as not enough events (either death or recurrence of  the tumor) occurred 
in the reference group (group 1; Figure 3B). Therefore, using multivariate trend analyses, we 
calculated hazard ratios for each additional marker showing unfavorable expression, as compared 
to the “all favorable” reference group. The calculated HRs were 1.46 (1.04-2.05; p=0.03) for 
OS, for DSS 3.81 (1.72-8.45; p=0.001) for DSS, 2.86 (1.59-5.13; p<0.001) for LRRFS and 2.94 
(1.66-5.22; p<0.001) for DRFS. Combining all three markers resulted in better stratification and 
separation of  the patient groups as compared to the single markers or the combinations of  only 
two of  the studied markers.
Discussion
Aberrant gene expression is a common feature of  cancer cells, which is caused by a combination 
of  gene mutations and aberrant regulation of  gene expression by epigenetic mechanisms, 
including DNA methylation, microRNAs and histone modifications. Histone modifications play 
a crucial role in many cellular processes during embryonic development, cell proliferation and 
cellular differentiation (2). In cancer, aberrant expression of  histone modifications has been 
described frequently (1). Therefore, we investigated the nuclear expression of  three well-studied 
histone modifications in colon cancer. 
In this study, we observed that nuclear expression of  histone trimethylation on H3K4, H3K9 
and H4K20 has prognostic value in early-stage colon cancer. Changes in expression of  key 
histone modifications are found in early-stage tumors, which would be expected because tumor 
cells require instant changes in gene expression and chromatin structure in order to promote 
cell proliferation and tumor cell survival. Several epigenetic factors have been shown to be 
altered in early-stage cancer, including histone-modifying enzymes and histone modifications 
(19,20), DNA methylation (21,22) and microRNAs (23). We only observed differences between 
the patient groups in colon tumors, whereas in rectum tumors no difference was observed. 
The observed differences between the colon and rectum tumors with respect to the studied 
histone modifications may be due to differences in biology of  the tissues of  origin. Several 
other studies have suggested that rectum and colon tumors show differential gene expression 




of  aberrant expression of  prognostic histone modifications, such as described in this study 
in early-stage colon cancer, could facilitate the risk assessment and subsequent decisions for 
treatment for specific patient groups at early stages of  the disease.
The results of  the survival analyses of  the individual markers reflect our expected results 
based on the cellular functions of  the respective histone modifications. Trimethylation of  
H3K4 is a modification found on gene promoter regions and is associated with activation of  
gene transcription (26), and higher expression of  H3K4me3 in tumors could lead to aberrant 
gene transcription, including genes required for cell survival, proliferation and migration. In 
literature, poor prognosis was indeed reported for patients with tumors showing high expression 
of  H3K4me3 (4). Histone modification H4K20me3 is a known repressive mark (13), and key 
modification regulating compaction of  the chromatin in pericentric regions, which makes it 
crucial for proper chromosome segregation during cell division and for maintenance of  genome 
integrity (12). Consequently, loss of  H4K20me3 was expected to be associated with a worse 
prognosis for the patient, which has indeed been shown in literature (9). Finally, for H3K9me3, 
literature shows conflicting results with respect to patient survival and prognosis (6,7,27,28), 
depending on the type of  cancer. Histone modification H3K9me3 is associated with silencing 
of  gene transcription (26), and can hence be involved in aberrant silencing of  tumor suppressor 
genes (i.e. DCC; 29). On the other hand, H3K9me3 prevents aberrant expression of  (onco)
genes and represses the abundant repetitive sequences in the genome (30-32). On the basis of  
the function of  H3K9me3 as a silencing modification, we expected H3K9me3 expression to be 
comparable to H4K20me3 expression with respect to clinical outcome. Our results confirmed 
the hypotheses based on these individual functions, as high expression of  H3K4me3 and low 
expression of  H3K9me3 and H4K20me3 are correlated with shorter patient survival and higher 
chances of  tumor recurrence. 
Combined marker analyses showed that favorable expression of  all markers (low H3K4me3, high 
H3K9me3 and high H4K20me3, as based on the individual marker analyses) was associated with 
the best prognosis with respect to patient survival and tumor recurrence. With each additional 
marker showing more unfavorable expression, the HR increased significantly about 3-fold for 
DSS, LRRFS and DRFS, indicating that combining all three methylation marks resulted in 
better separation of  the patient groups as compared to individual markers. Combining multiple 
markers in survival analyses can thus be beneficial in identifying high-risk patient groups and to 
determine treatment strategies accordingly. To our knowledge, this is the first study to combine 
these three markers in survival analyses. In literature, multiple histone modifications have been 
studied in cancer tissues but have never been combined in survival analyses (27,33-36). In 
addition, expression of  histone modifications was not always correlated to clinical outcome (37), 
or were found to have no prognostic value in cancer (38).
Conclusions
In conclusion, in this study we have shown that combined nuclear expression of  histone 
trimethylation on H3K4, H3K9 and H4K20 is prognostic in early-stage colon cancer and that 
combined expression of  the three histone modifications provides better stratification of  patient 
groups and therefore provides a better risk assessment as compared to the individual markers. 
The clinically prognostic value of  the histone modifications presented in this study underlines 
the consequences of  epigenetic dysregulation in tumorigenesis.
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The apoptosis pathway of  programmed cell death is frequently deregulated in cancer. An intact 
apoptosis pathway is required for proper response to anti-cancer treatment. We investigated the 
chromatin status of  key apoptosis genes in the apoptosis pathway in colorectal cancer cell lines 
in relation to apoptosis induced by chemo-, immune- or radiation therapy. Using chromatin 
immunoprecipitation (ChIP), we measured the presence of  transcription-activating histone 
modifications H3Ac and H3K4me3 and silencing modifications H3K9me3 and H3K27me3 at 
the gene promoter regions of  key apoptosis genes Bax, Bcl2, Caspase-9, Fas (CD95) and p53. 
Cell lines DLD1, SW620, Colo320, Caco2, Lovo and HT29 were treated with cisplatin, anti-Fas 
or radiation. The apoptotic response was measured by flow cytometry using propidium iodide 
and annexin V-FITC. The chromatin status of  the apoptosis genes reflected the activation status 
of  the intrinsic (Bax, Bcl2, Caspase-9 and p53) and extrinsic (Fas) pathways. An active intrinsic 
apoptotic pathway corresponded to sensitivity to cisplatin and radiation treatment in cell lines 
DLD1, SW620 and Colo320. An active Fas promoter corresponded to an active extrinsic 
apoptotic pathway in cell line DLD1. mRNA expression data correlated with the chromatin 
status of  the apoptosis genes as measured by ChIP. In conclusion, the results presented in this 
study indicate that the balance between activating and silencing histone modifications, reflecting 
the chromatin status of  apoptosis genes, can be used to predict the response of  tumor cells to 
different anti-cancer therapies and could provide a novel target to sensitize tumors to obtain 
adequate treatment responses.




Resistance to cell death is one of  the capabilities acquired during tumor development and was 
therefore named as one of  the hallmarks of  cancer (1,2). The apoptosis pathway, responsible 
for programmed cell death, is indeed one of  the pathways frequently deregulated in cancer (3). 
The level of  apoptosis has been previously shown to have prognostic value in rectal cancer    
(4-6). As deregulation of  the apoptotic pathway could lead to resistance to anti-cancer therapies, 
reactivation of  the pathway is an attractive target to sensitize tumors for anti-cancer treatment 
(7-9). Both the extrinsic and intrinsic apoptotic pathways have been studied as possible targets 
for anti-cancer therapy (10), but more information about the complex regulation of  the pathway 
is still warranted for the design of  apoptosis-based anti-cancer therapies for solid tumors.
Anti-cancer treatments are directed towards inducing cell death in tumor cells by inducing 
DNA damage (activating the intrinsic apoptotic pathway) or by initiating an antitumor immune 
response (activating the extrinsic apoptotic pathway). An intact apoptotic response is required 
in order for these treatment regimens to have the intended effect of  tumor cell death (11,12). 
Epigenetic mechanisms, including DNA methylation and histone modifications, are key 
regulators of  gene expression and are frequently deregulated in cancer (13-15). Changes in 
epigenetic regulation of  expression of  apoptosis genes could influence the response of  tumor 
cells to anti-cancer treatments. Therefore, in this study we investigated whether the chromatin 
status of  key apoptosis genes in both the intrinsic and extrinsic apoptotic pathways could be 
used to predict the response of  a tumor cell to anti-cancer treatment regimens.
We selected several apoptosis genes on the basis of  their prognostic value in various cancers in 
literature (16,17), that are likely to play key roles in the apoptotic process. The selected genes were 
Fas (CD95) representing the extrinsic apoptotic pathway, and Bax, Bcl2, Caspase-9 (Casp9) and 
p53 representing the intrinsic pathway. We studied the cellular mRNA levels and the presence 
of  both activating and silencing histone modifications at the promoter regions of  each of  these 
apoptosis genes using chromatin immunoprecipitation (ChIP) in six colorectal cancer cell lines. 
Subsequently, activation of  the extrinsic apoptotic pathway was studied in the colorectal cancer 
cell lines using anti-Fas antibodies, and activation of  the intrinsic pathway was studied using the 
chemotherapeutic agent cisplatin or by radiation treatment. The level of  apoptosis induction 
upon treatment was then measured by flow cytometry and correlated to the chromatin status of  
the apoptosis genes as measured by ChIP. The chromatin status of  each of  the apoptosis genes 
was correlated to mRNA expression levels using gene expression assays.
Materials and methods
Cell lines and treatment
Colorectal cancer cell lines HT29, Lovo, Colo320, SW620, DLD1 and Caco2 were cultured 
under standard conditions, as described by the American Type Culture Collection (ATCC; 
Manassas, VA, USA), using T25 tissue culture flasks (Greiner-Bio One, Alphen aan den Rijn, 
The Netherlands). Dose-response curves were generated to determine an optimal dose and 
incubation time at which a maximum of  20% cell death (corresponding to 80% surviving cells) 




incubation times tested were 8, 16, 24 and 48 hours. After incubation, cells were harvested 
and cell death was quantified using trypan blue staining. The percentage of  surviving cells was 
determined as follows: 100% - (number of  dead cells / total number of  cells (dead+surviving)). 
Cells were treated with cisplatin (cis-Diammineplatinum (II) dichloride; Sigma-Aldrich, St. Louis, 
MO, USA) or anti-Fas (clone CH11; Millipore, Billerica, MA, USA) or were irradiated with 
X-rays at 6 Gy/min in tissue culture medium using an Andrex Smart 225 radiation instrument 
(200kV, 4mA; Andrex Radiation Products AS, Copenhagen). Following treatment with cisplatin, 
anti-Fas or radiation, the percentage of  apoptotic cells was determined using flow cytometric 
analysis on a BD LSRII flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Apoptotic 
cells were defined as cells with a positive signal for annexin V-FITC (5µl in a total volume of  
100µl; ImmunoTools 31490013, Friesoythe, Germany) and a low signal for propidium iodide 
(PI, 1µM; Calbiochem, San Diego, CA, USA). Cell lines were considered as sensitive to treatment 
when a ≥5% increase in the percentage of  apoptotic cells between the untreated controls and 
the treated cell lines was detected.
Chromatin immunoprecipitation experiments
Chromatin immunoprecipitation (ChIP) experiments were performed for the following histone 
modifications: acetylated histone H3 (H3Ac, activating), trimethylation of  lysine 4 at histone 
H3 (H3K4me3, activating), trimethylation of  lysine 9 at histone H3 (H3K9me3, silencing), 
and trimethylation of  lysine 27 at histone H3 (H3K27me3, silencing). ChIP experiments were 
performed according to a custom protocol, as described in (18), with some modifications. All 
ChIP experiments were performed in duplicate. Briefly, cell lines were trypsinized, centrifugated 
for 3 minutes at 1000 rpm and washed once with phosphate-buffered saline (PBS). Cells were 
then incubated in a 1% formaldehyde solution (in PBS) for 10 minutes at room temperature. The 
crosslinking reaction was stopped by adding 0.125M glycine solution and incubating for 5 minutes 
at room temperature. After centrifugation, cell pellets were washed twice with PBS supplemented 
with 20mM sodium butyrate. Cells were lysed by adding cell lysis buffer supplemented with 
20mM sodium butyrate, 1:100 diluted proteinase inhibitor cocktail (PIC; Sigma-Aldrich) and 
1:100 diluted phenylmethanesulfonyl fluoride (PMSF, 36978, Fisher Scientific, Landsmeer, 
The Netherlands) and incubating on ice for 5-10 minutes. After complete lysis of  the cells, 
samples were sonicated using a Soniprep 150 ultrasonic disintegrator (MSE (UK) Ltd, London, 
UK), producing DNA fragments of  100-400 bp (checked by gel electrophoresis). The DNA 
concentration was measured using a nanodrop (Thermo Scientific; Waltham, MA, USA), and 
10µg of  chromatin was used as input for each of  the ChIP reactions. Samples were incubated 
overnight (16 hrs), rotating at 4ºC, with one of  the following antibodies: anti-H3K4me3 (ab8580, 
Abcam, Cambridge, UK), anti-H3K9me3 (ab8898, Abcam), anti-H3K27me3 (ab6002, Abcam), 
anti-H3Ac (06-599, Millipore) and anti-IgG (ab2410, Abcam). An “input” sample was used as 
the non-precipitated (no antibody) control. After overnight incubation, the chromatin-antibody 
complexes were incubated with protein G magnetic beads (Dynabeads, Thermo Scientific) for 
4 hours, rotating at 4ºC. Magnetic beads with the bound chromatin-antibody complexes were 
washed with subsequently low salt buffer, high salt buffer, lithium-chloride buffer and twice with 
TE pH 8.0 buffer. Chromatin-antibody complexes were eluted using freshly prepared elution 
buffer. DNA-protein-antibody complexes were denatured by incubating the eluted samples with 
0.2M NaCl for 15 min at 95ºC and subsequently with 0.5µg proteinase K (Sigma-Aldrich) for 
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15 min at 60ºC. DNA clean-up was performed using phenol-chloroform-isoamyl alcohol (Sigma-
Aldrich), followed by chloroform-isoamyl alcohol (Sigma-Aldrich). DNA was precipitated 
overnight by adding 0.6M sodium acetate, 1 ml ethanol and 1 µl glycogen (20 mg/ml; 77534, 
Affymetrix, Cleveland, OH, USA) to a total volume of  1.4 ml. After centrifugation, cell pellets 
were resuspended in 30 µl TE and 3 µl of  each sample was used for PCR. 
PCR of  apoptosis genes
PCR reactions of  the duplicate experiments were performed using iQ™ SYBR ® Green supermix 
(2x) (Bio-Rad Laboratories, Hercules, CA, USA). Primers were designed in the promoter regions 
of  each of  the respective apoptosis genes and melting temperatures (Tm) were optimized 
for each of  the individual primer sets. The following primer sequences were used: Bax-F 
5’-TGCCCGAAACTTCTAAAA-3’ and Bax –R 5’-CGTGACTGTCCAATGAGC-3’ (Tm 58ºC); 
Bcl2-F 5’-GCAGAAGTCTGGGAATCG-3’ and Bcl2-R 5’- GCATAAGGCAACGATCC-3’ (Tm 
58ºC); Casp9-F 5’-CGGAAGCGGACTGAG-3’ and Casp9-R 5’-CAGAGCTGGTCCACCTG-3’ 
(Tm 60ºC); Fas-F 5’-CCAACTTCCCAGGTTGAA-3’ and Fas-R 5’-GCACAAATGGG 
CATTCC-3’  (CD95; Tm 56ºC);  p53-F  5’-CTTACTTGTCATGGCGACT-3’ and p53-R 
5’-CTGGACGGTGGCTCT-3’ (Tm 60ºC). Housekeeping genes GAPDH (active) and 
MYT (silenced) were used as controls to verify accurate detection of  the individual histone 
modifications compared to the input sample. Primer sequences were as follows (Tm for both 
PCR reactions was 60°C): GAPDH-F 5’-TACTAGCGGTTTTACGGGCG-3’, GAPDH-R 
5’-TCGAACAGGAGGAGCAGAGAGCGA-3’ and MYT-F 5’-GCTGTGGGGAAAGGT 
AAGTC-3’, MYT-R 5’-ATGTCTCCTCTGTCAGACGC-3’.
Thermal cycling conditions were as follows: hot start for 10 minutes at 95°C, followed by 40 cycles 
of  denaturing for 10 sec at 95°C, annealing for 30 sec at the optimized Tm and extension for 30 
sec at 72°C. Melting curves were generated after every PCR run to ensure a single PCR product 
was amplified. Relative enrichment (the percentage of  product precipitated as compared to the 
non-precipitated “input” sample) of  each the respective histone modifications was calculated 
using the following formula: 2^- (Ct value “input” sample – Ct value precipitated sample). 
Real-time quantitative PCR for mRNA expression
RNA was isolated from each of  the colorectal cancer cell lines using TRI Reagent (Life 
Technologies, Bleiswijk, The Netherlands), according to the manufacturer’s protocol. Reverse 
transcription of  mRNA was performed using a High Capacity RNA-to-cDNA kit (Life 
Technologies). Quantitative duplex real-time PCR reactions were performed in duplicate using 
FAM-labeled commercially available Taqman Gene Expression assays (Life Technologies) for 
Casp9 (Hs00609647_m1), TP53 (Hs01034249_m1), Bcl2 (Hs00608023_m1), Bax (Hs000180269_
m1), Fas (Hs00236330_m1), GAPDH (Hs99999905_m1) and MYT (Hs01027966_m1). 
VIC-labeled HPRT1 (Tamra quencher; Hs02800695_m1, Life Technologies) was used as an 
internal housekeeping gene control within each duplex PCR reaction. For each individual PCR 
reaction, Ct values were normalized against Ct values of  HPRT1 in the same reaction (ΔCt). 
Real-time PCR reactions were performed on a 7900 HT Fast Real-time PCR system (Applied 






For each of  the six colorectal cell lines included in this study, dose-response curves were made 
to find the optimal dose and duration of  treatment with cisplatin, anti-Fas and radiation. Dose-
response curves following radiation treatment showed the most cell death in cell lines DLD1, 
SW620 and Colo320, and less response in cell lines HT29, Caco2 and Lovo (Figure 1). Cell lines 
DLD1, SW620 and Colo320 were sensitive to cisplatin treatment, showing higher percentages of  
dead cells as compared to cell lines Caco2, Lovo and HT29, that showed minimal cell death upon 
treatment with cisplatin (data not shown). Anti-Fas treatment induced marked cell death only in 
cell line DLD1, all other cell lines showed minimal cell death upon treatment with anti-Fas (data 
not shown). Treatment that resulted in a maximum of  20% cell death (corresponding to 80% of  
surviving cells at the time of  harvest) in either of  the cell lines after 24 hrs (for anti-Fas) or 48 
hrs (for cisplatin and radiation treatment) was considered to be the optimal treatment procedure, 
indicating induction of  apoptotic cell death but leaving a substantial surviving fraction to detect 
apoptotic cells that have initiated but have not finished the process at the time of  harvest. On 
the basis of  the survival curves obtained, we therefore chose for treatment of  all cell lines with 
40µM cisplatin for 48 hrs, with 250 ng/ml anti-Fas for 24 hrs and 6 Gy radiation followed by 
harvesting after 48 hrs. 
Figure 1
Dose-response curves and percentages of  apoptotic cells of  colorectal cancer cell lines following treatment. 
The percentage of  surviving cells (y-axis) was determined for cell lines Lovo, HT29. Caco2, SW620, Colo320 and 
DLD1, 48 hours after irradiation with different doses (x-axis). Cell lines were incubated with trypan blue and the 
surviving fraction was calculated as follows: 100% - (number of  trypan blue positive (dead) cells / total number of  cells 
(dead+surviving)). 
Flow cytometry detection of  the apoptotic fraction after treatment
In order to quantify the percentage of  apoptotic cells after treatment, flow cytometry analyses 
were performed to measure the apoptotic cell fraction of  each of  the cell lines upon treatment 
with cisplatin, anti-Fas or radiation. The apoptotic fraction was defined as the fraction of  
cells showing a positive signal for annexin V but a low signal for propidium iodide (19). The 
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was determined by comparing the apoptotic fractions before (untreated cell population) and 
after treatment. As for radiation and chemosensitivity, a large apoptotic fraction was observed 
after treatment as compared to the untreated population in cell lines DLD1, Colo320 (Figure 
2A) and SW620. Only a limited response (small apoptotic fraction) was observed for cell lines 
HT29, Caco2 and Lovo. 
Figure 2
Flow cytometry results after treatment with cisplatin, radiation or anti-Fas.  A. Shown are the flow cytometry 
results of  cell line Colo320 after treatment. Two experiments were performed, to measure the apoptotic cell fractions 
after treatment with radiation (upper panel) and after treatment with cisplatin or anti-Fas (lower panel). Untreated 
controls were included in both experiments. Cells in gate P4 were regarded as the apoptotic fraction (positive signal for 
annexin V and a low signal for propidium iodide). Cells in gate P3 are the living cell fraction, cells in gate P5 are dead 
cells. Cell debris has been excluded from the analyses (gates P1 and P2, not shown). The percentage of  apoptotic cells 
is indicated in the right bottom corner of  each figure.  B. Difference in percentages of  apoptotic cells between treated 
cells and untreated controls are displayed for each of  the cell lines after treatment with cisplatin (48 hrs), radiation (48 












Caco2 0.1 3.1 2.5 
Lovo 0.7 0.4 1.0 
DLD1 19.8 21.1 13.8 
HT29 3.1 0.4 0.6 
SW620 7.9 17.6 0.1 































































Treatment with anti-Fas resulted in an apoptotic response only in cell line DLD1, the other 
cell lines did not respond to anti-Fas treatment. Each cell line showing a ≥ 5% increase in the 
percentage of  apoptotic cells was considered “sensitive” to the respective treatment. Results 
are displayed in Figure 2B. The flow cytometry results confirmed the sensitivity of  all cell lines 
for induction of  apoptosis, as observed in the dose-response curves, to each of  the treatment 
regimens.
Chromatin immunoprecipitation and mRNA expression levels of  apoptotic 
genes
In order to investigate whether the chromatin status of  genes involved in the apoptotic pathway 
could be used to predict the response to chemo-, immune- or radiation therapy, we performed 
ChIP experiments for five key apopotic genes (Bax, Bcl2, Casp9, Fas and p53). Immuno-
precipitations were performed using antibodies against H3Ac, H3K4me3, H3K9me3 and 
H3K27me3, followed by real-time PCR for the genes of  interest. All ChIP experiments were 
performed in duplicate, with a mean difference in Ct values between the two measurements 
of  1.93 (range 0.04-3.80), indicating sufficient reproducibility of  the assay. In addition to the 
chromatin status of  the genes, we measured mRNA expression levels of  all genes (including 
control genes GAPDH and MYT) in each cell line and normalized the expression to the HPRT1 
signal in each individual reaction (ΔCt). HPRT1 Ct values were very constant across the different 
genes and duplicate reactions, with average Ct values between 21.3 and 22.7 for the different cell 
lines and a standard deviation of  0.6 over all measurements.
ChIP results for control genes
Control genes GAPDH (active housekeeping gene) and MYT (myelin transcription factor, 
silenced in colorectal tissues) were included in each ChIP experiment for assay validation. As 
expected, at the GAPDH promoter higher relative enrichment (the percentage of  precipitated 
DNA as compared to the non-precipitated “input” sample) of  active modifications H3Ac and 
H3K4me3 was observed as compared to the silencing modifications H3K9me3 and H3K27me3 
(Supplementary Figure 1A). At the MYT promoter, higher relative enrichment of  silencing 
histone modifications was observed as compared to the activating histone modifications 
(Supplementary Figure 1B). mRNA expression data confirmed active expression of  GAPDH, 
with higher relative expression (ΔCt values) compared to HPRT1, and silencing of  MYT 
(Supplementary Figure 1C). As the control genes GAPDH and MYT showed valid results, we 
continued with the immunoprecipitation experiments on apoptosis gene promoter regions.
ChIP results for apoptosis genes
The activation status of  the individual apoptosis genes, as determined by the ChIP experiments, 
was correlated with sensitivity of  the cell lines to chemo-, immune- or radiation therapy (Figure 
3). For example, cell line SW620 showed sensitivity to cisplatin and radiation treatment with 
differences in the percentage of  apoptotic cells between controls and treated cells of  7.9% and 
17.6%, respectively, but was not sensitive to anti-Fas treatment (difference 0.1% between controls 
and treated cells). Results from the ChIP experiments showed higher relative enrichment of  
silencing modification H3K9me3 on the Fas gene promoter as compared to the activating histone 
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modifications, and high relative enrichment of  activating histone modifications for Casp9 and Bax 
in cell line SW620 (Figure 3A). These ChIP results corresponded to an active intrinsic pathway 
(the pathway is turned “on”), and hence an expected response to DNA damaging agents such 
as cisplatin and radiation, and a silenced extrinsic pathway (the pathway is turned “off ”), which 
resulted in no response to anti-Fas treatment. For cell line DLD1, an active chromatin status of  
Casp9, Bax and Fas, as measured by higher relative enrichment of  activating modifications H3Ac 
and H3K4me3 (Figure 3B), corresponded to sensitivity to all treatments. Cell line Caco2 did not 
show induction of  apoptosis with any of  the treatment regimens. This cell line indeed showed 
high relative enrichment of  silencing modifications H3K9me3 and H3K27me3 as compared 
to the activating histone modifications for Casp9 and Fas, and bivalent histone modifications 
(both activating and silencing histone modifications present) on p53, Bcl2 and Bax (Figure 
3C), corresponding to silenced intrinsic and extrinsic pathways. Cell lines Colo320, HT29 and 
Lovo, showed a similar correlation between the chromatin status of  the apoptosis genes to the 
treatment response (Supplementary Figure 2). Table 1 provides an overview of  the chromatin 
status of  each of  the genes coupled to the response of  each of  the cell lines to chemo-, immune- 
or radiation therapy. An active chromatin status was assigned when higher relative enrichment 
was observed for active histone modifications, a repressed chromatin status when higher relative 
enrichment for silencing histone modifications was observed. Many gene promoters, however, 
showed bivalent promoters where both activating and silencing histone modifications were 
present in similar amounts. For example, the p53 gene showed a bivalent chromatin status in all 
cell lines. Overall, the chromatin status of  the predominantly active or silenced gene promoters 
did correspond well to the overall status of  the pathway (on or off), which in turn corresponds 
to the sensitivity of  the individual cell lines to treatment. 
For all cell lines, the chromatin status for each of  the apoptosis genes based on the ChIP results is shown, divided into 
the intrinsic and extrinsic apoptotic pathways. An “active” status was assigned to gene promoters showing higher relative 
enrichment for active modifications, a “silenced” status for gene promoters showing higher relative enrichment for 
silencing modifications. A “bivalent” status refers to gene promoters with both active and silencing modification present 
in equal amounts. The differences between the treated cell lines and untreated controls in percentages of  apoptotic cells 
as measured by flow cytometry are indicated for each cell line. Increases of  ≥5% apoptotic cells was defined as sensitivity 
to the respective treatments and are indicated in bold.
TABLE 1.   Transcriptional status of apoptotis genes based on ChIP results in correlation with response to therapy 
  Intrinsic pathway   Extrinsic pathway 
  
Casp 9 p53 Bcl2 Bax Pathway status 





cells)   
Fas Pathway status 
Anti-Fas    
(% apoptotic 
cells) 
SW620 Active Bivalent Bivalent Active ON 7.9% 17.6%   Silenced OFF 0.1% 
DLD1 Active Bivalent Bivalent Active ON 19.8% 21.1%   Active ON 13.8% 
Caco2 Silenced Bivalent Bivalent Bivalent OFF 0.1% 3.1%   Silenced OFF 2.5% 
Colo320 Bivalent Bivalent Active Active ON 9.8% 8.8%   Silenced OFF 0.3% 
HT29 Bivalent Bivalent Active Bivalent Non- conclusive 3.1% 0.4%   Bivalent 
Non- 
conclusive 0.6% 




In conclusion, these results indicate that the balance between activating and silencing histone 
modifications, reflecting the chromatin status of  the apoptotic genes, can be used to predict the 
response of  tumor cells to different anti-cancer therapies.
mRNA expression levels of  apoptotic genes
To correlate the chromatin status of  the genes as determined with the ChIP experiments with 
mRNA expression levels, we performed gene expression analyses for all apoptosis genes (Figure 
4). Fas mRNA expression was observed in cell lines DLD1, HT29 and Lovo, which showed high 
relative enrichment of  active histone modifications in the ChIP experiments. Low expression 
of  Fas mRNA was observed in cell lines where high relative enrichment of  silencing histone 
modifications was observed (SW620, Caco2 and Colo320). Caspase-9 showed high relative 
mRNA expression in all cell lines except Lovo, which indeed showed high relative enrichment 
of  silencing histone modifications in the ChIP experiments. Bcl2 showed low relative mRNA 
expression in all cell lines, but cell lines Colo320 and HT29 that showed high relative enrichment 
of  activating histone modifications showed only a slightly lower mRNA expression as compared 
to internal control HPRT1. Bax showed high relative mRNA expression in cell line DLD1 and 
only slightly lower relative expression as compared to HPRT1 in cell lines Caco2 and Colo320. 
Cell line Lovo showed a silenced Bax promoter in the ChIP experiments and indeed showed low 
relative mRNA expression. mRNA expression of  p53 was high in all cell lines, except Caco2, 
despite the bivalent status of  the p53 promoter in all cell lines. In conclusion, mRNA expression 
matches the chromatin status of  the apoptosis gene promoters in most of  the cell lines.
Figure 4
Messenger RNA expression of  apoptosis gene promoters. The average relative mRNA expression results (ΔCt) of  
the duplicate PCR reactions are shown for each of  the individual apoptosis genes in all cell lines. All Ct values shown 
were normalized to the HPRT1 signal in each individual PCR reaction. Error bars indicate the maximum and minimum 
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Results of  ChIP experiments for cell lines SW620, DLD1 and Caco2. Results of  the ChIP experiments are 
shown for cell lines SW620, DLD1 and Caco2. Immunoprecipitations have been performed using antibodies against 
active histone modifications H3Ac and H3K4me3 (indicated in green) and silencing histone modifications H3K9me3 
and H3K27me3 (indicated in red). IgG was used as a control for non-selective binding (indicated in gray). PCR was 
performed for apoptosis genes Casp9, p53, Bcl2, Bax and Fas. The respective histone modifications are indicated on 
the x-axis, the relative enrichment (the percentage of  precipitated DNA as compared to the non-precipitated input = % 
input) is indicated on the y-axis. Error bars represent the maximum and minimum values of  the duplicate experiments. 
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An intact and active apoptotic pathway is required for a proper response to anti-cancer therapies 
(11,12). We therefore investigated the chromatin status of  several key apoptosis genes in 
colorectal cancer cell lines, in correlation with the apoptotic response upon treatment with 
cisplatin, radiation or anti-Fas.
Our results regarding sensitivity of  the different cell lines to the treatment regimens were 
consistent with literature. Colorectal cancer cell lines DLD1, Colo320 and SW620 showed a 
strong apoptotic response upon treatment with cisplatin or radiation, whereas the other cell lines 
did not, which was also reported previously by other groups (20,21). As for sensitivity to anti-
Fas treatment, only cell line DLD1 showed an apoptotic response, the other cell lines showed a 
resistance to this therapy (22). The sensitivity of  each of  the cell lines to chemo-, immune-, or 
radiation therapy was also reflected in the chromatin status of  each of  the apoptosis genes based 
on the presence of  activating and/or silencing histone modifications at their promoter regions. 
The chromatin status of  each of  the apoptosis genes was also reflected in the mRNA expression 
profiles of  the individual cell lines. As expected, an active chromatin status of  the intrinsic 
pathway genes (Apaf1, Bax, Bcl2 and p53) was associated with sensitivity to treatment with 
cisplatin and radiation. Cell lines Lovo and DLD1 showed an active chromatin status of  the Fas 
gene. However, only DLD1 showed a response to anti-Fas treatment. Differential expression of  
other extrinsic apoptotic pathway factors, that we have not included in our study, might affect 
the apoptotic response upon stimulation with anti-Fas and might hence explain the sensitivity of  
cell line DLD1 and the non-response of  cell line Lovo upon treatment with anti-Fas. 
Many genes showed a bivalent chromatin status, defined as the presence of  both activating and 
silencing modifications at the same region. Bivalent chromatin marks key developmental genes 
and regulators, enabling the genes to be activated instantly when needed during development and 
differentiation (23,24). The bivalent promoter statuses as measured with our ChIP experiments 
are correlated with different effects on gene expression. For example, Bcl2 showed a bivalent 
chromatin status in four cell lines and showed repressed gene expression in these cell lines. On 
the contrary, the p53 gene showed a bivalent chromatin status in all cell lines but is associated 
with increased gene expression. As the bivalent chromatin status of  Bcl2 and p53 does not 
specifically correlate to the differential responses to therapy, these genes might not play a crucial 
role determining sensitivity to therapy in the respective cell lines.
Epigenetic regulation of  apoptosis genes has previously been studied (25,26) and expression of  
the studied genes has been correlated to prognosis in cancer (27-30). In addition, radiosensitization 
of  colorectal cancer cell lines has been described upon treatment with HDAC inhibitors (31,32) 
or Aurora B kinase (33). HDAC inhibitors have also been shown to enhance the response to 
cisplatin treatment (34). These studies indicate that sensitization of  cancer cells can be obtained 
by changing the epigenetic make-up in the cancer cell, by for instance changes in the epigenetic 
regulation of  apoptosis genes involved in the process of  cell death upon anti-cancer treatment. 
Knowledge of  specific changes in epigenetic mechanisms in cancer cells might provide new 
possible targets for anti-cancer therapy.
In conclusion, histone modifications at apoptosis gene promoter regions, reflecting the 
transcriptional status of  the gene, can be used to predict the sensitivity of  colorectal cancer cell 
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lines to anti-cancer treatment. In current clinical practice, personalized treatment is warranted to 
prevent over- and undertreatment of  colorectal cancer patients. Using information regarding the 
transcriptional activity of  both the intrinsic and extrinsic apoptotic pathways may provide critical 
information that is required to make an informed treatment decision for each individual patient. 
Future research should focus on developing methods to detect these histone modifications on 
apoptosis gene promoters in patient tissues, such as snap-frozen tumor biopsies, in order to make 
this information available in the clinic. The chromatin status of  the studied apoptosis genes might 
provide patient-specific information regarding the response to specific anti-cancer therapies. 
Because of  the potentially reversible nature of  epigenetic modifications, these modifications 
could provide novel targets to sensitize tumors to obtain adequate treatment responses.
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ChIP results of  active control gene GAPDH and silenced control gene MYT. Results of  ChIP experiments 
for active control gene GAPDH and silenced controlgene MYT are depicted for all cell lines (panels A and B). 
Immunoprecipitations have been performed using antibodies against active histone modifications H3Ac and H3K4me3 
(indicated in green) andsilencing histone modifications H3K9me3 and H3K27me3 (indicated in red). IgG was used as a 


















































































































































































































































































ChIP results for cell lines Colo320, HT29 and Lovo. Results of  the ChIP experiments are shown for cell lines 
Colo320, HT29 and Lovo. Immunoprecipitations have been performed using antibodies against active histone 
modifications H3Ac and H3K4me3 (indicated in green) and silencing histone modifications H3K9me3 and H3K27me3 
(indicated in red). IgG was used as a control for non-selective binding (indicated in gray). PCR was performed for 
apoptosis genes Casp9, p53, Bcl2, Bax and Fas. The respective histone modifications are indicated on the x-axis, the 
relative enrichment (the percentage of  precipitated DNA as compared to the non-precipitated input = % input) is
indicated on the y-axis. Error bars represent the maximum and minimum values of  the duplicate experiments. For 
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Colorectal cancer is one of  the most common diagnosed cancers worldwide, and is the second 
most important cause of  cancer mortality in Europe. Despite careful assessment of  tumor 
stage to decide on treatment strategies using the tumor, nodes and metastasis (TNM) staging 
system, large differences in patient survival and tumor recurrence are observed among patients 
with tumors with the same TNM classification. The general aim of  the work presented in this 
thesis was to identify new clinically prognostic biomarkers in colorectal cancer in order to 
better classify patients, which might aid in the decision-making process concerning anti-cancer 
therapies in the future. The work presented in this thesis is a starting point for finding new 
clinically prognostic biomarkers by studying epigenetic mechanisms regulating gene expression. 
Epigenetic mechanisms were studied at different levels: both DNA methylation and histone 
modifications were studied genome-wide and at specific gene promoter regions.
Chapters 2 and 3 report on DNA methylation studies that were performed in rectal cancer tissues 
from patients enrolled in the Dutch multicenter TME clinical trial. Chapter 2 describes the 
prognostic value of  DNA methylation of  repetitive retrotransposon sequence long interspersed 
element 1 (LINE-1), but not of  Alu repetitive sequences, in early-stage rectal cancer. Low 
methylation at LINE-1 sequences was shown to correlate with shorter patient survival and 
a higher probability of  tumor recurrence, which can be attributed to activation of  LINE-1 
retrotransposons which can reintegrate at random sites into the genome and can thereby interrupt 
regular gene sequences or influence DNA methylation of  neighboring genes. In addition, results 
suggested that high methylation at histone H3 lysine 27 (H3K27me3) when DNA methylation 
at LINE-1 was low could have a “protective” function in the cells by preventing deregulated 
gene expression when DNA methylation is absent. In contrast, high acetylation of  H3K9 in 
combination with high levels of  DNA methylation at LINE-1 sequences could be associated 
with a poor disease outcome through activation of  aberrant gene expression. In Chapter 3, 
DNA methylation was studied at promoter regions of  apoptosis genes functioning in both 
the intrinsic and extrinsic apoptosis pathway routes. Combined survival analyses of  intrinsic 
apoptosis pathway genes Apaf1, Bcl2 and p53 showed shorter survival and recurrence-free 
periods when an increasing number of  markers showed high methylation (all low, 1 high, 2 high 
or all high). The shortest survival, however, was observed for patients showing low methylation 
of  all markers, which – as was expected - correlated with high apoptosis (M30), but also with 
high proliferation (Ki-67).
In addition to DNA methylation, histone modifications were studied in colorectal cancer tissues, 
both globally and at gene-specific promoter regions. Chapter 4 describes the prognostic value 
of  global nuclear expression of  histone deacetylases SIRT1, HDAC1 and HDAC2 combined 
with histone modifications H3K56Ac and H4K16Ac. High expression of  histone deacetylases 
prevents aberrant gene expression, high levels of  H4K16Ac are associated with silenced repetitive 
sequences and high levels of  H3K56Ac are essential for proper non-homologous end-joining. 
Indeed, better patient survival and less tumor recurrence were observed when more markers 




the prognostic value of  Polycomb-group proteins EZH2, BMI1 and SUZ12 with associated 
histone modification H3K27me3 in colorectal cancer tissues. As would be expected from the 
transcriptional silencing function of  H3K27me3, high expression of  the histone modification 
and the three Polycomb-group proteins showed better patient survival and longer recurrence-
free survival in combined marker survival trend analyses. Better stratification of  patients was 
obtained by combining the expression data of  the investigated biomarkers as compared to the 
individual markers, underlining the importance of  investigating multiple markers simultaneously. 
In Chapter 6, the prognostic value of  histone methylation at several histone tail residues in early-
stage (TNM stage I and II) colon cancer was investigated. Low nuclear expression of  H3K4me3, 
and high expression of  H3K9me3 and H4K20me3 were associated with good prognosis, both 
in individual marker analyses as well as in combined marker analyses. Chapter 7 reports on the 
specific chromatin environment at apoptosis gene promoter regions that can be used to predict 
sensitivity of  colorectal cancer cell lines to cisplatin, anti-Fas or radiation therapy. The results 
presented in this study indicate that the apoptotic response of  individual cell lines is indeed 
correlated with the transcriptional status of  the apoptotic genes, as measured by the balance 
between activating and silencing histone modifications.
In conclusion, the study of  epigenetic mechanisms as presented in this thesis indeed resulted 
in the identification of  clinically relevant prognostic biomarkers. On a genome-wide level, 
deregulated DNA methylation on repetitive sequences (LINE-1) and deregulated expression of  
histone modifications and -modifying enzymes showed strong correlations to clinical outcome. 
At specific gene promoter regions, all related to the process of  apoptosis, DNA methylation was 
correlated to clinical outcome and the transcriptional status based on histone modifications was 
predictive for the response to therapy. Taken together, these results emphasize the importance 
of  deregulated epigenetic mechanisms in tumorigenesis. In the future, the described potentially 
reversible epigenetic mechanisms might provide a starting point for the identification of  
important epigenetic biomarkers and might eventually lead to the development of  tumor-









Discussion and future perspectives
In the past decades, the knowledge of  the tumorigenic process at the level of  genetics (including 
mutations and single nucleotide polymorphisms), gene transcription (regulated by epigenetic 
mechanisms), gene translation (including non-coding RNAs) and proteins (comprising 
biochemical pathways) has increased exponentially. There is a need for new prognostic 
(providing information on the likely clinical outcome on the basis of  tumor characteristics) and 
predictive (predicting the response to therapy on the basis of  tumor characteristics) biomarkers 
to advance the field of  individualized medicine for colorectal cancer patients. To date, only a 
few biomarkers that show changes in colorectal tumor tissues as compared to normal tissues 
have been implemented in clinical practice, including measuring CEA levels for postoperative 
surveillance (1) and assessment of  KRAS mutations to predict the response to anti-EGFR 
therapy (2). No other biomarkers have been recommended for use in clinical practice by the 
European Group on Tumor Markers (EGTM) (3).
In order to find clinically relevant biomarkers, understanding the underlying tumor biology is 
of  uttermost importance. Until recently, studies on finding new biomarkers have been focused 
on genetic changes in tumor tissues. Now it is becoming increasingly clear that genetics 
does not solely determine the course of  tumor development and progression. Epigenetic 
mechanisms, including DNA methylation and histone modifications, play a significant role in 
cancer development, progression, metastasis and drug resistance, and are therefore potential 
new biomarkers in colorectal cancer. In this thesis, epigenetic mechanisms were identified 
as prognostic biomarkers. In addition, the studied changes in epigenetic regulation provide 
information about the underlying tumor biology.
The dynamic nature of  epigenetic mechanisms – new options for therapy
Epigenetic mechanisms are dynamic modifications on DNA and histone proteins that are added 
or removed depending on the demands of  the cell under specific conditions. For example, in 
order for the cells to differentiate during embryonic development, changes in DNA methylation 
and histone modifications allow for genes to be switched on or off  at the correct stage of  the 
developmental process (4-7). Following cellular differentiation, epigenetic modifications ensure 
cell- and tissue-specific gene expression patterns and regulate gene expression in response to 
environmental stimuli (8). In cancer cells, numerous changes in epigenetic modifications occur 
that promote tumor development, progression and metastasis. Because of  their dynamic nature, 
epigenetic mechanisms are potentially reversible and therefore present as attractive targets for 
therapeutic intervention, especially since epigenetic alterations might also be the cause of  drug 
resistance in human cancer. Several cellular processes that could contribute to drug resistance 
have been described to be affected by aberrant epigenetic modifications in cancer, including 
enzymatic drug-metabolism, drug efflux, DNA repair and apoptosis (9-13). Reversion of  these 
aberrant epigenetic patterns might sensitize the tumor to anti-cancer treatments.
Epigenetic therapies in a clinical setting
Several epigenetic drugs have been extensively studied and are now tested in clinical trials for 
treatment of  hematological malignancies, including FDA-approved drugs 5-aza-2’-deoxycytidine 
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(decitabine; 14,15) and several histone deacetylase (HDAC) inhibitors (16,17). To date, epigenetic 
drugs are most effective in hematological diseases and have not shown any conclusive effectiveness 
of  antitumor activity of  any of  these drugs in solid tumors, including colorectal cancer (reviewed 
in ref  9). This suggests that more knowledge is needed concerning the complex tumor biology 
and the epigenetic mechanisms involved in the tumorigenic process in solid tumors. In addition 
to the limited effect of  epigenetic drugs in solid tumors, major concerns of  using epigenetic drugs 
such as DNA methyltransferase (DNMT) or HDAC inhibitors include their non-specificity and 
therefore the possibility of  unwanted side-effects of  the drugs. The inhibitors might reactivate 
genes that are normally silent and that might promote tumor aggressiveness in addition to or 
instead of  the expected reactivation of  tumor suppressor genes (18). Despite these concerns, 
increasing evidence suggests that combination treatment with HDAC inhibitors and DNMT 
inhibitors results in a synergistic response, leading to re-expression of  silenced genes, increased 
apoptosis and reduced tumorigenesis (19,20). In addition, combination of  epigenetic drugs 
and current standard therapy regimens might provide a more effective way of  treatment. More 
research is needed concerning the specific epigenetic changes in (colorectal) tumors, in order 
to provide targets for the development of  specific epigenetic drugs. In this thesis new potential 
biomarkers, including DNA methylation on specific genes or repetitive sequences and histone 
modifications and -modifying enzymes, were identified that might provide new targets for future 
epigenetic therapies, as will be discussed below.
Genome-wide DNA methylation
In this thesis, genome-wide DNA methylation was studied using LINE-1 and Alu repetitive 
sequences. Low levels of  LINE-1 methylation were found to be associated with poor prognosis, 
which can be explained by activation of  its retrotransposon activity and hence potential random 
insertion of  the sequences and/or changes in methylation of  surrounding gene regions. In 
contrast, Alu methylation was not found to correlate with prognosis, indicating that our findings 
in rectal cancer were LINE-1 sequence-specific and not generally applicable to the whole genome. 
This might explain why epigenetic drugs do not yet function optimally in solid tumors, including 
colorectal cancer: not all regions of  the genome are equally affected by changes in epigenetic 
modifications. Identification of  the (gene) regions that are differentially regulated and have 
prognostic or predictive value in colorectal cancer is therefore of  key importance in the search 
for new, clinically useful, biomarkers. The findings in this study also underline the importance 
of  the development of  more specific epigenetic drugs, targeting single epigenetic modifying 
proteins or maybe even sequence-specific epigenetic alterations. Furthermore, measuring 
LINE-1 methylation in biopsy tissues of  cancer patients might provide a good risk assessment 
for the potential development of  a distant recurrent tumor in individual patients.
Global histone modifications and –modifying enzymes
The studies concerning global histone modifications presented in this thesis have identified 
multiple prognostic biomarkers in colorectal cancer. Histone modifying enzymes including 
HDACs and EZH2 present as promising targets for epigenetic therapies, but most likely need to 
be combined with other – existing – therapies, as discussed above. The studies presented in this 




in better stratification of  patients into different risk groups as compared to individual markers, 
underlining the importance of  pathway-focused approaches. Considering this, future research 
should focus on combining multiple drugs targeting epigenetic enzymes. This might lead the way 
to success for epigenetic therapy in solid tumors. Risk assessment for individual patients based 
on the expression of  histone modifications and –modifying enzymes might add to the current 
TNM staging system.
Gene-specific epigenetic modifications
The transcriptional status (including both DNA methylation and histone modifications) of  
specific genes, as shown for apoptosis genes in this thesis, has prognostic and predictive value 
in colorectal cancer. DNA methylation of  combined intrinsic apoptosis pathway genes Apaf1, 
Bcl2 and p53 was found to be prognostic in our rectal cancer patient cohort. In literature, 
methylation of  apoptosis genes has also been linked to drug resistance. For example, methylation 
of  apoptosis effectors BNIP3 and DAPK has been shown to predict lower response rates to 
fluoropyrimidine-based treatment in gastric cancer (21). In addition to DNA methylation, we 
also studied histone modifications on apoptosis gene promoters. The transcriptional status 
of  the respective apoptosis genes, on the basis of  the presence of  activating and/or silencing 
histone modifications, were shown to correlate with the response to anti-cancer treatments, 
including chemotherapy, irradiation or immunotherapy. Determining the transcriptional status 
of  key genes in for example the apoptosis pathway in patient tissues (biopsies) may lead to 
specific decisions for therapy on the basis of  the biological make-up of  individual tumors. 
Continuing on the discussion above, current epigenetic therapies lack specificity and may thereby 
fail to be effective in several types of  solid tumors, including colorectal cancer. New therapies 
should be developed focused on reversing epigenetic alterations on specific genes or sequences 
in individual tumors that show prognostic and/or predictive value, thereby getting one step 
closer to individualized medicine. For this purpose, more research is needed to understand the 
mechanisms of  gene- or pathway specific epigenetic regulation by epigenetic modifiers such 
as DNMTs and histone-modifying enzymes. This knowledge will aid in the identification of  
clinically relevant biomarkers that can be used to develop new - epigenetic - therapies for solid 
tumors.
Future perspectives
Several epigenetic clinically prognostic biomarkers were identified in colorectal cancer in this 
thesis, including both genome-wide and gene-specific patterns of  DNA methylation and histone 
modifications. Knowledge of  tumor biology is of  key importance in the development of  new 
therapies and the making of  informed, patient-specific, treatment decisions. Pathway-focused 
approaches, as presented in this thesis, provide information regarding possible synergistic 
interactions of  biomarkers. This information will lead to identification of  new combinations of  
treatment regimens that enhance the anti-cancer effects in individual patients. Multidisciplinary 
medicine, combining the knowledge provided by biomarker research and results of  clinical 
trials, is therefore important to advance the field of  individualized medicine. In addition, newly 
validated biomarkers will add crucial information to tumor characterization instruments currently 
used in clinical practice, such as the TNM staging system. Adding information on epigenetic 
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modifications, will aid in identifying high-risk patients and predicting response to therapy based 
on tumor characteristics, and will thereby provide opportunities for individualized medicine.
In conclusion, the work presented in this thesis underlines the importance of  epigenetics in tumor 
development. The various studies presented show that epigenetic alterations have a profound 
impact on patient survival and tumor recurrence. Even though most cancer research has 
focused on the effect of  gene mutations on the tumorigenic process during the last decades, it is 
becoming increasingly clear that epigenetic mechanisms are important mediators in this process. 
A delicate interplay between genetics and epigenetics determines the fate of  each individual cell 
in the human body. Gene mutations cause changes in gene expression or stability/interactions 
of  the resulting mutated proteins, which all have downstream effects within pathways that are 
accompanied by changes in the epigenetic regulation of  these downstream factors. In addition, 
gene mutations in epigenetic modifiers will have direct effects on the transcriptional regulation 
of  many genes or gene regions. Therefore, epigenetic mechanisms are unquestionably tied to the 
tumorigenic process and should be considered as a grand new source of  information not only 
for identification of  prognostic and predictive biomarkers, but also for the development of  new, 
possibly tumor- and therefore patient-specific, anti-cancer therapies. 
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Darmkanker is wereldwijd één van de meest voorkomende soorten van kanker, en neemt 
een tweede plaats in als het gaat om sterfte door kanker in Europa (1). Ongeveer twee derde 
van de colorectale tumoren (dikkedarmkanker) ontstaat in het colon, en een derde in het 
rectosigmoid of  rectum. Colorectale tumoren worden geclassificeerd met behulp van het 
“tumor, nodes and metastasis” (TNM) stageringssysteem (2,3), en vervolgens wordt aan de 
hand van de geldende richtlijnen bepaald hoe de patiënt behandeld wordt. Colorectale tumoren 
worden primair verwijderd door middel van een operatie. Daarnaast wordt aan een deel van de 
patiënten aanvullende behandelingen gegeven in de vorm van chemotherapie en/of  bestraling. 
Met de introductie van pre-operatieve bestraling en de “total mesorectal excision” (TME) 
operatietechniek voor rectale tumoren, is het percentage van patiënten bij wie de tumor lokaal 
terugkeert gereduceerd van 11% naar 5% (4). Dit houdt echter ook in dat een groot deel van 
de patiënten (minimaal 94%) onnodig behandeld wordt met pre-operatieve bestraling, met kans 
op bijwerkingen zoals seksuele dysfunctie of  incontinentie (5,6). De huidige TNM classificatie 
van colorectale tumoren is vooralsnog ontoereikend, aangezien patiënten met tumoren in 
hetzelfde stadium grote verschillen laten zien in overleving en het terugkeren van een tumor (7). 
Er is dus een grote behoefte aan biomarkers die kunnen helpen bij het identificeren van hoog-
risicopatiënten en bij het bepalen van de behandelingsstrategie. Biomarkers zijn biologische 
markers die gemeten kunnen worden in bijvoorbeeld bloed of  tumorweefsel, en die gebruikt 
kunnen worden als indicatoren voor de aanwezigheid en het verloop van pathologische processen 
of  om de respons op therapie te bepalen. Tot op heden is maar een klein aantal biomarkers 
goedgekeurd voor gebruik in de kliniek, waaronder “carcinoembryonic antigen” (CEA) in het 
bloed voor post-operatieve monitoring en KRAS mutaties voor het eventueel toedienen van 
anti-EGFR therapie (8,9). Vele andere biomarkers zijn beschreven, maar er is voor deze markers 
onvoldoende bewijs om deze in de kliniek te gebruiken. Voor het vinden van klinisch relevante 
biomarkers is het begrijpen van de onderliggende tumorbiologie van groot belang. Met deze 
informatie van individuele tumoren kan per patiënt gekeken worden wat het risicoprofiel is 
en kunnen nieuwe therapieën ontwikkeld worden die ingrijpen op de in de tumor verstoorde 
processen.
Doel van dit proefschrift
Het onderzoek beschreven in dit proefschrift richt zich op het vinden van nieuwe prognostische 
biomarkers in colorectale tumoren op het gebied van epigenetische mechanismen, die kunnen 
voorspellen wat het klinisch verloop zal zijn met betrekking tot lokaal terugkeren of  metastasering 
(uitzaaien) van de tumor en overleving van de patiënt. 
Genetische en epigenetische veranderingen in tumoren
Een kankercel ontstaat doordat een serie van opeenvolgende veranderingen plaatsvindt, die 
ervoor zorgen dat de cel zich ongeremd kan vermenigvuldigen, niet dood gaat, en waardoor de 
cel kan metastaseren (uitzaaien) naar andere organen. Deze eigenschappen zijn beschreven door 
Hanahan en Weinberg als de “hallmarks of  cancer” (10,11). De veranderingen die leiden tot 
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tumorvorming kunnen hun oorsprong vinden op genetisch niveau, door bijvoorbeeld mutaties 
in specifieke genen, zoals beschreven in een model voor colorectale tumoren door Vogelstein 
(12). Deze veel voorkomende mutaties zijn in veel tumoren aanwezig, maar verklaren niet het 
ontstaan van alle tumoren.
Naast veranderingen in het DNA, is er in het wetenschappelijk onderzoek steeds meer aandacht 
voor de regulatie van genexpressie door epigenetische mechanismen. Epigenetica betreft 
de wetenschap die veranderingen in een organisme door modificatie van de genexpressie 
bestudeert, die niet worden veroorzaakt door veranderingen in de onderliggende DNA 
sequentie. De epigenetische mechanismen die in dit proefschrift aan bod komen beïnvloeden 
de genexpressie via regulatie van de lokale structuur van chromatine, het complex van histon 
eiwitten waar het DNA omheen gewikkeld is. In een “open” chromatine structuur kunnen 
transcriptiefactoren binden aan de specifieke genen in het DNA, wat vervolgens resulteert 
in expressie van het betreffende gen. Is de chromatinestructuur echter gesloten, zal er geen 
genexpressie plaatsvinden. De chromatinestructuur wordt gereguleerd door het toevoegen of  
verwijderen van chemische groepen aan het DNA (DNA-methylering) of  aan histon-eiwitten 
(histonmodificaties). Deze modificaties worden hieronder verder besproken. Veranderingen in 
deze epigenetische mechanismen zijn in verschillende typen tumoren beschreven (13,14).
DNA-methylering
De modificatie van DNA door het toevoegen van methylgroepen op Cytosines (DNA-
methylering) vertoont een specifiek patroon voor elk celtype (15,16) en is betrokken bij vele 
functies in de cel, zoals het uitschakelen van één van de twee X-chromosomen bij vrouwen, 
het onderdrukken van repetitieve sequenties en de regulatie van cellulaire differentiatie (17). 
DNA-methylering beschermt tegen het spontaan ontstaan van mutaties (18) en speelt ook een 
belangrijke rol tijdens de embryonale ontwikkeling, waar in de verschillende stadia op het juiste 
moment verschillende sets van genen tot expressie moeten komen (19,20). 
In tumorcellen vinden een aantal veranderingen plaats in DNA-methylering ten opzichte 
van normale cellen. Op globaal niveau neemt de hoeveelheid DNA-methylering af  (21), wat 
resulteert in activatie van sequenties die normaal gesproken onderdrukt worden, zoals repetitieve 
sequenties en oncogenen die celdeling bevorderen en celdood tegengaan (22-25). Daarentegen 
kunnen sequenties die normaal gesproken actief  zijn (geen DNA-methylering aanwezig), 
waaronder tumorsuppressor genen, juist gemethyleerd worden waardoor deze niet meer tot 
expressie komen. De prognostische waarde van DNA-methylering van vele genen is inmiddels 
beschreven in verschillende tumoren (26-29).
In dit proefschrift worden zowel globale als gen-specifieke veranderingen in DNA-methylering 
besproken. In hoofdstuk 2 wordt beschreven dat een lage mate van DNA-methylering in 
rectumtumoren op de repetitieve sequentie “long interspersed element 1” (LINE-1, dat 17% 
van het humane genoom beslaat) gecorreleerd is met kortere overleving en een grotere kans 
op het terugkeren van de tumor bij patiënten met rectumtumoren. LINE-1 sequenties, indien 
geactiveerd door verlies van DNA-methylering, kunnen zichzelf  verplaatsen in het genoom 
en daarmee andere genen verstoren, wat kan leiden tot tumorvorming. Ook kan de DNA-
methylering van omliggende genen worden veranderd door de aan- of  afwezigheid van DNA-
methylering op de LINE-1 sequenties, wat kan leiden tot bijvoorbeeld activatie van oncogenen. 
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DNA-methylering op een andere repetitieve sequentie, Alu (short interspersed elements), was 
niet voorspellend voor overleving en/of  terugkeer van de tumor, wat aangeeft dat de gevonden 
correlatie voor LINE-1 methylering specifiek is voor deze sequentie. Op gen-specifiek niveau 
wordt in hoofdstuk 3 beschreven dat methylering van drie genen betrokken bij apoptose 
(geprogrammeerde celdood), namelijk Apaf1, Bcl2 en p53, in rectumtumoren voorspellend is 
voor de overleving van de patiënt en terugkeer van de tumor. Een combinatie van veel celdood 
maar tegelijkertijd ook veel celdeling was gecorreleerd met de slechtste overleving en de hoogste 
kans op terugkeer van de tumor. 
De studies in deze twee hoofdstukken laten zien dat DNA-methylering op zowel genoom-wijd 
als op gen-specifiek niveau prognostische waarde heeft in rectumtumoren. Een goede risico-
inventarisatie voor individuele patiënten zal verkregen kunnen worden door het bepalen van 
DNA-methylering van de beschreven factoren in bijvoorbeeld biopsieweefsels.
Histonmodificaties
Acht histon-eiwitten vormen in vier paren een kern van eiwitten waar het DNA omheen 
gewikkeld is. Het uiteinde van deze histon-eiwitten kan gemodificeerd worden door de 
toevoeging of  verwijdering van onder andere methyl- en acetylgroepen. Histon-acetylering is 
geassocieerd met een open chromatinestructuur en dus activatie van genexpressie. Wat betreft 
methylering van histon-eiwitten bepaalt de specifieke locatie van methylgroepen op de histon-
eiwitten het effect van deze modificatie: 3 methylgroepen op het vierde aminozuur (lysine, K) 
op histon H3 (H3K4me3) zijn bijvoorbeeld activerend, terwijl diezelfde groepen op aminozuur 
27 op histone H3 (H3K27me3) juist geassocieerd zijn met een gesloten chromatinestructuur 
en dus genexpressie tegengaan. Daarbij is het aantal methylgroepen (een, twee of  drie) dat 
wordt toegevoegd ook van belang voor hun specifieke functie in de cel (30). De specifieke 
histonmodificaties worden toegevoegd of  verwijderd door zogenaamde histon-modificerende 
eiwitten, waaronder DNA methyltransferases (DNMTs) die methylgroepen toevoegen aan 
het DNA en histon deacetylases (HDACs) die acetylgroepen verwijderen van histon-eiwitten. 
Veranderingen in expressie van deze modificerende eiwitten, met als gevolg veranderingen in 
de aanwezigheid van bepaalde histonmodificaties, zijn veelvuldig gerapporteerd in verschillende 
tumoren (31,32), en hebben ook prognostische waarde (33-36).
In dit proefschrift zijn een aantal studies beschreven waarin is gekeken naar globale expressie van 
histonmodificaties en de bijbehorende histon-modificerende eiwitten. Hoofdstuk 4 beschrijft 
de prognostische waarde van histon deacetylases SIRT1, HDAC1 en HDAC2 samen met 
histonmodificaties H3K56Ac en H4K16Ac in colorectale tumoren, allen betrokken bij reparatie 
van het DNA en het onderdrukken van onder ander repetitieve sequenties. Hoge expressie 
van de combinatie van de drie histon deacteylases met een van beide histonmodificaties was 
geassocieerd met betere overleving en een kleinere kans op terugkeer van de tumor. In hoofdstuk 
5 wordt de prognostische waarde van Polycomb eiwitten EZH2, BMI1 and SUZ12 samen 
met de geassocieerde histonmodificatie H3K27me3 in colorectale tumoren beschreven. Hoge 
expressie van deze Polycomb eiwitten en H3K27me3 was gecorreleerd met betere overleving 
en een kleinere kans op terugkeer van de tumor. Expressie van histonmodificaties H3K4me3, 
H3K9me3 en H4K20me3, zoals beschreven in hoofdstuk 6, had alleen prognostische waarde in 
stadium I en II colon tumoren. Lage expressie van H3K4me3 en hoge expressie van H3K9me3 
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en H4K20me3 waren geassocieerd met een goede prognose, zowel in individuele marker analyses 
als in gecombineerde analyses.
Histonmodificaties hebben ook op gen-specifiek niveau predictieve waarde. In hoofdstuk 7 
wordt beschreven dat de aanwezigheid van activerende of  onderdrukkende histonmodificaties 
invloed heeft op de genexpressie van apoptose genen en daarmee op de gevoeligheid van 
colorectale cellijnen voor chemotherapie, immuuntherapie of  bestraling. Expressie van apoptose 
genen, door de aanwezigheid van activerende histonmodificaties, was gecorreleerd met een 
goede respons (celdood) op het toedienen van de verschillende therapieën.
In de beschreven studies naar histonmodificaties zijn verschillende prognostische factoren 
geïdentificeerd in colorectale tumoren. Deze studies onderstrepen het combineren van meerdere 
markers en dus op signaleringsroute-gerichte benaderingen (pathways) om de onderliggende 
tumorbiologie te kunnen ontrafelen. Vervolgstudies zullen zich dus ook moeten richten op 
het combineren van meerdere (epigenetische) therapieën om een beter behandelingseffect 
te verkrijgen. De bepaling van de aanwezigheid van histonmodificaties in biopsieweefsel kan 
belangrijke informatie opleveren wat betreft de keuze voor therapie voor individuele patiënten. 
Kennis van de regulatie van specifieke genen, zoals beschreven in het laatste hoofdstuk, zal in de 
toekomst hopelijk leiden tot het ontwikkelen van meer specifieke epigenetische therapieën, die 
gericht zijn op het behandelen van individuele tumoren.
Toekomstperspectieven
Vanwege de dynamische eigenschappen van epigenetische modificaties, die op elk moment 
toegevoegd of  verwijderd kunnen worden afhankelijk van de behoeften van de cel, zijn 
epigenetische mechanismen aantrekkelijke kandidaten voor het ontwikkelen van nieuwe 
therapieën. Epigenetische therapieën gericht op DNA-methylering (37,38) of  histon deacetylases 
(39,40) worden momenteel getest in klinische trials. Tot op heden zijn deze therapieën echter 
voornamelijk effectief  in hematologische ziekten (leukemieën), maar beduidend minder in 
solide (waaronder colorectale) tumoren. Voor het ontwikkelen van effectievere therapieën voor 
individuele patiënten met colorectale tumoren, is kennis van de onderliggende tumorbiologie 
essentieel. Ook zullen signaleringsroute-gerichte benaderingen belangrijk zijn in het identificeren 
van prognostische en predictieve biomarkers in colorectale tumoren. Multidisciplinair onderzoek, 
waarbij clinici en onderzoekers nauw samenwerken, is hierbij van groot belang, om kennis uit 
het wetenschappelijk onderzoek te kunnen toepassen en potentieel nieuwe behandelingen te 
testen in klinische studies. Klinisch relevante biomarkers zullen moeten worden toegevoegd 
aan de classificatiesystemen die momenteel in de kliniek gebruikt worden, zoals het TNM 
classificatiesysteem. Identificatie en toepassing van nieuwe biomarkers in de kliniek zal bijdragen 
aan betere classificatie van patiënten en daarmee een kans op gerichte behandeling van individuele 
patiënten.
Samenvattend onderstrepen de verschillende studies gepresenteerd in dit proefschrift dat 
epigenetische mechanismen een belangrijke rol spelen in het proces van tumorvorming. Er is de 
afgelopen decennia veel onderzoek gedaan naar genetische mutaties in tumoren, maar het wordt 
steeds duidelijker dat andere factoren zoals epigenetische mechanismen hierbij ook een grote rol 
spelen. Genmutaties kunnen bijvoorbeeld leiden tot verhoogde of  juist verlaagde expressie van 
het betreffende gen, waar dus ook veranderingen in de epigenetische regulatie van deze genen bij 
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betrokken zijn. Aangezien de expressie van een gen nooit op zichzelf  staat en altijd is verbonden 
met andere genen in dezelfde signaleringsroute, zal ook de epigenetische regulatie van deze 
andere genen worden beïnvloed door mutaties of  veranderingen in de epigenetische status van 
een individueel gen. Mutaties in epigenetische factoren zelf  zullen uiteraard ook grote gevolgen 
hebben voor de epigenetische regulatie van individuele genen en daarmee signaleringsroutes, 
en beïnvloeden daarmee het proces van tumorvorming. Epigenetische mechanismen zijn dus 
onbetwistbaar betrokken bij het proces van tumorvorming en moeten worden beschouwd als 
een grote bron van informatie, niet alleen voor het identificeren van prognostische en predictieve 
biomarkers, maar ook voor de ontwikkeling van nieuwe, mogelijk tumor- en daardoor patiënt-
specifieke, tumortherapieën.
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